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´If even the doctor does not know which treatment option would be best, how should 
I then decide what to choose? I am not a doctor, after all´. This could be the perception 
of a patient after receiving the diagnosis early-stage prostate cancer. In many cases, 
mild symptoms or an elevated PSA level in a (routine) blood test precede the diagnosis. 
Consequently, a man in a relative good health condition is suddenly confronted with 
a cancer diagnosis, which a patient may perceive as a serious and potentially life-
threatening disease. Diagnosis can feel overwhelming at such a moment and choice 
awareness may be lacking. Explanation follows about the disease, its multiple treatment 
options, the different associated procedures and their potential benefits and side-effects 
and can cause patients to feel overloaded with information and to experience high levels 
of decisional conflict. This example highlights that providing high quality health care 
consists of more than diagnosing and treating a disease. In many medical situations, 
including early-stage prostate cancer, multiple appropriate treatment methods are 
available, as well as an option not to treat (immediately). In case of medically equivalent 
options, not only the medical content is relevant, but patient preferences and other 
personal circumstances determine which option provides the best patient-treatment 
fit. Optimal treatment choice is therefore dependent on shared doctor-patient decision 
making, consisting of discussion of all options, including the pros and cons so that the 
patient and doctor together come to a conclusion what would be the best option for 
this patient. However, this process of shared patient-doctor decision making, beyond 
the exchange of relevant medical information, is challenging. 
First, evidence has shown that many patients are dissatisfied with the information they 
receive, patients sometimes lack choice awareness, or perceive discordance between 
the experienced and desired level of involvement in the decision process 1-6. Moreover, 
health-care providers sometimes misinterpret patient preferences, which may result 
in treatment choices that are not concordant with patients values, and evidence also 
reveals that healthcare providers can be prone to overestimating the degree to which 
they already engage patients in a shared decision making process 7, 8.  To properly inform 
patients, enable them to take a more active role and to stimulate a joint patient-doctor 
decision process, patient decision aids (DA) can provide assistance in achieving shared 
decision making in routine clinical care 9, 10. After exposure to a DA, patients report 




At the start of the research project described in this dissertation, no patient DA including 
all active treatment options as well as the choice option not to start active treatment 
right away, was available and routinely used in care for prostate cancer patients in the 
Netherlands, even though prostate cancer is the most common cancer in man in the 
western world, including the Netherlands11, 12. The main goals of the project described 
in this dissertation were therefore: (1) Develop, (2) implement and (3) evaluate a DA 
for patients newly diagnosed with early-stage prostate cancer in everyday care in 
multiple healthcare centers in the Netherlands. For the purpose of improving national 
implementation, a consortium (JIPPA) was formed, consisting of three regional DA 
research groups that had each developed a DA for prostate cancer patients. Within the 
consortium, the same methods for patient evaluations and determining implementation 
rates were used, to facilitate comparison across the three studies.   
To set the stage, the research described in this dissertation also presents (1) a retrospective 
analysis of decision roles and information satisfaction as reported by prostate cancer 
patients who are long after their initial treatment decision and who received care before 
the start of the JIPPA implementation project, as well as (2) an analysis of the change 
in patients´ self-reported health-related quality of life in the period before and  after 
prostate cancer diagnosis, before treatment onset. The DA was tested within a cluster 
randomized trial. Novelty of this trial included a pragmatic approach, a long-term follow-
up (12 months), and a detailed analysis of DA implementation and usage rates. The 
current chapter aims to describe the theoretical background and models underlying 
these studies. 
Prostate cancer
Prostate cancer (Pca) is the most common cancer in men in the western world, and is 
diagnosed mostly in men between the ages of 50 and 70 11, 12. In the Netherlands, around 
10,000 men are diagnosed with Pca every year (www.cijfersoverkanker.nl). In many 
patients, Pca is detected at an early stage 13. At this stage, multiple medically equivalent 
treatment options are available 14. Deciding between those options is challenging: a 
doctor can often not present a single superior option from a purely medical perspective, 
and patients are often not aware of differences between available treatments or their 
own preferences associated to these treatments 15, 16. Careful treatment counseling is 
therefore required, which should at least include adequate information provision and 
elicitation of patient-preferences 9. 
The prostate is part of the male reproductive system and is located below the urinary 
bladder and surrounds the urethra. The main function of the prostate is the production 




during puberty, regulated by hormones (testosterone). A healthy prostate has the 
size comparable to a walnut 18. Men from 50 years and older frequently experience 
problems from growth of the prostate. Usually this is a benign enlargement of the 
prostate, which is not caused by cancer. With Pca, there is an uncontrolled growth of the 
prostate glandular cells. This changes the structure of the prostate gland, resulting in 
enlargement of the prostate and hardening of the prostate tissue 19.
In this dissertation, when the term Pca is used, we refer to prostate cancer at a localized 
stage. At this stage the cancer cells are located within the prostate (stage T1 or T2; Figure 
1), without progression through the prostatic capsule and into surrounding tissue (T3) 
or other organs (T4) 20. Pca progression during the localized stage is usually slow, and 
multiple, equally effective options can be considered for treatment, as well as the option 
not to treat immediately, as the tumor may not progress to an advanced stage at all 14. 
Figure 1. Location of the prostate and tumor 
stages. 
© Cancer Research UK / Wikimedia Commons (CC BY-SA 4.0)
Figure 2. Three dimensional image of a 
prostate with cancer, after needle biopsy 21 
Growing number of Pca patients
In 1970, prostate specific antigen (PSA) was discovered as an indicator for Pca 22. The level 
of PSA can easily be measured with a simple blood test. An elevated PSA level might be 
an indication for Pca and reason for further investigation, such as a rectal examination, 
imaging, and prostate biopsy (Figure 2). During the 1990’s, PSA testing became common 
practice, and consequently, Pca detection has increased significantly 23. As Pca mostly 
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develops at an older age, aging of our population, and the still increasing use of PSA 
testing contributes to an expected continued growth of Pca detection over the next 
decade 13, 24.
The probability of developing Pca at some point in life is estimated at just below 20%, 
while some studies showed that up to 50% of men between 70 and 80 years of age show 
some evidence of Pca 25. However, most of these cancers will be non-aggressive  and 
men will die of other causes without ever experiencing Pca symptoms 26. Nevertheless, 
many men, when knowing that cancer is detected, feel the urgent need for treatment, 
even if the cancer might never develop symptoms and is unlikely to be fatal 27. 
Preference-sensitive treatment options
The most endorsed curative treatment options for Pca (surgery, brachy therapy, and 
external radiotherapy) promise comparable chances on successful treatment and long-
time survival 14. However, each treatment has specific side-effects that can significantly 
impair a patient’s quality of life (e.g. impotence, incontinence) 28-31. These side-effects 
could even be perceived as worse than the cancer symptoms themselves. Alternatively, 
active surveillance can be a safe option for many men to postpone or avoid treatment 
without harming further survival perspectives. However, life then has to be continued 
with the knowledge of an untreated tumor being present 32, 33.
Without an obviously superior option, the best suiting treatment for an individual patient 
depends on various factors and is preference-sensitive 34. First, clinical characteristics 
such as tumor size, co-morbidities and the physical condition of the patient, determine 
eligibility for one or more treatments. Second, personality characteristics and individual 
preferences determine which treatment the patient feels most comfortable with. For 
example, Patient A’s fear for tumor progression may outweigh the perceived risk and 
burden of treatment side effects, resulting in a choice for surgery or radiotherapy. Patient 
B, on the other hand, might be reassured that active surveillance is as safe as immediate 
treatment, and chooses to postpone treatment and avoid the side effects associated to 
treatment. If patients’ preferences would not be taken into account, and Patient A would 
be assigned to active surveillance, his daily life could be disturbed by anxiety about 
tumor progression, while if Patient B would have undergone surgery immediately and 
suffer from side effects, regret about the chosen treatment could impair quality of life to 
a greater extent in his case compared to a patient who accepted the risks of side effects 




Medical decision making 
Historically, most medical decisions were characterized by a strong focus on the 
disease itself -not the patient suffering from it- and the expertise of the doctor 35. The 
more complex the disease or proposed treatment was, the more dominant the voice 
of the doctor was and, as a result, patients could feel excluded from this process.  The 
exchange of information between a doctor and patient was often limited to the amount 
that was required to obtain a patient´s informed consent for undergoing treatment. 
Partly, this paternalistic model existed because many medical conditions only had a 
single treatment 36. 
From the 1980´s onwards awareness increased that with advances in medical treatments, 
more complexity was introduced in deciding about which treatment would be best. For 
example, different treatments can have the same expected survival outcome, but may 
differ in the adverse treatment effects and risks involved. In such situations, a doctor 
can no longer solely rely on the medical characteristics to determine the best solution. 
Patient preferences and personal circumstances should then be evaluated to further 
guide the tradeoff between risks and benefits. Consequently, a more active patient role 
became necessary 35. 
With increasing patient involvement, interest grew to deliver healthcare that is both 
effective and appropriate. Value-based healthcare was introduced as a term that aimed 
at optimal patient value while reducing health care costs 37. An important driver in the 
development of value-based healthcare consisted of the observation of regional variation 
in treatments for the same disease. Routine clinical practice displayed wide treatment 
variations which could not be explained by illness severity or patient preferences alone 
38. This variation has also been observed in Dutch Pca care 39. Unwarranted regional 
variations in clinical practice for the same disease can be an indication for impaired 
healthcare quality. Care that is delivered does then possibly not reflect the latest 
scientific guidelines or patient preferences, but health-care provider preferences or 
financial incentives instead 40, 41. Shared patient-doctor decisions may help to counter 
practice variation: When treatments reflect patient preferences, the same variation in 
treatments should be found across different regions or hospital locations 42, 43.
Shared decision making
Shared decision making (SDM) is a key concept throughout this dissertation. Definitions 
of SDM vary,  but all include ‘a balanced presentation of options and outcomes tailored 
to the individual patient’s risk’ and ‘active engagement with the patient to help clarify 
his own values and preference’ 44. Active engagement does not necessarily mean that 
14
Chapter 1
the patient should always have an active role in evaluating options, information and 
decision-making, but it does require that the patient is aware that multiple options 
are available to him and that his personal values and preferences matter for selecting 
the most appropriate option.  This ensures health care is centered around the patient, 
instead of focusing on the disease or treatment options 9. 
Shared decision making (SDM) can help to achieve patient-centered care, as patients 
become more involved into their medical decision. SDM also contributes to the delivery 
of appropriate care. That is, when all available options are discussed, and patient values, 
preferences and circumstances are taken into account, it is more likely that the selected 
treatment is the optimal treatment for this particular patient, concordant with the 
individual patient’s values and preferences and suiting his or her personal circumstances. 
This ensures that the inevitable scarce resources are allocated appropriately. 
Benefits from SDM are found on multiple levels. First, there is an ethical imperative 
related to SDM, consisting of respecting patient autonomy 9. Second, when being fully 
informed about all options and personal values have been taken into account, decision 
outcomes (e.g. chosen treatments) tend to be more conservative 45. Consequently, SDM 
contributes to reduce over-treatment and possibly reduces (societal) health costs 46. 
As such, SDM may also contribute to the sustainability of our healthcare system. Third, 
patient-reported outcomes after SDM include less decisional conflict, higher satisfaction 
with received care, less decisional regret, and better quality of life, although evidence 
for the latter two outcomes is less conclusive 47.
Procedures in SDM
Most SDM models can be translated into three steps towards a final treatment decision 
and start at the moment when it becomes clear that a decision has to be made 6, 9, 48. A 
model that is brief and practical to translate to existing Pca care paths is the Three-talk 
model, with a Team, Option, and Decision talk 49. The content of each step is summarized 
in Figure 3.
In Pca care, a multidisciplinary team (e.g., urologist, pathologist, radiologist, radiation 
oncologist, and oncology nurse) reviews all available evidence from previous tests 
and consents on what treatments can be considered according to the best available 
scientific evidence and relevant clinical guidelines. After the patient has received the 
Pca diagnosis, the aim of the Team talk is to explain all treatment options for which 
the patient is eligible and to provide additional information materials. Next, the aim 
of the Option talk is to weigh all benefits and risks from all options against personal 




path to navigate patients through this step. Nurses often have more time available for 
counseling patients compared to doctors, and patients can perceive less of a power 
imbalance in conversation with a nurse 50. After all options and patient values have been 
explored, the aim of the Decision talk is to make the treatment decision. Pca patients 












Pca diagnosis and 
choice awareness 
(Team talk) 
Choice of    
treatment     
(Decision 
talk) 
       Pca 
treatment 
Treatment        
counseling 
(Option talk) 
Shared decision making: 
Reviewing options and 
establishing informed 
preference 
Display of options for 
treatment 
Reviewing options and 
reaching informed 
preferences 
Figure 3. Three steps in SDM models, with the Three Talk model 49.
Decision aids 
Even with stepwise models such as the Three Talk Model described above, it can be 
difficult for patients and doctors to initiate SDM and engage in a shared decision 
making process. Patients are often unaware that multiple options are available and that 
their preferences matter to select their personally optimal treatment option 51. Doctors 
frequently misinterpret the desired level of patient involvement and overestimate the 
extent of SDM they already display 52-54.
To overcome these barriers in the execution of SDM, a variety of decision support 
interventions have been developed, of which decision aids (DAs) are the most 
comprehensive 55. DAs come in multiple formats, ranging from concise paper leaflets 
to elaborate online tools. Regardless of their format, DAs provide balanced information 
about treatment options, with equal attention for the advantages and disadvantages of 
all options. DAs aim to help patients achieve an informed treatment preference. Some 
DAs therefore include implicit or explicit exercises to help patients to clarify personal 
values 9, 10, 56. Quality criteria to guide DA development are provided by the International 




A Cochrane review of the effects of DAs for various medical and screening decisions, 
including 105 RCTs, reveals that with a DA, patients are more knowledgeable, have more 
accurate expectations, and are more aware of what matters most to them 10. In terms 
of quality of care, DAs help doctors and patients to talk more about really matters; not 
only what is medically possible, but also which goals the patient would like to achieve 
with treatment. In this way, a DA helps to lower decisional conflict, and establish a more 
valued patient-doctor relation. Increased satisfaction is often found for satisfaction with 
the choice, and the process of decision-making, including the preparation. However, 
satisfaction with the DA or overall information satisfaction has been studied less. Long-
term studies into effects on regret are also rare. Overall, exposing patients to DAs does 
not seem to lead to adverse reactions, such as increased anxiety levels 10.
Implementation
Although many studies found beneficial DA effects, uptake of DAs in routine clinical 
care is still low, and existing Pca specific DAs vary in quality 10, 55, 58, 59. Research on 
implementation of DAs in routine clinical practice, including Pca care, is also scarce 
60. Consequently, much of the current DA results are obtained within the setting of 
RCTs, which limit the external validity of these findings for daily routine practice 61, 
62. Moreover, many DA studies were single center studies, with small samples 10. This 
supports the need for a more pragmatic approach with multiple study sites, to enhance 
structural implementation and gain a better understanding of the effects of decision 
aids in regular, everyday clinical practice. The research and implementation project 
described in this dissertation has been designed with those aims in mind, as described 
in more detail below. 
Studies that did report DA implementation results have mostly been limited by a 
focus on the number of distributed DAs only 45, 63. The relative reach within the patient 
population, or actual usage of the tool is therefore often unknown 45, 64. Web-based 
DA dissemination provide opportunities to track usage, but usage can often not be 
linked to patient-reported outcomes (e.g. decision conflict, or DA evaluation). The 
studies reported in this dissertation aimed to provide a more structured approach 
to the evaluation of implementation by reporting about (1) reach within the eligible 
patient sample per hospital, about (2) actual usage in terms of usage of the different DA 




For dissemination of the DA in clinical routine we followed the Ottawa Hospital Research 
Institute (OHRI) Implementation Toolkit, which is based on the Knowledge to Action 
Framework 65-67. The OHRI Toolkit describes five steps to implement DAs in clinical 
routine; 1. Identify the decision; 2. Find patient DAs; 3. Identify implementation barriers 
and explore ways to overcome them; 4. Implement DAs; 5. Monitor use and outcomes. 
In the research and implementation project presented in this dissertation, the decision 
that should be supported is the treatment choice in early-stage Pca (step 1). A suitable 
DA to be used within Dutch clinical care was developed as part of the current research 
project, building on a pre-existing, patient DA for Canadian patients with early-stage Pca 
(step 2). The third step from the OHRI Toolkit, concerns barriers (as well as facilitators) to 
DA use and SDM implementation. Important implementation barriers that are known 
from the literature8, 50 include that patients do not feel knowledgeable enough and 
perceive a power imbalance in the patient-doctor relation. Doctors are insufficiently 
trained to initiate SDM and use DAs during clinical counseling, and often report time 
constraints to introduce and use DAs.  Facilitators include that tools must not be 
disruptive of common routines, and easy to use 8, 50, 55. To assess the extent to which the 
current DA was still prone to these barriers and facilitators, patients and care providers 
evaluated them in questionnaires as part of the studies included in this dissertation. 
Implementation of DAs (step 4), followed a pragmatic approach in the current study, by 
allowing hospitals to include the DA within existing information routines. The DAs web-
based design allowed to track and link usage to reported outcomes (step 5).
Next to the number of DAs distributed, usage of the DA, and patient and care providers´ 
evaluations of barriers and facilitators, evaluation of implementation requires a broader 
approach. Besides the tool itself, and its users (patients and care providers), also the 
organization (e.g. hospital management) and external context (e.g. legislation, clinical 
guidelines) in which the DA is embedded, should be taken into account. Such a broad 
evaluation approach is provided by the Measurement Instrument for Determinants of 
Innovation (MIDI), which identifies barriers and facilitators at these four levels 68. The 
first level consists of the innovation itself. In case of a DA this relates to aspects such as 
flawless functioning, and user-friendliness.  The second level focuses on the user. With a 
DA, this relates to both the care provider who introduces the DA (e.g., received training), 
and the patient who actively engages with the tool (e.g., expectations prior to usage). At 
the third level is the hospital management that should provide sufficient resources (e.g. 
time, people, money) to work properly with the DA. Finally, the fourth level is the socio-
political level to which the DA should comply. With the DA this relates to the content 
that should be consistent with relevant clinical guidelines and to the technical usage 
aspects which should comply with privacy legislations.  
18
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To investigate DA efficacy in a real world context, and to enable a thorough 
implementation analysis, the pragmatic cluster randomized trial reported in this 
dissertation was set up according to a hybrid effectiveness-implementation design, 
where simultaneous to testing the intervention, data was gathered on implementation 
69. In sum, the value of this dissertation lies in the pragmatic approach to contribute to 
the limited knowledge on implementing DAs in routine practice, while still being able 
to test the DA in a solid manner.  
AIMS AND ORGANIZATION OF THIS DISSERTATION
The main objectives of the studies presented in this dissertation were:
• To assess the current state of information provision, and the impact of diagnosis 
and treatment decision-making in Pca care on patient-reported outcomes;
• To develop an online Dutch DA with values clarification exercises to support Pca 
treatment decision-making;
• To assess the impact of this online treatment DA on patient-reported outcomes and 
care providers’ evaluations;
• To analyze implementation results of the current DA and two other novel Dutch Pca 
treatment DAs.
SDM requires an active patient role, and DAs can help patients in achieving such a role. 
The aim of Chapter 2 was to investigate in a sample of Pca patients who already made a 
treatment decision in the past (average 48 months ago), what role preference they have, 
and how this role preference was associated with their satisfaction with the information 
that was received at the time of decision-making.  To more closely investigate the 
impact of receiving a Pca diagnosis and the subsequent decision-making process, 
Chapter 3 describes the changes in health-related quality of life (HRQoL) in the time 
between undergoing biopsy (pre-diagnosis) and making a decision about treatment in 
case Pca was detected. Furthermore, it was assessed if personality traits were associated 
with changes in HRQoL.
The development and pilot-testing of the DA that was developed is described in 
Chapter 4. The rationale and study design of the pragmatic, cluster randomized Prostate 
Cancer Patient Centered Care (PCPCC) trial are presented in Chapter 5. The aim of the 
PCPCC trial was to assess the impact of the DA on patient-reported outcomes, and care 




The patient-reported outcomes are presented in two parts. First, Chapter 6 presents 
effects of the DA on patient-reported decision process outcomes immediately after 
treatment decision-making, with decisional conflict as primary outcome measure, 
and knowledge and satisfaction as secondary outcomes. Satisfaction was assessed in 
terms of information satisfaction, and preparation for decision-making. Anxiety and 
depression symptoms were included as covariates, as they could potentially be affected 
by the DA, as well as have an effect on the other outcomes. Secondly, in Chapter 7, 
a 12-months follow-up is presented with the effects on decisional regret (primary), 
treatment satisfaction and information satisfaction (secondary) are presented. It was 
expected that undergoing treatment and experiencing potential side-effects could 
influence how patients in retrospect would evaluate the information that was received. 
Besides anxiety and depression, the patient-doctor relation was included as covariate. 
The aim of Chapter 8 was to compare care providers’ evaluations of DA counseling 
to standard information routines. Implementation and usage results of the DA are 
presented in Chapter 9. 
Next to the DA studied in the previous chapters of this dissertation, two other Pca DAs 
were developed and tested simultaneous in The Netherlands. In Chapter 10, a joint 
evaluation of the implementation results is presented. 
In Chapter 11, the main findings of this dissertation will be discussed, and the 
implications for future research and clinical practice are outlined. 
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PROSTATE CANCER SURVIVORS WITH A 
PASSIVE ROLE PREFERENCE IN TREATMENT 
DECISION-MAKING ARE LESS SATISFIED WITH 
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Objective - To investigate decision-making role preferences and their association with 
the evaluation of information received in a sample of low and intermediate risk prostate 
cancer (Pca) survivors. 
Methods - Cross-sectional study involving 562 men diagnosed with low or intermediate 
risk Pca (median time since diagnosis of 48 months), measuring preferred decision-
making role (Control Preference Scale) and the evaluation of information received 
(EORTC QLQ-INFO25). Analyses were performed using ANOVA, chi-square tests and 
multivariable linear regression models.
Results -  Men who preferred a passive role were older and less educated than other 
preference groups and more often selected a non-invasive treatment option (all with 
p<.001). The passive role preference group reported having received less information, 
judged the received information as less helpful and indicated lower overall satisfaction 
with information received (all with p<.05). Role preference groups did not differ in their 
desire to receive more information.
Conclusion - Compared to non-passive preference groups, the preference for a 
passive role in Pca treatment decision-making is associated with less satisfaction with 
information received.  
Practice implications - Assessment of role preferences and tailored information-
provision could improve satisfaction with information received and perhaps may 
ultimately lead to improved patient participation in treatment decision making. 
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1. INTRODUCTION
Shared decision-making (SDM) is widely recognized as best practice in preference-
sensitive treatment decision-making 1-3. Following the principles of SDM, a clinician 
shares the best available evidence on the treatment alternatives and the patient 
receives support in sharing his personal values and preferences 4. Across several 
medical conditions it has been found that a large majority of patients (75%) prefers 
this collaborative or even a more active role, though leaving a substantial proportion 
of patients (25%) preferring a passive role in treatment decision-making 5. Some 
studies with SDM interventions such as decision support tools show improved patient 
involvement, while other studies show little variability over time, indicating that role 
preferences could represent an intrinsic personality trait that is consistent over time 
and situations 1, 6. Although patients prefer different roles for involvement in treatment 
decision-making, information provision practices are often standardized for all patients. 
Whereas the variation in decision-making role preferences has been studied before, its 
relation with the evaluation of information received has so far remained untested 3, 5, 7, 8. 
The present study aims to investigate the association between decision-making 
role preferences and the evaluation of information received in a sample of low and 
intermediate risk (stage cT1 and cT2) prostate cancer (Pca) patients. Incidence of low and 
intermediate risk Pca is growing due to an aging population and increased use of PSA 
screening 9-11. Available treatments for low and intermediate risk Pca offer oncologically 
equivalent outcomes, but come with different treatment side-effects that could have 
a significant impact on quality of life, emphasizing the need for proper information 
provision and careful determination of patients’ preferences and characteristics 12, 13. 
However, it was found that one in three Pca patients is dissatisfied with information 
received 14. Our hypothesis is that patients with a passive role preference require less 
information than patients with a preference for an active decision-making role. However, 
for satisfaction with information received we hypothesize that patients with a passive 
role preference are equally satisfied with information received as they prefer to delegate 





2.1 Participants and data collection
Seven hospitals in the southern area of the Netherlands Cancer Registry (NCR) 
participated in this study. Per hospital a random selection was made of 150 Pca patients 
who were diagnosed between 2006 and 2009 (stage cT1-cT3).  Patients with a cT3-
stage tumor were later excluded from this sample as their treatment alternatives and 
medical condition are less comparable to the cT1 and cT2 stage. Data was collected 
in October 2011 within Patient Reported Outcomes Following Initial treatment and 
Long term Evaluation of Survivorship (PROFILES). PROFILES is a registry for the study 
of the physical and psychosocial influence of cancer and its treatment from a dynamic, 
growing population-based cohort of both short- and long-term cancer survivors. 
PROFILES contains a large web-based component and is linked directly to clinical data 
from the NCR 15. Urologists sent their (former) patients a letter to inform them about 
the study and to invite them to complete an online questionnaire. On request, patients 
received a paper questionnaire that could be returned in a pre-stamped envelope. 
Patients consented on linking questionnaire data to their clinical data from the NCR. 
Earlier studies on related topics have been carried out within in the same sample 14, 16. 
Our study protocol was reviewed and centrally approved for all participating hospitals 
by the medical ethics committee of one of the participating hospitals.
2.2 Measures
2.2.1 Socio-demographic and clinical characteristics
Clinical and patient information was obtained from the NCR (i.e., date of birth, date of 
diagnosis, disease stage, and initial treatment). The questionnaire included questions on 
socio-demographic variables (i.e., marital status, employment status, and educational 
level).
2.2.2 Preferred decision-making role
The Control Preferences Scale (CPS) was used to assess the role a patient prefers in 
treatment decision-making 17. Responses to this single item question range on a 
unidimensional scale from passive (‘I prefer to leave all decisions regarding treatment to 
my doctor’) to active (‘I prefer to make the decision about which treatment I will receive’). 
The five answer categories are condensed into three categories, with the first two roles 
combined as passive, the middle role as shared decision-making (collaborative), and the 
last two roles as a preference for an active role. The CPS has been used to measure role 
preferences worldwide for multiple medical conditions and proven to be a valid and 
reliable measure 18-20.
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2.2.4 Evaluation of information received
The evaluation of information received was assessed with the EORTC QLQ-INFO25 
questionnaire 21. The EORTC QLQ-INFO25 consists of four subscales which assess the 
perceived receipt of information about (i) the disease; (ii) medical tests; (iii) treatment, 
and (iv) other care services. Additionally, eight single items assess the receipt of 
information in different formats (e.g. written information, information on CDs or tape/
video), evaluation of the amount of information and satisfaction with the amount and 
helpfulness of information. All responses were given on a four-point Likert scale (1- 
not at all, 2-a little, 3-quite a bit, 4-very much), except for four single items that have a 
binary yes/no scale. Subscales were converted to a 0-100 outcome. Reliability of the full 
scale (α >.91) was excellent, subscale reliability (range between α=.74 and α =.89) was 
acceptable to good. 
2.2.5 Health-related Quality of Life
We used a general measure for health-related quality of life (HRQoL) in cancer patients 
(EORTC QLQ C30) and supplemented this with a Pca specific module (EORTC QLQ PR25) 
22, 23. Both scales were used to assess functional outcomes and symptom burden, as a 
previous study reported a negative correlation between HRQol and satisfaction with 
information received 14. All responses were given on a four-point Likert scale (1- not at 
all, 2-a little, 3-quite a bit, 4-very much), except for two single items evaluating Global 
health on a seven-point scale. Subscales were converted to a 0-100 outcome. Reliability 
of the full C30 was excellent (α >.92), for the full PR25 scale reliability was good (α >.77), 
subscale reliability (range between α=.63 and α =.91) was good. Three symptom scales 
(Nausea, Bowel, Hormonal) and one functional scale (Sexual functioning) were excluded 
for further analysis because of poor internal consistency (α <.60)
2.3 Statistical analyses
Patient and tumor characteristics were compared between decision-making role 
preference groups by using analyses of variance (ANOVAs) for continuous variables and 
chi-square analyses for categorical variables. Mean scores on the EORTC-QLQ-INFO25 
and HRQoL-scales for different decision-making role preference groups were compared 
using ANOVA and LSD post hoc-tests or chi-square analyses for dichotomous items. 
Independent sample t-tests were conducted to investigate potential differences in 
satisfaction with information received between the two tumor stage groups (cT1 and 
cT2). For all EORTC-INFO-25 subscales linear regression analyses were carried out to 
investigate the association of these scales with decision-making role preference groups, 
controlling for age and educational level as being previously identified variables 
associated with role preferences 5. As we assumed, received information could be 
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different depending on the selected treatment, linear regression analyses were repeated 
per treatment group (active surveillance, surgery, radiotherapy). Multicollinearity was 
checked in all relevant analyses. All analyses were performed using SPSS version 20.0 
(Statistical Package for Social Sciences, Chicago, IL, USA). P-values <.05 were considered 
statistically significant.
3. RESULTS
The questionnaire was completed by 562 participants (71%). Non-responders were 
older than responders (mean 68.9 vs. 66.5, p<.001), men with unverifiable addresses 
did not differ in age compared to responders. Also, no group differences were found 
in tumor stage between respondents, non-respondents and patients with unverifiable 
addresses (p=.306). Questionnaires were filled in with a median of 48 months since 
diagnosis. Time since diagnosis was not correlated to decision-making role preferences, 
(r(612) = .059, p= .141.
3.1 Univariate results
Fifty-nine percent of the responders preferred a collaborative decision-making (CDM) 
role, whereas 19% preferred a passive (PDM) role and 22% preferred an active (ADM) 
role. Men with a preference for a PDM role were on average older, had lower education 
levels and  more often had a lower socio-economic status (SES), compared to men with 
a CDM or ADM role preference (Table 1). 
Men with a preference for an ADM role had more often received surgery or brachytherapy 
as initial treatment, while men with a preference for a PDM role had more often received 
active surveillance or external radiation therapy (p<.001). Role preferences were not 
related to clinical characteristics (tumor stage and Gleason score) or marital status 
(Table 1).
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All 100 (19) 320 (59) 118 (22)
Age at diagnosis, mean (SD) 68.5 (7.1) 66.5 (7.0) 64.0 (7.4) <0.001
 <55 4 (4) 21 (7) 10 (8)
 56-65 34 (34) 114 (36) 66 (56)
 66-75 44 (44) 155 (48) 34 (29)
 76> 18 (18) 30 (9) 8 (7)
Marital status 0.722
 Married/living together 85 (86) 272 (86) 104 (89)
 Other 14 (14) 44 (14) 13 (11)
Education <0.001
 Primary education 21 (21) 45 (14) 13 (11)
 Secondary education 27 (27) 77 (25) 22 (19)
 Intermediate education 36 (37) 121 (38) 34 (29)
 Bachelor or master degree 15 (15) 73 (23) 48 (41)
Socio economic status (SES) 0.018
 Low 15 (15) 53 (17) 15 (13)
 Medium 43 (43) 126 (40) 31 (27)
 High 37 (37) 129 (41) 66 (58)
 Institutionalized 5 (5) 6 (2) 2 (2)
Pathological T category 0.176
 cT1 65 (65) 184 (58) 62 (53)
 cT2 35 (35) 136 (43) 56 (47)
Gleason score 0.272
 2-6 58 (60) 187 (60) 74 (65)
 7 29 (30) 77 (25) 30 (26)
 8-10 9 (10) 48 (15) 10 (9)
Initial treatment (obtained from NCR1) <0.001
 Radical prostatectomy 20 (20) 81 (25) 42 (36)
 Brachytherapy 4 (4) 53 (17) 25 (21)
 External beam radiotherapy 17 (17) 30 (9) 7 (6)
 Surveillance 28 (28) 65 (20) 24 (20)
 Hormone therapy 12 (12) 43 (13) 8 (7)
 Other 19 (19) 48 (15) 12 (10)
Satisfaction with information provision 0.002
 Dissatisfied 46 (48) 92 (29) 33 (28)
 Satisfied 50 (52) 222 (71) 83 (72)
1 Netherlands Cancer Registry
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Men with a preference for a PDM role reported having received less information, 
having perceived this information as less helpful, and reported lower satisfaction with 
information received. Across preferred decision-making roles there was no statistically 
significant difference in the desire for more or less information (Table 2). Effect sizes 
when comparing all three groups were small (table 2) 24. When directly comparing PDM 
and ADM role preference groups, effect sizes range from d=.32 to d=.56, indicating 
a medium effect size 24. Time since diagnosis was not correlated to satisfaction with 
information received or any of the EORTC-INFO-25 subscales (all with p>.05). Five of 
the 17 analyzed HRQoL subscales showed a statistically significant difference across 
decision-making role preferences (table 2). Most relevant differences were found on 
Physical functioning, which was lower for men with a PDM role preference and sexual 
activity, which was higher for men with an ADM role preference (all with p<.05).
As the cT1 and cT2 tumor stages were equally distributed among the subgroups we 
decided to combine both tumor stages in further analyses. 
3.2 Multivariable linear regression
Controlled for age, education, physical functioning and sexual activity, the preference for 
a PDM role was associated with more negative evaluations of the amount of information 
provided on specific content (medical tests, treatments and other services), the overall 
amount of received written information, and the helpfulness and satisfaction of the 
received information (Table 3). To test the assumption if specific treatments affected 
outcomes, analyses were also conducted per treatment group. This did not yield 
treatment specific outcomes (data not shown). Moreover, no hospital specific effects 
were found on the distribution of decision-making role preferences or the evaluation of 
information received (data not shown).
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Table 2. EORTC-INFO-25, QLQ-C30 and PR25 scales means (± SD)
EORTC-INFO-25
Preferred decision-making role
p value η²Passive Collaborative Active
Information about the disease 50.1 (21.3)* 55.6 (22.2) 56.9 (21.6) 0.060
Information about medical tests 53.9 (28.3)* 64.4 (27.4) 66.2 (30.6) 0.003 0.02
Information about treatments 44.9 (29.7)** 56.5 (25.4) 60.5 (26.5) 0.000 0.04
Information about other services 14.5 (19.8)* 21.4 (25.7) 22.0 (27.1) 0.045 0.01
Information about other places of care 15.8 (28.5) 21.0 (31.5) 18.1 (30.1) 0.301
Information about things you can do to help 
yourself
19.4 (28.9) 25.1 (31.1) 24.3 (31.0) 0.283
Written information 63.5 (48.4)** 80.5 (39.7) 83.1 (37.7) 0.001 0.03
Information on CD/audio/video 3.1 (17.4) 4.7 (21.3) 10.2 (30.4)* 0.045 0.01
Satisfaction with information received 52.8 (26.3)* 62.4 (27.4) 62.4 (28.0) 0.008 0.02
Helpfulness of information received 56.8 (27.0)* 67.4 (25.0) 67.3 (26.3) 0.002 0.02
Want more information (%) 26.5% 24.4% 29.7% 0.529
Want less information (%) 3.1% 2.3% 3.4% 0.761
EORTC-QLQ-C30
Global Health 76.8 (17.8)* 78.0 (17.0) 81.5 (17.1) 0.089
Physical functioning 81.4 (18.1)* 85.1 (17.6) 88.3 (17.5) 0.017 0.02
Role functioning 80.7 (27.5) 82.9 (24.7) 86.5 (22.2) 0.219
Emotional functioning 87.0 (17.9) 88.1 (17.7) 90.6 (16.0) 0.277
Cognitive functioning 83.3 (19.4) 84.9 (20.0) 87.1 (18.5) 0.349
Social functioning 89.5 (20.5) 90.5 (18.9) 91.1 (16.0) 0.808
Fatigue 19.6 (21.4) 19.5 (21.6) 14.2 (18.4)* 0.053
Pain 14.8 (22.8) 14.1 (22.7) 13.8 (23.0) 0.945
Dyspnoea 20.4 (27.8)* 14.1 (24.6)* 11.3 (20.5)* 0.021 0.01
Insomnia 21.3 (30.9) 18.0 (26.9) 14.1 (23.2)* 0.141
Appetite 3.7 (13.3) 3.7 (13.4) .6 (4.3)* 0.046 0.01
Constipation 6.0 (14.6) 5.9 (17.4) 6.3 (17.0) 0.978
Diarrhoea 7.3 (19.5) 4.7 (14.1) 3.7 (12.9) 0.193
Financial 2.4 (8.7) 5.1 (13.4)* 2.3 (9.5) 0.033 0.01
EORTC-QLQ-PR25
Sexual activity 23.6 (21.2) 26.9 (22.5) 32.6 (23.9)* 0.011 0.02
Urinary 20.7 (15.2) 18.5 (14.3) 17.7 (14.4) 0.292
Incontinence 18.4 (30.3) 14.8 (23.8) 15.9 (25.8) 0.796
* p<0.05 in post hoc LSD-test
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4. DISCUSSION AND CONCLUSION
This study showed that decision-making role preferences are associated with the 
perceived amount of information, helpfulness and satisfaction with information 
received. Men with a PDM role preference indicated having received less information, 
found it less helpful and were less satisfied with the information received. Despite this 
more negative evaluation, men with a PDM role preference did not differ from the 
ADM and CDM preference groups in their desire to have received more information. 
Functional outcomes and symptom burden could not explain the differences between 
decision-making role preferences. 
Previous reports that age and education are related to decision-making role preferences 
were confirmed in our study 5. Overall, younger and higher educated men more often 
preferred an ADM role. A PDM role preference was found more often across older 
and less educated men. Although the response rate in our study was quite good and 
similar to comparable studies from the PROFILES registry 25, 26, we observed that non-
responders in our study were slightly older compared to responders. It should therefore 
be taken in consideration that the proportion of men preferring a PDM role is slightly 
under represented in our sample. It is therefore expected that less non-responders 
would have further strengthened our findings. 
Our finding that men with a PDM role preference were generally more negative about 
information received is surprising as it would be expected from this group to rely less on 
information provided. Although one in four men with a PDM role preference indicated 
a desire to have received more information, this is comparable to what was found in 
men with a preference for an ADM or a CDM role. An earlier study in Pca patients on 
the information needs of the different decision-making role groups found that different 
role preference groups require information about the same topics 27. However, there is 
also evidence that some patients rely to a greater extent to personal factors –like the 
opinion and experience of others- than only the information provided when making a 
treatment decision 28. It could therefore be that it is not the content or amount of the 
provided information that is most troublesome for men with a preference for PDM, but 
that the provided information is not what they primarily  need to base their decision on. 
A previous study on the relation between HRQoL and satisfaction with information 
received in a similar sample indicated an association between functional outcomes, 
symptom burden and the evaluation of information received 14. In the current study 
these HRQoL outcomes were not able to explain the differences between role preference 
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groups on the information scales. This could indicate HRQoL and decision-making role 
preferences both explain separate areas of the variation within the information scales. 
To investigate this causality, a prospective study on this topic is needed.
To improve information provision practices to men with a preference for a PDM role, 
early recognition of role preferences may be needed. Although we found age and 
education level to be associated with decision-making role preferences, we also found 
that the effect of role preferences is still existent when controlling for age and education 
level. Previous studies indicated that demographics like age and education only explain 
20% or less of the variability in preferences 29. Additional explanation for differences in 
preferences could therefore be found in personality variables 30-32. The role of personality 
traits in the involvement in the decision-making process should be investigated more 
thoroughly, so that interventions to support information provision and the decision-
making process could be targeted more specifically. 
The finding in this study that even four years after diagnosis a substantial part of the 
responders indicated a PDM role preference, although having gained knowledge about 
their condition and insights on the consequences of earlier decisions, is somewhat 
surprising. Other studies have found that if preferences are assessed retrospectively, 
more patients indicate a preference for a passive role, particularly in samples of cancer 
patients compared to non-cancer patients 33. This could explain why still 20 percent of 
men indicated a passive role preference in this study. It could also be that experience 
with the decision-making process made patients more aware of the burden and 
difficulty of the decision they faced, increasing the tendency -in hindsight- to prefer 
a less active role. Increased stress levels and the feeling of being overwhelmed by the 
provided information are known to cause impaired cognitive processing 34, 35. This could 
lead to preferring to simplify a complex situation by deferring the decision to a doctor 
overseeing all offered alternatives. Shared decision-making literature also suggests 
disentangling process involvement from the actual decision responsibility 36. This 
implies patients still can have an active role in the process leading to the treatment 
decision, but prefer to leave to actual decision to the clinician.  
We did not observe hospital specific effects on decision-making role preferences, 
which could indicate that the preferences indicated in this study represent a stable 
trait. Further, it may also indicate that there is a certain level of information provision 
all hospitals fulfill to but that the patients’ role preference possibly does not fit this non-
tailored approach in information provision.
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The median time of 48 months between diagnosis and survey carries the risk for recall 
bias. However, if present, it is most likely that this bias is distributed randomly across 
all decision-making role preference groups in our sample. Although it is in the human 
nature that some information is forgotten over time, there is evidence that recall is not 
associated with age 37 38 39. This could be an indication that our finding that older men 
prefer a passive role more than younger men is not caused by a group specific recall bias. 
Though, it should be taken in consideration that the receipt of information following Pca 
diagnosis is likely to be disturbed by the complex nature of the information and emotion 
involved to receiving the diagnosis 40. Compared to that situation, our respondents were 
free from the distress of diagnosis and treatment decision-making at the moment of 
survey. This could reduce generalizability of our results to patients who are closer to 
diagnosis.
Another limitation of this study is that we only measured the preferred decision-
making role post-treatment without having information about the actual role during 
treatment decision-making. While other studies report only small proportions of 
extreme discordance between preferred and experienced role, it is also known that 
role preferences can change during the decision-making process 5 7 36. For this change 
in preference to occur, a patient must be aware of the importance of being involved. 
Often, patients assume there must be one superior treatment option instead of multiple 
preference-sensitive alternatives, and therefore not realizing the actual possibility to 
choose 1. However, all patients in our sample have previous experience in treatment 
decision-making. 
A major strength of this study was the population-based sample of Pca survivors that 
was available. Also, the response rate was high. However, the cross-sectional design 
of this study does not allow to determine causal relations between decision-making 
role preference and evaluation of information received. More research is needed to 
determine the direction in this relationship. 
To broaden our understanding of the nature of role preferences and its relation with 
information provision and treatment decision-making, a prospective study should 
look into the process of patient involvement from the moment of Pca diagnosis. The 
role preferences identified in the current research could be interpreted as a trait, since 
evaluation took place long after diagnosis. This trait could lead to behavior or attitudes 
in patients that cause clinicians to provide less information or misinterpretation of 
preferred roles 41 42. Distress following diagnosis or improved insight in the decision 
40
Chapter 2
could change the trait preference in a state preference for a more active or passive 
role DM 43, 44. A longitudinal study is needed to look into the development of decision-
making role preferences and its consequences for health outcomes 45.
CONCLUSION
We present evidence that the preference for a PDM role is associated with the perception 
of having received less information, less helpfulness of and satisfaction with the received 
information. This research suggests that current information provision practices do not 
optimally fit the needs of patients who prefer a PDM role compared to patients with a 
non-passive role preference. 
CLINICAL IMPLICATIONS
Much of the information in clinical practice is given following standard formats. 
Clinicians should be aware of the fact that even if the provided information is objectively 
of good quality, it does not necessarily fit information needs of patients with a PDM role 
preference. For improving patient-centered care this further emphasizes the importance 
of assessing role preferences throughout the decision-making process and tailor both 
information provision and decisional support to these preferences.
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Objective – To test if patients’ health-related quality of life (HRQoL) declines after 
prostate biopsy to detect Pca, and treatment decision-making in case Pca is confirmed, 
and whether personality state and traits are associated with these potential changes in 
HRQoL.
Methods – Patients who were scheduled for prostate biopsy to detect Pca (N=377) 
filled out a baseline questionnaire about HRQoL (EORTC QLQ-C30 and PR25), ‘big five’ 
personality traits (BFI-10), optimism (LOT-r), and self-efficacy (Decision Self-efficacy 
Scale) (t0). Patients with confirmed Pca (N=126), filled out a follow-up questionnaire on 
HRQoL within two weeks after  treatment was chosen but had not yet started (t1).
Results – HRQoL declined between t0 and t1, reflected in impaired role and cognitive 
functioning, and elevated fatigue, constipation, and prostate specific symptoms. 
Sexual activity and functioning improved. Baseline HRQoL scores were unrelated to the 
selection of a particular treatment, but for patients who chose a curative treatment, 
post-decision HRQoL showed a greater decline compared to patients who chose active 
surveillance. Optimism was associated to HRQoL at baseline, decisional self-efficacy was 
positively associated to HRQoL at follow-up. No associations between HRQoL and the 
‘big five’ personality traits were found.
Conclusion – Patients who have undergone prostate biopsy and treatment decision-
making for Pca, experience a decline in HRQoL. Choosing treatment with a curative 
intent was associated with greater decline in HRQoL. Interventions aimed at optimism 
and decision self-efficacy could be helpful to reduce HRQoL impairment around the 
time of prostate biopsy and treatment decision-making.
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1. BACKGROUND
An aging population and increased use of prostate cancer (Pca) screening contribute to 
a growth in Pca detection in The Netherlands and other Western countries 1-3. When Pca 
is suspected, patients undergo prostate biopsy 4. In The Netherlands only, at least 25,000 
Dutch men undergo this procedure every year, resulting in approximately 10,000 Pca 
diagnoses (Netherlands Cancer Registry, 2015) 5. The largest proportion of Pca diagnoses 
consist of localized cancer (stage I or II), for which surgery, radiotherapy (either brachy or 
external beam), and active surveillance (AS) are seen as equally acceptable treatments 
4, 6. However, adverse effects from treatment can impair patients’ health-related quality 
of life (HRQoL) 7-10. Common side-effects from treatments with curative intent (surgery, 
radiotherapy) include sexual, urinary and bowel-related complaints 9, 11, while AS can 
increase anxiety symptoms due to postponing treatment 12, 13. Therefore, impact on 
HRQoL is an important factor when considering treatment options 14-16.
Changes in HRQoL after Pca treatment are well described, and generally consist 
of a major decline in HRQoL in the first 1-2 years after treatment 9, 17-19. Besides the 
consequences of treatment, changes in HRQoL are related to psychological factors. 
Optimism and self-efficacy are associated with better HRQoL outcomes, while anxiety, 
depression and personality traits (e.g. neuroticism, distress) are associated with worse 
HRQoL outcomes 20-23. However, most of these studies measured HRQoL from diagnosis 
onwards, lacking a pre-diagnosis baseline to also capture the psychological burden 
from prostate biopsy, receiving a Pca diagnosis, and treatment selection. Studies that 
did take a pre-diagnosis baseline, focused on a specific (older) patient population and 
did not measure immediately before and after diagnosis 24, 25.
To increase our understanding about the impact of Pca on HRQoL, including receiving 
a Pca diagnosis and choosing treatment, this study measured HRQoL pre-biopsy and 
post treatment decision-making. Our hypothesis was that a significant decline in 
HRQoL would already appear prior to treatment onset from the psychological burden 
of diagnosis and treatment decision-making. Moreover, we expected changes in HRQoL 





2.1 Participants and recruitment
Between January 2013 and May 2014, ten Dutch hospitals participated in this study and 
recruited 388 patients who were scheduled for a first prostate biopsy due to suspected 
Pca  (Mage=66.5, SD=6.6; Figure 1). A host hoc power analysis revealed that this sample 
size was sufficient to achieve a power of .80 for detecting differences with an effect size 
from Cohen’s d=.2 (with alpha .05). During consultation, patients were informed that the 
goal of the study was to investigate quality of care in prostate examination and quality 
of life of patients undergoing this procedure. Together with an information letter, 
patients received the first questionnaire (t0) on paper and a pre-stamped envelope to 
return the questionnaire. Follow-up questionnaires were sent to patients whose biopsy 
result confirmed Pca. These patients received this second questionnaire and a pre-
stamped envelope at their home address within two weeks after treatment decision-
making (t1). Diagnosis and the moment of treatment decision-making were monitored 
for all included patients from their (electronic) medical record. After review of the study 
protocol, the medical ethics review board of the initiating hospital waived the need for 
formal ethical approval (reference 2012.103) and all participating hospitals approved 
conducting the study. All patients signed informed consent.
2.2 Questionnaires
2.2.1 Demographics and clinical data
Participants were asked to indicate their age, education, marital status, last known 
prostate specific antigen (PSA) level, and choice of treatment. PSA levels were asked 
at both t0 and t1 to control for the possibility that treatment had already taken place 
before completing the t1 questionnaire.
2.2.2 Health-related quality of life
Health-related quality of life (HRQoL) was measured with the Dutch version of the 
EORTC QLQ-C30 questionnaire, which assesses functional HRQoL aspects (physical, 
role, cognitive, emotional, and social functioning, and global health) and symptoms 
common for cancer patients (fatigue, nausea, pain, dyspnea, sleep disturbance, appetite 
loss, constipation, diarrhea, and financial impact) 26. The prostate cancer-specific EORTC 
QLQ-PR25 module was added to assess prostate cancer specific (urinary, bowel, and 
hormonal) symptoms and (sexual) functioning 27. Scale reliability was low for the bowel 
and hormonal symptoms, and sexual activity subscale (alpha’s 0.50-0.60), and adequate 
(alpha ≥0.70) for all other subscales. Similar scale reliability scores have been found 
earlier 27.
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2.2.3 Psychological factors
As possible moderating variables, three measures for individual differences measures 
were included. First, the Big Five Inventory-10 (BFI-10) was included to measure 
extraversion, agreeableness, conscientiousness, neuroticism, and openness; also known 
as the ‘big five’ personality traits 28. The BFI-10 was included in t0. With only two items 
per trait, low reliability scores were found (α<.50), which is common for this scale  29. A 
subsequent confirmatory factor analysis confirmed five underlying factors, with each 
set of two items per trait yielding highest factor loadings.
Secondly, dispositional optimism, a generalized expectation that good things will 
happen, was assessed with the Life Orientation Test-Revised (LOT-R) 30. Some minor 
textual adjustments were made to an existing and previously validated Dutch version 
of the LOT-R 31. Scale reliability was sufficient (α=.67).
Thirdly, the Decision Self-Efficacy Scale was used as a subjective measure of the 
perceived ability to make a healthcare decision 32. Rather than focusing on one specific 
decision, the goal of this scale was to measure feelings of self-confidence in a healthcare 
setting.  The scale was included at t0 to measure a person’s baseline decisional self-
efficacy before the distress from diagnosis. In absence of an existing and validated Dutch 
version of this scale, a forward-backward translation was made by two researchers and 
the result was evaluated and consented on by two other researchers who were not 
involved to the translation. Scale reliability was good (α=.85).
2.3 Statistical analysis
Descriptive statistics are presented as means and standard deviations (SD) for continuous 
variables and as frequencies and percentages for categorical variables. Mean HRQoL 
scores at t0 were compared to the scores obtained at t1 using paired-samples t-tests. 
The association between personality traits and HRQoL scores were assessed using 
bivariate correlation analyses (Pearson’s). Linear regression modelling was carried out 
with global health as dependent variable and personality characteristics as independent 
variables, controlling for age, education, PSA levels and diagnosis (dummy variable; for 
t0 only). All analyses were performed using SPSS version 22.0 (Statistical Package for 




Three hundred and eighty eight patients gave informed consent of which 377 patients 
completed the first completed the first questionnaire (t0, response rate 97.2%). All 
patients whose biopsy confirmed Pca (n=126 patients, 32%), received the follow-up 
questionnaire (t1, response rate 63%) (Figure 1). There were no statistically significant 
differences in demographics between patients with cancer and patients without cancer 
at t0, between responders at t0 and t1, or between responders and non-responders at 
t1. Patient demographics are presented in Table 1.
3.1 Health-related quality of life
At the pre-biopsy baseline (t0), HRQoL did not differ between patients whose biopsy 
result confirmed Pca, and patients with a negative biopsy result (Table 2). After 
receiving diagnosis and treatment decision-making (t1), patients reported worse role 
and cognitive functioning and more symptoms (fatigue, constipation, urinary, bowel, 
and hormonal). Sexual activity and functioning improved after treatment was chosen 
(all with p<0.05, Table 2).
 388 patients scheduled for prostate biopsy consented to participate  
          
          
  377 Patients filled out first 
questionnaire (97.2%) 
  11 Patients did not return first 
questionnaire (2.8%) 
  
          
           
254 patients with 
negative biopsy 
result 
 123 patients 
diagnosed with Pca 
 3 patients 
diagnosed with Pca 
 8 patients with 
negative biopsy 
result 
          
          
   126 patients received follow-up 
questionnaire after diagnosis 
   
          
      
 80 patients filled out follow-up 
questionnaire (63.5%) 
  46 patients did not return follow-up 
questionnaire (36.5%) 
 
          
 Figure 1. Patient flow
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Table 1. Demographics







≤ 65 years 106 (44%) 40 (33%) 24 (30%)
66-75 years 115 (48%) 73 (60%) 50 (63%)
≥ 76 years 20 (8%) 9 (7%) 5 (6%)
Education
Low 109 (43%) 48 (39%) 31 (39%)
Medium 60 (24%) 37 (30%) 25 (31%)
High 78 (31%) 36 (29%) 23 (29%)
Other/not specified 4 (2%) 2 (2%) 1 (1%)
Current occupation
Employed 70 (28%) 28 (23%) 15 (19%)
Not employed 183 (72%) 93 (77%) 64 (81%)
Partnership
Partner 224 (89%) 115 (94%) 74 (95%)
No partner 28 (11%) 7 (6%) 5 (6%)
Children
Yes 228 (91%) 118 (96%) 77 (96%)
No 24 (9%) 5 (4%) 3 (4%)
Prostate Specific Antigen (PSA)
≤ 5 ng/ml 42 (17%) 19 (16%) 19 (25%)
5.01-10 ng/ml 125 (49%) 59 (48%) 37 (49%)
≥ 10.01 ng/ml 85 (34%) 44 (36%) 20 (26%)
Selected treatment
Active surveillance 26 (34%)
Radical prostatectomy 22 (29%)
Radiotherapy 28 (37%)
Numbers do not always add up to the same total due to item non-response
Differences between groups did not reach statistical significance 
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Global Health 83.5 (14.8) 83.7 (15.4) 80.7 (16.1) -3.0
Physical functioning 94.2 (10.4) 94.3 (10.1) 92.8 (12.7) -1.5
Role functioning 94.7 (14.9) 96.0 (12.9) 86.1 (24.2) -9.9 ***
Emotional functioning 85.3 (16.0) 85.0 (16.8) 83.4 (19.9) -1.6
Cognitive functioning 91.2 (15.0) 92.3 (12.5) 88.9 (16.9) -3.4 *
Social functioning 95.0 (13.9) 96.2 (10.1) 93.9 (14.3) -2.3
Fatigue 11.4 (17.3) 10.7 (15.5) 17.0 (22.3) 6.3 **
Nausea/vomiting 1.0 (4.7) 1.1 (5.2) 2.4 (11.9) 1.3
Pain 6.8 (15.8) 5.8 (12.6) 9.4 (19.8) 3.6
Dyspnoea 7.7 (16.9) 6.5 (15.3) 6.8 (17.3) 0.3
Insomnia 14.4 (23.8) 13.8 (21.5) 15.0 (25.6) 1.2
Appetite loss 1.9 (8.2) 2.0 (7.9) 4.7 (16.8) 2.7
Constipation 1.7 (8.0) 4.2 (12.7) 7.7 (20.0) 3.5 *
Diarrhea 4.0 (13.4) 3.4 (11.0) 6.8 (18.9) 3.4
Financial difficulties 2.6 (12.3) 0.8 (5.3) 2.6 (12.9) 1.8
Prostate specific
Urinary symptoms 15.9 (13.4) 13.3 (11.8) 17.6 (15.6) 4.3 *
Bowel symptoms 3.0 (6.3) 2.7 (5.8) 5.6 (10.5) 2.9 **
Hormonal symptoms 3.5 (5.8) 3.8 (5.8) 7.0 (9.4) 3.2 ***
Sexual activity 63.1 (21.6) 61.5 (22.2) 65.4 (21.3) 3.9 **
Sexual functioning 22.9 (20.3) 23.4 (19.6) 34.5 (24.0) 11.1 *
All scales are 0-100; for functioning subscales, full functioning is represented by a score of 100, for symptoms, absence of 
symptoms is represented by score of 0.
All comparisons at t0 between patients with and without cancer were non-significant





In case Pca was detected, symptoms and functioning reported prior to biopsy (t0) was 
not associated to selection of a particular treatment. At the time point after treatment 
decision-making (t1), men who chose a curative treatment reported reduced functioning 
and more symptoms compared to men who selected AS (Table 3). No associations were 
found between treatment choice and personality characteristics (data not shown).
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Global Health 86.4 (15.8) 87.9 (10.5) 81.4 (14.4) 75.0 (18.8)
Physical functioning 93.9 (10.1) 94.2 (10.7) 93.3 (13.2) 92.3 (15.3)
Role functioning 97.0 (9.8) 97.0 (9.8) 95.5 (16.0) 79.7 (29.3) **
Emotional functioning 89.8 (14.5) 92.0 (13.0) 85.1 (17.7) 77.6 (23.7) *
Cognitive functioning 90.5 (13.5) 92.1 (10.2) 91.2 (12.1) 85.5 (20.9) *
Social functioning 93.1 (11.0) 99.2 (3.6) * 96.8 (8.6) 90.5 (18.7) *
Fatigue 10.1 (12.8) 8.6 (12.8) 10.5 (16.1) 21.6 (26.8) **
Nausea/vomiting 3.0 (8.4) 2.3 (5.9) 0 (0.0) 16.5 (2.7)
Pain 5.3 (14.9) 3.0 (8.4) 7.0 (14.3) 15.4 (25.8)
Dyspnoea 7.6 (14.9) 6.1 (16.7) 7.9 (19.7) 8.8 (20.0)
Insomnia 9.1 (15.2) 6.1 (16.7) 16.7 (24.2) 22.8  (31.1)
Appetite loss 4.5 (11.7) 1.5 (7.1) 2.6 (9.1) 8.8 (22.8)
Constipation 1.5 (7.1) 1.5 (7.1) 4.4 (13.8) 13.2 (26.3) *
Diarrhea 3.0 (9.8) 3.0 (9.8) 4.4 (11.4) 11.4 (24.8)
Financial difficulties 0.0 (0.0) 1.5 (7.1) 0.9 (5.4) 3.5 (17.0)
Prostate specific
Urinary symptoms 19.3 (12.9) 14.1 (10.4) 10.3 (8.7) 19.0 (18.4) **
Bowel symptoms 2.2 (6.3) 2.2 (4.5) 3.1 (5.2) 8.6 (13.4) *
Hormonal symptoms 3.9 (4.9) 5.6 (6.7) 3.0 (4.9) 6.4 (10.0) *
Sexual activity 60.9 (27.3) 63.0 (18.1) 58.6 (20.3) 68.0 (20.9) *
Sexual functioning 25.0 (17.9) 23.8 (19.6) 22.2 (16.4) 29.6 (18.4)
All scales are 0-100; for functioning subscales, full functioning is represented by a score of 100, for symptoms, absence of 
symptoms is represented by score of 0.




Prior to biopsy (t0), optimism was a significant predictor for global health (B=.31, p<.001). 
After receiving diagnosis and treatment decision-making (t1), a positive association 
was found between global health and decisional self-efficacy (B=.29, p=.04). Of the Big 
five traits, extraversion (B=.14, p=.03), and neuroticism (B=-.17, p=.01), were significant 




This study investigated the HRQoL impacts of undergoing prostate biopsy, receiving 
Pca diagnosis and choosing treatment. Prior to prostate biopsy, when Pca is suspected 
but not yet confirmed, HRQoL was similar between patients who were later confirmed 
to have Pca and patients without Pca. When a Pca diagnosis was received, and treatment 
was chosen but had not yet started, patients reported more symptoms and reduced 
functioning compared to the pre-biopsy baseline. HRQoL at baseline did not predict 
treatment choice, but patients who chose a curative treatment instead of AS, reported 
more symptoms and reduced functioning compared to patients who chose AS. Overall 
global health at baseline was related to optimism, after diagnosis and treatment selection 
an association with decisional self-efficacy was found.
4.1 HRQoL outcomes
Differences in HRQoL between patients who selected curative treatment over AS is not 
surprising. Men eligible for AS could be expected to be in a more favorable condition 
compared to men who need (immediate) curative treatment 33. However, it is remarkable 
that most HRQoL differences were not present in our sample at baseline, but were 
only reported after diagnosis and treatment selection. Moreover, the highest level of 
urinary symptoms at t0 were reported by men who later selected AS, while after the 
treatment decision was made, most symptoms were reported by men who selected a 
curative treatment. Therefore, changes in HRQoL appear to be influenced by the impact 
of diagnosis and treatment decision-making, rather than by changes in the patient’s 
physical condition. Possibly, the Pca diagnosis made men more aware of their symptoms 
and led them to attribute their overall condition more to their disease. Increased 
symptom burden and impaired functioning at t1 could also be explained by cognitive 
dissonance reduction 34; consequently of a finalized treatment decision, men could be 
motivated to justify this decision as being the right one. This could have resulted in a 
revised HRQoL evaluation at t1 to make it consonant with the characteristics that would 
fit to the selected treatment 35, 36. If biopsy itself caused a decline in HRQoL, all patients 
should have reported lower HRQoL at t1, while this was only the case for patients who 
chose a curative treatment, patients from the AS group even reported (non-significant) 
improvements 37.
Earlier studies on physical and psychological outcomes in Pca patients highlighted the 
perceived masculinity threat men could experience 38, 39. This threat affects how men 
cope with their condition and the perceived threat could cause a further decline of 
HRQoL after treatment. Although most of the work on masculinity threats in Pca patients 
focused on post-treatment outcomes, it is likely that this perceived threat is already 
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present from diagnosis onwards. In our results, reduced role functioning and increased 
sexual functioning (compensatory behavior) could be indicative for the presence of a 
masculinity threat 40, 41.
4.2 Personality factors
Optimism and decisional self-efficacy were associated with better global health, this 
is in line with previous research that found optimism and decisional self-efficacy to be 
associated with less distress and better coping 21, 42. In the current study, patients scoring 
higher on optimism report better HRQoL prior to biopsy, when Pca was suspected but 
not yet confirmed.. After diagnosis, and a treatment decision was required, optimism 
seemed to play less of a role and decisional self-efficacy, the subjective feeling of 
being able to take the right action, making good decisions and to ask questions, was 
positively associated to HRQoL. This adds to previous findings about knowledgeable 
(and therefore possibly more self-efficated) patients reporting better HRQoL 43.
Instead of focusing on a single trait (e.g. neuroticism), this study investigated a broader 
spectrum of the big five personality traits. At t0, extraversion and neuroticism were 
related to global health, while at t1 no relations were present anymore. Hence, we found 
no evidence of a moderating role of specific traits affecting changes in HRQoL. Another 
explanation could be that the brief measure we used was not sensitive enough to also 
detect statistically significant differences in the smaller t1 sample. Future studies should 
use more extensive measures to investigate this relation in more detail.
4.3 Study limitations
Some limitations need to be discussed.  First, no detailed clinical data about tumor 
stage was available, and PSA was self-reported by participants. However, patients were 
only eligible for inclusion if Pca was suspected, following pre-biopsy screening (rectal 
examination and PSA testing). Therefore, we were still able to sample a homogeneous 
patient population. And although we had no registration of the number of patients 
refusing participation, the average Pca detection rate in our sample was similar to what 
was expected based on literature 5. Secondly, drop-out of men without Pca diagnosis 
and non-response at t1 led to a limited number of patients per treatment group available 
for further analyses. Moreover, the comparison between t1 and t0 on group level had 
sufficient power, however, the subgroup comparisons were lacking power. As we found 
no statistically significant differences in patient characteristics between responders 
and non-responders, we estimate the risk for selection bias was low. Our results should 
therefore be seen as exploratory findings on the development of HRQoL in Pca patients 




Based on the changes in HRQoL we found in this study, future studies should focus on 
determining the impact of the individual aspects of undergoing biopsy, receiving Pca 
diagnosis, and selecting treatment. Compared to the current design, this would require 
an additional measurement in between receiving diagnosis and making a treatment 
decision.
Furthermore, the current study did not follow-up on patients with a negative biopsy 
result. To have a complete comparison of HRQoL after prostate biopsy, post-biopsy 
HRQoL should also be compared between patients with a positive and patients with a 
negative biopsy result. Recently, a prospective study found similar HRQoL before and 
after diagnosis between Pca patients on AS and a non-cancer control group, indicating 
HRQoL of patients on AS is similar to that of patients without cancer 44. However, it 
would be interesting to investigate if decisional self-efficacy is still associated to HRQoL 
outcomes when no treatment decision has to be made.
4.4 Clinical implications
This study emphasizes the impact of undergoing prostate biopsy, receiving a Pca 
diagnosis, and selecting treatment. Clinicians’ should be aware that optimism and 
decisional self-efficacy are associated to HRQoL prior to treatment onset. To ensure 
that optimism does not backfire post-treatment, it is important to ensure accurate risk 
perceptions in patients about the chances of treatment success and the occurrence of 
treatment side-effects. Interventions to stimulate shared decision-making, like decision 
aids, could be helpful for achieving this, as well as to contribute to patients’ decisional 
self-efficacy levels 45.
4.5 Conclusion
So far, most studies investigating HRQoL in Pca patients have focused on the impact 
of treatment, while neglecting the psychological burden caused by diagnosis and the 
treatment selection process. This study showed that prior to treatment onset, patients 
reported reduced functioning, more symptoms and lower overall global health, in 
particular if a curative treatment was selected. During clinical counseling, managing 
optimism when Pca is suspected (before and after biopsy) and (decisional) self-efficacy 
when Pca is confirmed, could help to reduce the pre-treatment impact on HRQoL.
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A GLOBAL, INCREMENTAL DEVELOPMENT 
METHOD FOR A WEB-BASED PROSTATE CANCER 
TREATMENT DECISION AID AND USABILITY 







L.V. van de Poll-Franse




Many new decision aids (DAs) are developed while aspects of existing DAs could also 
be useful, leading to a sub-optimal use of resources. To support treatment decision-
making in prostate cancer (Pca) patients, a pre-existing evidence-based Canadian DA 
was adjusted to Dutch clinical setting. After analyses of the original DA and routines in 
Dutch Pca care, adjustments to the DA structure and content were made. Subsequent 
usability testing (N=11) resulted in 212 comments. Care providers mainly provided 
feedback on medical content, patients commented most on usability and summary 
layout. All participants reported the DA was comprehensible and well-structured and 
would recommend DA use. After usability testing final adjustments to the DA were 
made. The presented methods could be useful for cultural adaptation of pre-existing 
tools into other languages and settings, ensuring optimal usage of previous scientific 
and practical efforts and allowing for a global, incremental DA development process.
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BACKGROUND
Decision aids (DAs) are tools designed to support the process of shared decision making 
(SDM) between patients and their clinician 1, 2. DAs can have multiple formats (e.g. leaflets, 
website), but should at least create choice awareness, offer balanced information and 
stimulate patients to consider their preferences 3. In general, DAs are associated with 
increased knowledge, more accurate risk perceptions and more conservative treatment 
preferences 4. The International Patient Decision Aids Standards (IPDAS) provides DA 
developers consensus-based criteria to ensure DA quality 5. To help DA developers, a 
checklist is available that includes nine categories to which the DA should comply (e.g. 
Provide sufficient information about the decision and using high quality evidence) 6.
A particularly fruitful area for the application of DAs is prostate cancer (Pca) care. Pca 
is the most common cancer in men in the Western world 7. Pca treatment guidelines 
do not indicate a single superior treatment option but recommend a shared treatment 
decision between clinician and patient 8. However, selecting the best suiting treatment 
from the available alternatives can be a burden for many patients. The process involves 
careful consideration of the risks and benefits of multiple treatments and weighing 
this against preferences and personal characteristics. Decision-making is further 
complicated by sub-optimal information provision and a possible misinterpretation of 
patient preferences by clinicians, which emphasizes the potential benefits from DAs in 
Pca care 9-11.
Recent reviews of Pca DA trials concluded that current Pca DAs provide good quality 
information and help to increase patients’ knowledge 12, 13. Despite improved information 
provision, current DAs do not guarantee that SDM takes place. Moreover, content, format 
and presentation of Pca information within DAs varied substantially, with many failing 
to comply to all components of the IPDAS criteria 12, 13. The most identified shortcomings 
consisted of not including physicians and patients during DA development, a lack of 
balanced information on all options and the absence of explanation about the evidence 
used in the DA 13. Rather than resolving these issues with current tools, often new tools 
are developed elsewhere. This further increases the variety and number of available 
tools, though routine use in clinical practice of these tools remains limited 14.
As many care providers articulated the need for a suitable Dutch DA, we built an 
interactive website based on an existing evidence-based online Canadian DA, developed 
by Feldman-Stewart and colleagues 15-19 as a starting point for further development 
in the Dutch situation. This paper describes the development process of the DA and 




The DA development process and usability testing among relevant user groups 
consisted of six stages and was based on the model described by Kushniruk 20. 
This model describes the typical system development starting from initial analysis, 
prototype development and evaluation, but allows for more input and changes in 
every development step compared to more traditional methodologies that have a fixed 
order of steps. Each stage was worked on by a multidisciplinary development team of 
urologists, psychologists and engineers (N=6). This section will discuss the stages in the 
development process, the final DA as outcome is described in the results section.
Stage 1: Translating the pre-existing DA
The background and validation of the existing Canadian DA has been described 
thoroughly, with particular focus on the information needs of Pca patients when making 
a treatment decision 15-19. The validity of all topics covered by the original DA for Dutch 
patients was also confirmed by an earlier cross-country comparison (including The 
Netherlands) of information needs in prostate cancer patients 21. Therefore, all content 
from the original DA was translated from English to Dutch.
Stage 2: Evaluating Dutch clinical routine
To investigate typical conversation flow in consultations about Pca treatment decision-
making, all non-clinicians within the development team observed consultations between 
patients and urologist in the outpatient clinic of the initiating hospital. In addition to 
these observations of actual consultations, role playing was used to emphasize the 
steps clinicians usually take in treatment decision-making consultations with a patient. 
Role playing was performed by the two clinicians involved in the development team, 
with one of them simulating the patient role. Other members from the development 
team observed with special focus on the structure of the simulated consultations.
Stage 3: DA re-design
Following the observations from stage 2, the original DA was re-designed to fit with 
typical conversation flow as observed in stage 2. Moreover, the translated textual content 
from stage 1 was further adjusted to comply with Dutch and European treatment 
guidelines. All content was re-written according to standards for creating web-based 
text to ensure readability and comprehensibility for all literacy groups (e.g. maximum 
of 10-15 words per sentence and 5-10 sentences per paragraph, clear headings and 
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active phrasing) 22 23. Readability and comprehensibility was later assessed by an expert 
in medical communication from the initiating hospital, who was not involved to the 
further development of the DA.
Stage 4: Development of explicit values clarification exercises
For use in patient decision aids, IPDAS defines that values clarification exercises (VCEs) 
should ‘help patients to clarify and communicate the personal value of options’, in order 
to ultimately increase congruence between personal preferences and the selected 
treatment option 24. However, without clear design guidelines for VCEs a variety of 
exercises have been developed with little knowledge about which features actually 
work best 25-27 28 . A recent review suggests that VCEs should at least include trade-offs 
between option attributes in order to encourage value congruent decision-making 29. 
Therefore, from all topics covered in the DA, those topics that differentiate between 
treatments were selected to create explicit VCEs. To present these topics as a trade-off, 
statements were presented in such way that an answer to each statement was related to 
a (type of ) treatment. VCEs were developed within the development team and reviewed 
from the perspective of the disciplines present in the development team (urology, 
psychology, engineering design). After consensus by the development team, VCEs were 
added to the DA. The content and phrasing of the VCEs was further evaluated during 
usability testing.
Stage 5: Usability testing
After completion of the first version of the adjusted DA a usability test was conducted 
among patients and care providers (N=11).
Setting and participants
Participants for usability testing were recruited in the initiating hospital in the southern 
region of The Netherlands, by the clinicians from the development team. Four urologists 
(not involved to the DA development), two oncology nurses, one radiation oncologist 
and four Pca patients with recent experience in Pca treatment decision making agreed 
to participate in usability testing. All patients were between 55 and 65 years of age and 
within six months of Pca diagnosis. Patients with experience in the decision situation 
were selected because they were expected to be better able to imagine the situation 
of just having received a Pca diagnosis 30. IPDAS therefore also requires that DA testing 
is performed by experienced patients 6. Care providers were included in this usability 
test to ensure the DA content and usability would match their usual routines and their 
experiences with patients facing Pca treatment decisions. Also, care providers’ review 
during development is required by IPDAS 6. All care providers included in usability 
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testing were affiliated to the initiating hospital, but not involved in any other stage of 
DA development. Care providers ages ranged from 35 to 60 and all had a minimum of 
five years of experience in their current position. All participants were instructed to use 
the DA from the perspective of a patient diagnosed with low-risk Pca and eligible for all 
four treatments covered in the DA (active surveillance, surgery, brachytherapy, external 
beam radiotherapy). No specific further usage instructions were given in order to let 
participants use the DA as naturalistically as possible.  
Participants were asked to think aloud when navigating through the DA and to 
mention every remark or difficulty they encountered during DA usage. This procedure 
is commonly used to investigate human-computer interactions and has been applied 
before for DA usability testing as well 31. The usability test was run in two simultaneous 
sessions in the outpatient clinic of the initiating hospital, with two observers from the 
development team present in each session. The observers monitored if the participants’ 
verbalization matched their DA usage (e.g. saying navigation was easy accompanied by 
clicking on the correct buttons). As the DA only consists of a limited number of steps, 
if any action was not verbalized by the participant, a clarifying question was asked to 
the participant. During DA usage participants did not receive further feedback or other 
instructions from the observers. Each participant was given 30 minutes to use the DA 
followed by a fifteen minute semi-structured interview. The goal of the interview was to 
reflect on DA usage in addition to the comments made while using the DA. Interviews 
are commonly added to think-aloud procedures to ensure that the most important 
aspects have been covered during the usability test and to reduce the risk of bias in 
the interpretation of participants’ verbalizations 32. The interview covered five questions 
asked to all participants: 1. ‘What were your expectations upfront?’ 2. ‘What is your first 
impression of the DA?’ 3. ‘Was the information understandable and useful?’ 4. ‘What were 
positive aspects?’ 5. ‘What can be improved?’ Only patients were then asked: 1. ‘Would 
you recommend this to other patients?’ and 2. ‘What feeling did the DA gave you?’ Care 
providers were asked if they would offer this DA to patients. Participants were then 
thanked for their participation and received a bottle of wine as token of appreciation 
for participating.
Measures and Analysis
As a first step, all notes from all sessions and observers were combined and labeled 
as either general comments about the DA or related to a specific section of the DA. 
All comments were then further categorized to Usability, Layout, Language, Content, 
Amount, Values Clarification or DA Summary. Next, the accuracy and urgency of all 
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comments was discussed by the development team to determine the implications for 
DA adjustments. If consensus was reached on the need for changes, this led to final 
adjustments in the DA.
Stage 6: Final adjustments
Usability testing resulted in final adjustments to the DA (described in Results section). 
Finally, the DA was evaluated for compliance with the IPDAS criteria 6.
RESULTS
Decision aid
Stage 1 resulted in a plain text translation of the original Canadian DA on a prototype 
website. From the observations of conversation flow in clinical practice (stage 2) it 
was learned that following diagnosis clinicians often do not go into detail about all 
treatment options immediately. If eligible for active surveillance, treatment options are 
first presented as a consideration between active surveillance and curative treatment, 
before curative treatments options are discussed in more detail. In order to tailor the 
DA to this typical conversation flow during consultation, the DA was designed into four 
steps. Table 1 provides an overview of all topics covered in DA steps 1 to 3.
DA step 1: General Pca information
This introducing step provides background information about Pca in general. The 
anatomy of the prostate and the commonly used terms PSA and Gleason are explained.
DA step 2: Active surveillance versus curative treatment
The pros and cons of not treating immediately are compared to (immediate) curative 
treatment (Table 1). Specific treatment characteristics are not yet discussed in detail. 
Step 2 ends with VCEs on topics that require trade-offs between curative treatment and 
AS (Table 2).
DA step 3: Surgery versus radiotherapy
If patients are still undecided or have a preference for curative treatment following 
step 2 they continue to step 3. This step explains the difference between surgery and 
radiotherapy in more details (Table 1). An example page from this step is provided in 
figure 1. Patients who already prefer AS after step 2 are allowed to skip this step. Step 3 
ends with VCEs on topics that differentiate between surgery and radiotherapy (Table 2). If 
patients already indicated a preference for AS in step 2, continuing with step 3 is optional.
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Table 1. Content covered in Dutch DA
Step 1: Introduction
What is prostate cancer?
What do PSA and Gleason mean?
How does prostate cancer progresses?
What is the effect on my life expectancy?
Step 2:  Curative treatment versus active surveillance
What is active surveillance?
What treatments are there? 
What are the advantages?
What are the disadvantages?
What are the risks?
What is the chance of a rising PSA?
What is the risk of dying from prostate cancer?
Step 3: Surgery versus radiotherapy
What is the procedure for surgery?
What is the procedure for radiation therapy?
What are the advantages?
What are the disadvantages?
What is the risk for erectile dysfunction?
What is the risk for bladder dysfunction?
What is the risk for bowel problems?
How do I know if treatment was successful?
What if the cancer progresses or treatment is not successful?
DA step 4: Summary
An overview of how many topics have been read and the responses to VCEs are provided 
in a printable summary at the end of the DA (figure 2). This summary can be taken 
by the patient to the next consultation with the clinician in order to further facilitate 
shared decision-making. Alternatively, the summery can be accessed online during 
consultation.
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Table 2. DA Values clarification Exercises (VCEs)
Step 2:  Curative treatment versus active surveillance
Topic Reasons for active surveillance Reasons for treatment
Acceptance of deferring 
treatment
I am confident enough that I will be treated on 
time
I do not want to postpone treatment 
because I do not want to be too late
Avoiding possible 
unnecessary treatment
If treatment might be unnecessary,I would rather 
wait
I prefer treatment,even if it might be 
unnecessary
Acceptance of treatment 
side-effects
I find possible treatment side effectslike erectile 
and urinary dysfunctions difficult to accept’
I find the possible treatment side effects 
acceptable’
Step 3: Surgery versus radiotherapy
Topic Reasons for surgery Reasons for radiotherapy
Treatment procedure I find it important that all cancer cells are 
removed from my body
I find it important that the cancer cells 
die andnot grow further
Treatment side-effects I find bowel problems worse than incontinence I find incontinenceworse than bowel 
problems
Secondary treatment I am comforted by the thought that I can have 
radiation if surgery is unsuccessful
I accept that surgery is difficultafter 
radiation
Fear for surgery I am not anxious about surgery I am anxious about surgery
Usability testing
Usability testing resulted in 212 usability and content comments. Care providers 
mainly reported feedback on the specific radiotherapy related content, a need for more 
descriptive notes to accompany the illustrations and risk representations. Patients 
mainly reported usability remarks and comments about the DA summary section. 
All participants reported that the writing style was comprehensible and that the DA 
structure and navigation were clear. A summary of the results from the think-aloud 
procedure and interview results are presented in Table 3. In addition to the usability 
items, all care providers (100%) indicated they would offer the DA to patients and 
all patients (100%) indicated they would recommend the DA to other patients. After 
discussion of the results in the development team, three main adjustments to the final 
DA were made: (1) accompanying legends were added, (2) radiotherapy content was 
adjusted, and (3) the DA summary section was simplified. The final version of the DA 
complied to all IPDAS criteria 6 (Table 4).
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Figure 1. Screen from DA step 3, information about active treatments
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DISCUSSION
This paper describes the development of a Dutch Pca treatment DA, based on an 
evidence-based Canadian Pca treatment DA and the subsequent usability testing 
among relevant user groups. Results of usability testing show that the DA was evaluated 
positively by patients and care providers and both groups would recommend use of 
the DA in clinical practice. The described development method could be useful for 
adaptation of other pre-existing and validated tools to different cultural or local 
circumstances.
Development of DAs is an effortful process and usually involves multiple rounds of 
assessing needs, required content and preferred structure among patients and care 
providers 33. An important benefit of the proposed model of adapting a pre-existing 
tool is that these steps are already taken. For the current DA, the content was previously 
validated 15-19, and a cross-cultural comparison also confirmed importance of the 
included topics to Dutch patients 21.
The availability of validated content made it possible to focus more on the fit between 
DA structure and typical conversation flow in routine clinical practice. Many DAs have 
been developed for use independent from the consultation 34, which may have led to 
a suboptimal fit between conversation flow during consultation and DA structure. A 
known barrier related to limited DA uptake in clinical practice is that clinicians often 
find DAs impractical to use or that other consultation specific factors limit structural 
DA implementation 35. Therefore, additional observations of clinical consultations and 
role playing took place and identified a two-step approach in discussing Pca treatment 
alternatives with patients. Instead of offering four alternative treatments simultaneous, 
a first step contains choosing between active surveillance and curative treatment and a 
second step discusses curative treatments in more detail. By also transferring this two-
step approach from consultation into the DA, it is expected that patients experience a 
more natural fit between consultation and DA usage. Moreover, the DA provides direct 
support to the clinician’s explanation.
To further improve facilitation of SDM we added two features to the DA. First, VCEs were 
developed and added to the DA. Second, the DA ends with a printable summary of 
preferences and responses to the VCEs that the patient can bring to his clinician for 
discussion. The summary provides the clinician with insight on what matters most to 
the patient and to what extent the patient has formed a preference or is still undecided. 
The following consultation and additional decisional support (e.g. consultations with 
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nurses, radiotherapists) can then be adjusted accordingly. A cluster RCT is in progress 
to evaluate the efficacy of this DA and to test whether decision outcomes align with 
patients’ preferences and values 36.
 Literature reports mixed findings from using VCEs in DAs and provide no clear guidelines 
for VCE design 25, 26, 28, 37, 38 .  However, there are indications to assume the benefit of VCEs 
emerge after the decision is made and that VCE design should at least incorporate 
trade-offs between treatment attributes 19, 29. In the absence of design guidelines, 
further development of the VCE within the current DA was based on consensus within 
the development team. However, future research should look into the effectiveness of 
the VCE features used in this DA.
A specific aspect that needs to be investigated further is the labeling of VCE outcomes. 
For the current DA, the development team decided to label VCEs outcomes with 
corresponding treatments. With a strong initial treatment preference (pre-DA) it could 
be that labeling may lead to patients seeking confirmation of their initial preference 
rather than achieving actual preference elicitation or misinterpreting information 39. 
However, for clarity reasons we believed the VCEs should have labeled outcomes to make 
patients aware of the consequence of their preference (e.g. when valuing incontinence 
worse than bowel problems, a patient should place radiation therapy over surgery on 
this topic). With this insight the responses to the VCE contribute to the construction of 
an informed treatment preference. We expect labeled VCEs support this process better 
compared to unlabeled items. To gain more understanding on the development and 
usage of VCEs, more studies are needed to investigate VCE effectiveness and optimal 
presentation formats.
A potential limitation of the current development and usability test was the relatively 
small sample used in usability testing (N=11). However, our sample included all relevant 
user groups; patients, urologists, nurses and a radiotherapist. All participants in usability 
testing consented on the usability and acceptability of the DA to a point where it 
seemed saturation was reached and it was not expected additional participants would 
have resulted in new insights. The point of saturation in qualitative research is often 
reached within 6 to 12 participants 40.
CONCLUSION
The newly developed Dutch Pca treatment DA was evaluated positively by patients and 
care providers, both groups would recommend DA usage to others. Patients consented 
on easy usability and care providers confirmed the accuracy of the provided information. 
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Adapting an existing tool to a (culturally) different setting and adjusting it to local 
circumstances seems a useful alternative to an entirely new development process. This 
could free resources to focus on other important aspects like DA implementation.
Practice implications
The process of developing and testing the DA as described in this paper could be 
applied to the (cultural) adaptation of other pre-existing tools to different languages 
and clinical settings. As it enhances focus on usability and fit with clinical practice, it 
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Background: At an early stage, prostate cancer patients are often eligible for more 
than one treatment option, or may choose to defer curative treatment. Without a pre-
existing superior option, a patient has to weigh his personal preferences against the 
risk and benefits of each alternative to select the most appropriate treatment. Given 
this context, in prostate cancer treatment decision-making, it is particularly suitable to 
follow the principles of shared decision-making (SDM), especially with the support of 
specific instruments like decision aids (DAs). Although several alternatives are available, 
present tools are not sufficiently compatible with routine clinical practice. To overcome 
existing barriers and to stimulate structural implementation of DAs and SDM in clinical 
practice a web-based prostate cancer treatment DA was developed to fit clinical 
workflow. Following the structure of an existing DA, Dutch content was developed and 
values clarification methods (VCMs) were added. The aim of this study is to investigate 
the effect of this DA on (shared) treatment choice and patient reported outcomes.
Methods/design: Nineteen Dutch hospitals are included in a pragmatic, cluster 
randomized controlled trial, with an intervention and a control arm. In the intervention 
group, the DA will be offered after diagnosis, and a summary of the patients’ preferences, 
which were identified with the DA, can be discussed by the patient and his clinician during 
later consultation. Patients in the control group will receive information and decisional 
support as usual. Results from both groups on decisional conflict, treatment choice 
and the experience with involvement in the decision-making process are compared. 
Patients are requested to fill in questionnaires after treatment decision-making but 
before treatment is started, and 6 and 12 months later. This will allow the development 
of treatment satisfaction, decisional regret and quality of life to be monitored. Clinicians 
from both groups will evaluate their practice of information provision and decisional 
support.
Discussion: This study will describe a web-based prostate cancer treatment DA with 
VCMs. The effect of this DA on the decision-making process and subsequent patient 
reported outcomes will be evaluated.






Prostate cancer (Pca) is the most common malignancy in men in the western world, and 
in The Netherlands where more than 10,000 new prostate cancer patients are diagnosed 
each year 1. Incidence is still growing due to earlier detection and an ageing population 
2-4. Based on demographic developments only, the incidence of prostate cancer in The 
Netherlands is expected to increase by 49% between 2011 and 2030 5.
For the treatment of localized (low and intermediate risk) prostate cancer, the most 
common curative treatment options include radical prostatectomy, external beam 
radiotherapy (EBRT), and brachytherapy. Each curative treatment option has a specific 
risk profile concerning the occurrence of treatment side effects (for example. impotence, 
incontinence, and bowel problems). Because curative treatment may not always be 
necessary as initial treatment for low-risk Pca, active surveillance can be considered a 
valid option for avoiding or deferring the need for curative treatment. Active surveillance 
has some known psychosocial barriers like anxiety and uncertainty about disease 
progression which can withhold patients from choosing this option, although active 
surveillance is increasingly applied in clinical practice 6,7.  Clinical practice guidelines do 
not provide strong treatment recommendations given a lack of convincing evidence 
indicating superiority of any of the available options 8. Choosing the most suitable 
treatment option therefore requires a patient to evaluate the treatment procedure, 
risk for side-effects and the chance of success for all available options. Combined 
with personal preferences and characteristics, identifying the best suitable treatment 
option is a difficult and stressful exercise for many patients 9,10. Further complicating 
factors are clinicians’ misinterpretation of patients’ preferences, (information) needs 
and the patient’s preferred role in the decision-making process 11-15. Eventually, this may 
result in the clinician dominating in the treatment decision-making at the expense of 
the patients’ preferences. It is possible that expressing a dominant clinician view may 
contribute to observed regional variations in the management of prostate cancer 16-20.
During the past decade, several decision aids (DAs) have been developed with special 
focus on prostate cancer care. Instruments range from information booklets to tailored 
web-based tools. The variety in the formats used may have contributed to the finding 
that effects on decisional outcomes have been inconsistent across randomized trials and 
that no effects on choice have been found 21,22. Systematic reviews further emphasize that 
many previous studies are at high risk of selection bias due to inadequate concealment 
or blinding of data collectors and outcomes assessors, and that more studies are needed 
to determine how DAs can be implemented best in clinical practice 21,22.
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Determining the effect of a DA intervention and finding optimal implementation 
methods are both aims of the current trial. A web-based prostate cancer treatment DA 
was developed to fit with Dutch clinical workflow. Based on the structure of an existing 
DA developed by Feldman-Stewart and colleagues 23,24, Dutch content was written and 
values clarification methods (VCMs) were added. Adaptation of the DA was based on 
the International Patient Decision Aid Standards (IPDAS) 25.
METHODS/DESIGN
Objectives and hypothesis
The main objective of this study is to investigate the impact of the DA on shared 
decision-making and treatment choice. It is hypothesized that DA usage will improve 
prostate cancer knowledge and satisfaction with information provision and therefore 
better prepare patients for clinical encounters and the following decision-making, which 
will result in lower levels of decisional conflict compared to standard care. Further, it is 
expected that better knowledge and less decisional conflict will also result in improved 
treatment satisfaction, less regret and ultimately improved health-related quality of life 
(HRQoL). In terms of actual choice we expect less variation in selected treatments in the 
intervention group compared to the control group.
A secondary aim is to investigate optimal implementation, as previous studies 
have emphasized the need to gain more insight on this matter 21. From the patient 
perspective it is expected that some subgroups will experience more benefit from DA 
usage than others. To identify these groups, the moderating role of age, preferred role 
in the decision-making process, specific health skills (for example, health numeracy 
and literacy) and personality on the main outcomes will be investigated. Healthcare 
providers in the intervention group will be asked their opinion about implementation 
of the DA. This will be compared with an evaluation of information provision and 
decisional support as provided by healthcare providers in the control group.
Study design
The design for this study is a two-armed pragmatic, cluster randomized controlled trial 
(CRCT). Clustering is performed at the hospital level, meaning that all included patients 
from a participating hospital are in the same study group. Participating hospitals can 
therefore provide the same type of care to all of their patients, making a CRCT less prone 
to contamination bias 26. The study will be longitudinal, including patients immediately 




outcomes from both arms will be compared.  Involved healthcare professionals will 
be included in a survey-study to evaluate their opinion on working with the DA. A 
comparison will be made with procedures of usual care from the control group.
The description of this design follows the CONSORT recommendation for reporting on 
trials (www.consort-statement.org) with the extensions for pragmatic 27 and cluster 28 
randomized trials.
Randomization
Nineteen Dutch hospitals have been randomized to either ‘usual care’ (arm 1) or ‘usual 
care + DA’ (arm 2). With this so-called pre-randomization, the conventional sequence 
of obtaining informed consent followed by randomization is reversed 29. This pre-
randomization is needed because we make clinicians aware (when introducing the DA) 
of the principles of shared decision-making and the characteristics of the DA. This could 
affect the control group if they were recruited within the same hospital.
To prevent potential imbalance between the two arms that could arise from hospital 
characteristics (for example, hospital size and treatment profile), two strata were 
included in the randomization procedure. First, if cooperation between two hospital 
locations leads to overlap in medical staff or patients visiting both locations, there is 
a risk for contamination bias if these hospital locations are not in the same cluster. In 
our sample, four pairs of hospitals have this overlap in hospital staff or patient visits. To 
maintain variability in hospital characteristics within each cluster, only two pairs were 
allowed to enter the same cluster. The second criterion is related to hospital specific 
treatment variation. In The Netherlands, hospitals that perform robot-assisted radical 
prostatectomy indicate a significant larger proportion of their patients for surgery 
compared to other hospitals 4. At the moment of randomization, three hospitals from 
our sample are known for having robotic surgery facilities to treat prostate cancer 
patients, and only two of these hospitals were allowed to join the same cluster.
Randomization was performed by a statistician not involved in the study and blind 
to the identity of the hospitals, using SPSS version 19.0 (Statistical Package for Social 
Sciences, Chicago, IL, USA). As a first step, the four paired hospitals were randomized 
(block size = 2).  Next, the remaining 11 hospitals were also block randomized (block size 
= 6, with the last position unused). A set seed was chosen that fulfilled to the criteria that 
only two robot facilitated hospitals were allowed into the same cluster. The generated 
group order was then applied to a pre-existing list of participating hospitals, which was 
sorted in alphabetical order. As there is an uneven number of hospitals participating 
in this study, the largest cluster that was formed was identified as intervention cluster.
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Study population, inclusion criteria and exclusion criteria
The DA is developed for the initial treatment decision in early-stage prostate cancer. 
In order to be eligible to participate in this study, a subject must meet the following 
inclusion criteria:
1. Patient is diagnosed with low or intermediate risk prostate cancer (EAU/ESTRO 
criteria) [30].
2. Patient is eligible for at least two of following treatment options: active surveillance, 
radical prostatectomy, brachytherapy, external beam radiotherapy.
3. Patient has access to a PC, laptop or tablet with internet connection.
Exclusion criteria are:
1. A combination of PSA ≥ 10 and Gleason = 7 (which defines high risk prostate 
cancer).
2. Cognitive impairment or being too ill at time of the study.
3. Insufficient understanding of the Dutch language to complete questionnaires and 
understand the DA.
Intervention
After being diagnosed with prostate cancer, but before a treatment decision has been 
made, patients in the intervention arm receive access to the online DA. Healthcare 
providers are instructed to introduce the DA and the study at diagnosis. However, the 
pragmatic nature of this trial allows hospitals to integrate the introduction of the DA 
with their standard information provision routines if that follows later due to follow-
up diagnostics or an additional consultation with (oncology) nurses. In daily practice, 
this means that either the urologist or the (oncology) nurse introduces the DA to the 
patient. To use the DA, patients receive a card from their urologist stating their relevant 
disease characteristics (PSA, Gleason, and eligible treatment options) and a personal 
username and password to gain online access to the DA. If a nurse introduces the DA 
and accompanying access card, the urologist should provide the requested clinical 
characteristics to the nurse, either by filling in the card or by leaving a note in the 
patients’ record.
The DA offers a stepwise guidance through the decision process. In the first step, general 
information about prostate cancer is provided. The second step offers the consideration 
between active surveillance and curative treatment (surgery or radiotherapy). Values 
clarification statements are presented in this step to elicit a patient’s preference based 




treatment (‘I am confident enough that I will be treated on time, if necessary’ versus ‘I do 
not want to postpone treatment because I do not want to be too late’), avoiding possibly 
unnecessary treatment (‘If treatment might be unnecessary, I would rather wait’ versus ‘I 
prefer treatment, even if it might be unnecessary’) and the acceptance of treatment side 
effects (‘I find possible treatment side effects like erectile and urinary dysfunctions difficult 
to accept’ versus ‘I find the possible treatment side effects acceptable’). Each statement is 
related to one of the two offered treatment alternatives in this step. On a slider scale, 
patients can indicate for each set of statements the strength of their preference towards 
one of the alternatives.
Following the same structure, the next step supports the consideration between surgery 
and radiotherapy. For surgery, three common methods are discussed (laparoscopic, 
open and robot assisted). For radiotherapy this consists of brachytherapy and EBRT. 
Again, information provision is followed by values clarification statements. The VCMs in 
this step emphasize the main differences between surgery and radiation therapy (both 
brachy and EBRT) in terms of treatment procedure (‘I find it important that all cancer 
cells are removed from my body versus I find it important that the cancer cells die and not 
grow further‘), side effects (‘I find bowel problems worse than incontinence’ versus ‘I find 
incontinence worse than bowel problems’), secondary treatment (‘I am comforted by the 
thought that I can have radiation if surgery is unsuccessful’ versus ‘I accept that surgery is 
difficult after radiation’) and fear for surgery (‘I am not anxious about surgery’ versus ‘I am 
anxious about surgery’). If a patient already indicated a preference for active surveillance 
in the previous step, the program allows patients to ignore this part and continue to the 
last step. As a conclusion, the final step asks patients to indicate their final treatment 
preference and briefly explain their choice. The DA does not provide a treatment advice, 
but helps the patient to reach an informed preference. A summary then provides an 
overview of all answers to the statements and the patients’ final preference. To discuss 
this summary with their urologist, the summary can be printed or accessed online 
during the next consultation.
All statements used in the VCMs were developed by a team of urologists, psychologists 
and engineers based on previous experience and observation of conversations where 
treatment decisions were discussed. The statements were evaluated during usability-
testing among patients, urologists and nurses (N=10).
Recruitment
Patients in both arms will be recruited by their treating urologist. When meeting the 
inclusion criteria, the urologist will use a letter and leaflet, in which the study is clarified, 
to invite eligible patients to participate. The letter and accompanying leaflet about the 
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study will state that we would like to investigate the information provision and decision-
making process in general, without explicitly mentioning that a DA is the subject of this 
study. This reduces potential bias from emphasizing that the DA is an addition to usual 
care, as the perception of any addition to usual care may evoke improved satisfaction 
on itself. It will also avoid a situation where patients in the control group feel that 
they are withheld from a potentially helpful tool. Patients are not informed about the 
randomization at the hospital level.
For all logistics involved to distributing and processing the questionnaires, the PROFILES-
application will be used.  ‘Patient Reported Outcomes Following Initial treatment 
and Long term Evaluation of Survivorship (PROFILES)’ is a registry for the study of the 
physical and psychosocial impact of cancer and its treatment from a dynamic, growing 
population-based cohort of both short and long-term cancer survivors. PROFILES was 
developed in 2009 by a joint research group from Tilburg University and Comprehensive 
Cancer Centre South (CCCS) with a grant from the Netherlands Organization for 
Scientific Research (NWO) 31. PROFILES enables data collection management, from 
inviting patients to participate in studies to collecting patient-reported outcomes data 
via web-based or mailed questionnaires and provides a supporting helpdesk. Patients 
can send their informed consent form, which they receive with the information letter, 
to PROFILES. On the informed consent form patients can indicate whether they want 
to receive questionnaires via email or regular mail. Approximately 1 to 2 weeks after 
treatment decision-making (T1) patients receive either the invitation (email) to fill in an 
online questionnaire or a paper version at their home address. In the case of a paper 
version, a stamped self-addressed envelope is provided to the patient to return the 
questionnaire. If patients do not fill in their questionnaires within two weeks, a reminder 
letter or email will be send. Patients will be assured that non-participation does not 
result in differential follow-up care or treatment. The PROFILES-application allows for 
managing the follow-up questionnaires, which are sent at 6 and 12 months following 
T1.
Outcome measures
Table 1 shows an overview of all outcome measures and the moment of measurement.
Primary outcomes
Primary outcome is decisional conflict. The decisional conflict scale (DCS) 32,33 evaluates 
the level of decisional conflict on five subscales; the feeling of being well-informed; the 




of uncertainty about best choice; and  the effectiveness of the decision. The level of 
decisional conflict is measured at T1. The DSC is widely accepted and applied as main 
outcome measure in (Pca) DA trials 24,34-36.
Table 1. Outcome measures
Outcomes Instrument T1 T2 T3
Shared decision-making outcomes
Decisional conflict Decisional Conflict Scale X
Decisional regret Decisional Regret Scale X X
Pca Knowledge Pca decision quality instrument X
Satisfaction with information SCIP-B X
Decision-making preparedness Preparation for DM-scale X
Decision-making role PSDM-scale X
Perceived doctor-patient relationship Single item X X X
Actual treatment choice and health outcomes
Initial preference and treatment choice Single items X
Treatment satisfaction Single item X X
Health-related Quality of Life EORTC QLQ-C30 X X X
EORTC QLQ-PR25 X X X
Side-effect impact IIQ-7 subset for emotional state X X
Acceptance & Control over health status Subjective experienced health (SBG) X X X
Secondary outcomes
Secondary outcome measures can be categorized as either shared decision-making 
outcomes or health outcomes. Shared decision-making outcomes consist of decisional 
regret 37, perceived and preferred decision-making role 38, and preparation for decision-
making to assess a patient’s preparation for decision-making and dialoguing with his 
clinician 39. Furthermore, a single-item question will evaluate the perceived patient-
doctor relationship and the development of this relationship over time.  Also, satisfaction 
with information provision 40 and knowledge 41 will be assessed.
Health outcomes refer to the actual treatment choice and any changes in treatment 
preference during the decision-making process. Treatment satisfaction will be measured 
with a single-item question: ‘Are you satisfied with the way your treatment was or is 
executed?’ To assess health-related quality of life (HRQoL) the EORTC QLQ-C30 [42] will be 
used. This questionnaire is developed specific to assess HRQoL in cancer patients. Much 
of the content of the questionnaire is appropriate for extended monitoring of health 
96
Chapter 5
status, including scales assessing physical, role, cognitive and emotional functioning, 
fatigue and sleep problems, and overall health and quality of life. This core instrument 
is supplemented with the prostate cancer-specific HRQoL questionnaire EORTC QLQ-
PR25 43. This 25-item questionnaire assesses urinary, bowel and sexual symptoms and 
functioning, and the side-effects of hormonal treatment, though hormonal treatment 
is not offered as initial treatment in this study’s sample. Health outcomes are further 
assessed by means of an evaluation of side-effect impact 44,45 and health status 
acceptance and subjective control 46.
Other measures
Table 2 shows an overview of the other measures. Decision aid users are asked to 
evaluate the DA by indicating for 25 statements if it applies to the responder or not. 
The first 11 statements are formulated negatively (for example ‘I found the decision aid 
too difficult’), followed by 14 positively formulated statements (for example ‘I found 
the decision aid pleasant to use’). Although literature reports positive effects from the 
usage of DAs in general 47, there may be subgroups that will not benefit from DA-usage. 
To identify these subgroups, additional measures on (health) skills and personality are 
included.  Objective measures for health literacy and health numeracy are used, with 
the HRS Experimental numeracy module 48 and the STOHFLA-brief 49, respectively. The 
Decision Self-Efficacy Scale is used as a subjective measure of the perceived ability to 
make a decision 50.
Table 2. Other measures




Self-efficacy Decision self-efficacy scale X
Health numeracy HRS Experimental numeracy module X
Health literacy STOHFLA-brief X
Psychosocial variables  
Anxiety and depression HADS, PC-max X X X
Personality LOT-R, BFI-10 X
Information seeking preferences API, NFC-short, Maximization scale X




Comparable to health skills, the relation of personality to beneficial DA-usage will be 
investigated. Some studies suggest a link between personality and treatment choice 51,52. 
Following these studies, some relevant aspects of personality will be taken into account: 
hospital anxiety and depression (HADS-scale) 53, prostate specific anxiety (MAX-PC) 54,55, 
optimism (Life Orientation Test – Revised) 56, the big five personality dimensions (Big 
Five Inventory-10) 57, information seeking preferences (subscale from the Autonomy 
preference index) 58 and maximization tendencies (Maximization scale) 59.
Sociodemographic variables and additional healthcare utilization
Standard sociodemographics will be asked on age, marital status, occupation, and 
education. Also, patients will be asked to report any additional healthcare utilization 
(general practitioner or other medical specialist) in the past 12 months to assess whether 
this affects the decision-making process.
Healthcare providers’ evaluation
Healthcare providers in the intervention arm will be asked their opinion about 
implementation of the DA in qualitative interviews as well as questionnaires at the end 
of patient inclusion (approximately after 12 months). This questionnaire will be based 
on the MIDI-instrument 60, which is developed for the evaluation of implementing an 
innovation in a healthcare setting. The questionnaire will focus on usage of the DA (for 
example ‘Did you offer the DA to all eligible patients?’) and evaluate the pros and cons 
of the DA with help of statements (for example ‘The DA is practical in use’).  Healthcare 
providers in the control condition will be asked to evaluate the current information 
provision and decision-making processes, their expectation of DA-usage and motivation 
for implementation.
Sample size calculation
The sample size for this study is determined by power analysis with decisional conflict 
as the primary measure. To be able to detect a clinically relevant minimum effect size 
61 of .50, power is set at .80 and alpha at .05. With 19 hospitals (clusters) that agreed to 
participate, it is needed to estimate the intra-class coefficient (ICC). The ICC assesses 
the proportion of variance explained by clusters. Higher ICC values decrease effective 
sample size and statistical power. ICC ranges from 0 to .1 are considered common 
in medical literature 62. A more specific review of ICC values in (cluster) RCTs with 
psychosocial measures is provided by Bell and McKenzie 63, which also included a 
cluster RCT evaluating a group support tool for prostate cancer patients 64. The median 
estimated value for 82 longitudinal ICCs from 15 included studies was 0.0007, and the 
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range found for decisional conflict was between 0 and 0.02. Given the considerable 
variability in ICCs that is found in literature, ICC for the current trial is set conservative 
at 0.01.
The attrition rate is set at 25% to compensate for non-response to the questionnaires. 
This rate is comparable to studies in similar populations and following the same methods 
as this study does 65,66. Calculations show that a design with 19 clusters of 20 patients 
(380 patients in total) achieves a power of .8. Taking into account a 25% attrition rate 
between the first and third questionnaire, the total sample size (rounded) will be set at 
475 patients. This results in a recruitment of 25 patients per hospital.
Statistical analysis
All analyses will be conducted using SPSS version 19.0 (Statistical Package for Social 
Sciences, Chicago, IL, USA). A 0.05-significance level will be adopted in all statistical tests.
We will perform a descriptive statistical analysis of organizational (hospitals) and socio-
demographic (patients) characteristics in order to assure the comparability of the 
intervention and control groups. Baseline measures and changes in outcome variables 
over the study period for each study arm will be presented as means (± SD).
The main outcome decisional conflict is measured at T1 and will be compared between 
both groups (intervention and control). Multilevel modelling will be carried to take the 
hierarchical structure of the data into account by specifying random effects at both 
hospital and patient level. The least square mean proportions will be estimated and 
compared to assess the effect of the DA on decisional conflict.
The secondary outcomes will also be compared between both groups using multilevel 
modelling. Some of the secondary measures consist of repeated measures (for example 
HRQoL and decisional regret) and will be treated according the appropriate mixed-
model approach, that is repeated measures anova/ancova will be used for outcomes 
with two time points (decisional regret, treatment satisfaction) and a random coefficient 
approach will be used for outcomes with three time points (HRQoL) 67.  Observed 
variation in treatment choice during the trial period will be compared between groups 
and at level of the individual hospital. For this second comparison each hospital’s 





Potentially confounding variables (for example, personality, health skills, and age) will 
be explored for their impact on the primary and secondary outcomes. Missing data and 
drop-outs will be described.
Ethical considerations
The research protocol was examined by the accredited regional Medical Research Ethics 
Committee ‘METC Brabant’, and concluded that participants are not subjected to any 
procedure or imposed to perform any behavior. With this conclusion the obligation 
to fulfill the specific requirements of the Dutch law for Medical Research involving 
Human Subjects (WMO) was waived (reference: NW2014-03). The science committee of 
the initiating hospital has approved the study protocol (reference: WB/mt/14.030). All 
participating patients will sign an informed consent form.
DISCUSSION
This study investigates the effect of an interactive, web-based, treatment decision aid 
for early-stage prostate cancer. It compares impact on the decision-making process and 
patient reported outcomes from an intervention group with a control group. Included 
patients will be followed for 12 months to investigate long term consequences from 
the intervention on regret, treatment satisfaction and quality of life. Randomization will 
take place at the hospital level, meaning that once included, all patients within in one 
hospital receive the same treatment. Compared to randomization on the level of the 
patient, this design is less prone to contamination bias. The strength of this study is 
the initial involvement of 19 participating hospitals. With this large number, a proper 
variation of local circumstances can be taken into account that might affect structural 
adaptation of the DA in clinical practice. The large number of participating hospitals also 
requires careful management by the researchers during the trial period. Motivating all 
involved doctors, nurses and assistants requires careful monitoring of inclusion progress 
per location, and adaptation to specific circumstances. Another challenge is to take the 
treatment variation per hospital into account. If past-year treatment characteristics 
appear to be imbalanced between both arms, we may decide to adjust for past year 
treatment, based on hospital-specific treatment profiles obtained from the Netherlands 
Cancer Registry.
Although we are aware of the fact that individual differences between clinicians could 
also affect decision outcomes, there are some considerations that justify taking the 
institution as the unit of analysis. First, diagnosis and offered treatment plans are often 
the result of multi-disciplinary consideration (for example, urologists, radiotherapists, 
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and oncologists). Secondly, specialization often leads to some clinicians seeing the 
majority of Pca patients within an institution. Taking the clinician as unit of analysis 
could lead to too small clusters in some cases. On the other hand, clinician specialization 
could also lead to patients visiting multiple clinicians within a hospital before a final 
decision is made, making it difficult to attribute a treatment decision to a certain 
clinician. Third, information provision and decisional support is often provided by 
specialized (oncology) nurses. Typically they assist more than one clinician which could 
contaminate individual clinicians’ data. Finally, regional variation in treatment practices, 
which is expected to be influenced by DAs as explained in previous sections, is generally 
reported at the hospital level. This indicates that there are influences at the hospital 
level driving practice variation that go beyond individual differences between clinicians 
within a hospital. The reported variation in selected treatments between hospitals is 
available for hospitals included in our study, though no data is available on individual 
clinician’s variability.
While carefully designed and reviewed by experts, some content of the DA can remain 
the subject of discussion among healthcare providers. As every urologist, radiotherapist 
or nurse can be seen as an expert on prostate cancer from their own perspective; all have 
their own preference in formulating and presenting options, facts and risks involved to 
prostate cancer and its treatment alternatives. The original DA is tested thoroughly and 
documented for the topics that should be addressed in the DA, which we took over 23,24. 
All adjustments that were made to adjust the DA to Dutch clinical setting are based on 
the IPDAS criteria 25 for DA development. All textual content is derived from Dutch and 
European treatment guidelines.
A potential limitation of our DA is that a device with internet connection is needed to 
use the DA, which could affect our sample and consequently our findings. Although 
we are aware that this could be a relevant issue in many regions in the world, we do 
not expect biased results in our trial. The World Bank has estimated internet access 
in The Netherlands is among the highest in the world, with 94% of the households 
(2013) having internet access (www.worldbank.org). Even in older age groups (65 to 75 
years) regular internet access is at 80%, and this percentage is rapidly increasing (2013, 
Statistics Netherlands). Internet is routinely referred to as part of information provision 
in standard care. As most of our questionnaires (in both groups) are sent via email, 
internet access and the ability to use it is also required in both groups, assuring group 




Our trial has defined decisional conflict as primary measure. As previously mentioned, 
the DCS is a widely accepted and applied measure in DA evaluations. However, 
the DCS is also subject to some discussion in the literature about its usefulness as 
outcome measure in DA evaluations 68. This is mainly due to its limitation to identify 
a good decision as a person’s underlying sensitivity to uncertainty may not be fully 
represented in a high or low decisional conflict score. For example, a high score on 
the DCS could also represent the effort that one takes to be involved in the decision-
making process and absorbing all available information and therefore becoming aware 
of the difficulty of the decision. Although we are aware of this potential limitation of 
the DCS, we believe decisional conflict represents the best available affective-cognitive 
outcome measure that captures the uncertainty involved to prostate cancer treatment 
decision-making. Uncertainty about disease progression, treatment success and side-
effect impact are key elements of the decision-making process in prostate cancer care. 
Preliminary investigations prior to the current study taught us that decisional conflict 
levels are substantial; we expect that our DA will be able to reduce these levels and 
that this potential reduction is meaningful. For meaningful interpretation of our effects 
we also have additional outcome measures available that can support our findings or 
can indicate bias if present. Many of our secondary measures focus on the decision-
making process (knowledge, satisfaction with information provision, decision-making 
role) rather than the outcome in terms of a ‘good’ or ‘bad’ decision, this ensures that our 
conclusions on the usefulness of the DA will not solely depend on interpretation of the 
DCS.
On a broader level, this study will augment the current paucity of information regarding 
the implementation of DAs in (Dutch) routine clinical practice, its impact on the 
treatment decision-making process and long term effects. This will help patients and 
clinicians to establish optimal patient-treatment fit. As we hypothesized the effects could 
involve improved patient involvement and knowledge resulting in higher decision and 
treatment satisfaction and ultimately reduce regret and improve quality of life.
Finally, the results of this project will contribute to the increasing awareness of shared 
decision-making and improving patient centered care in the treatment of prostate 
cancer. This study can provide the scientific evidence needed to include the use of a DA 
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IMPACT OF A WEB-BASED PROSTATE CANCER 
TREATMENT DECISION-AID ON PATIENT-
REPORTED DECISION PROCESS PARAMETERS: 





L.V. van de Poll-Franse




Purpose – To compare patients’ evaluation of the treatment decision-making process in 
localized prostate cancer between counseling that included an online decision aid (DA) 
and standard counseling.
Methods – Eighteen Dutch hospitals were randomized to DA counseling (n=235) or 
the control group with standard counseling (n=101) in a pragmatic, cluster randomized 
controlled trial. The DA was provided to patients at, or soon after diagnosis. Decisional 
conflict, involvement, knowledge and satisfaction with information were assessed with 
a questionnaire after treatment decision-making. Anxiety and depression served as 
covariates.
Results – The levels of decision involvement and conflict were comparable between 
patients in both groups. Patients with a DA felt more knowledgeable but scored equally 
well on a knowledge test as patients without a DA. Small significant negative effects 
were found on satisfaction with information and preparation for decision-making. A 
preference for print over online and depression and anxiety symptoms were negatively 
associated with satisfaction and conflict scores in the DA group.
Discussion – The DA aimed to support shared decision making, while outcomes for a 
majority of DA users was comparable to patients who received standard counseling. 
Patients who are less comfortable with the online DA format or experience anxiety or 
depression symptoms, could require more guidance toward shared decision making. 
To evaluate long-term DA effects, follow-up evaluation on treatment satisfaction and 





In a clinical area where multiple equal effective treatments are available for the same 
medical condition, the preference-sensitive treatment selection that is then required 
can be challenging for patients as well as physicians 1-3. Treatment selection for localized 
prostate cancer (Pca), the most commonly detected cancer in men in the Western 
world, is such an area 4. When diagnosed at a localized stage, Pca can be managed 
with equal successful curative treatments (surgery or radiotherapy), or by following an 
active surveillance (AS) protocol without harming survival perspectives 5-8. Although 
oncologically equivalent, treatments differ in their impact on quality of life, risk of side 
effects and perceived burden, therefore, Pca treatment guidelines do not indicate a 
single superior treatment option, but recommend shared decision-making (SDM) 
to come to the best patient-treatment fit 5, 6, 9-11. Moreover, many Pca patients have a 
poor understanding of differences in treatment risks prior to choosing treatment, are 
dissatisfied with information received, and experience regret after treatment 12-14. With 
SDM and more decision support these problems can be resolved.
SDM requires patients to share preferences, uncertainties, and the desired level of 
participation in the decision process. A physician should be aware of the patient’s 
preferred level of involvement and take this into account to adequately provide all 
available information about eligible options, including risks, benefits and scientific 
uncertainties 15, 16. However, patient preferences for involvement are often misinterpreted 
by care providers and many patients are dissatisfied with the information they received 
17-20.
To facilitate and improve the process of SDM, patient decision aids (DAs) were developed 
to help patients to increase choice awareness, provide high quality information, structure 
the decision process, and to help clarify preferences and values 21-23. Simple DAs are plain 
paper versions, while more elaborate DAs are built as interactive websites that include 
explicit values clarification methods 24, 25. DA effects are typically studied by comparing 
patient reported outcomes following decision-making between a DA group and a usual 
care group. In a review of DAs across all medical screening and treatment decisions, it 
has been shown that DAs contribute to improved patient involvement in the treatment 
decision, less decisional conflict and more conservative treatment choices 26.
In the specific area of Pca treatment decision-making, DA results are less conclusive. 
Positive effects are seen for improved patient education (knowledge, information 
satisfaction), but mixed effects are found for other decision process measures such 
as decisional conflict 27. Often the studied Pca DAs did not fully comply with the 
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International Patient Decision Aid Standards (IPDAS), mostly because of missing DA 
development information or unbalanced presentation of treatment benefits and risk. 
Furthermore, they lacked a user-centered design or were not specifically aimed at 
facilitating SDM in the patient-doctor encounter 27-30.
In the absence of a Dutch Pca treatment DA that included a values clarification method, 
a novel web-based DA was developed with a specific user-centered focus on facilitating 
SDM 31. A cluster randomized controlled trial (RCT) that compared DA counseling to a 
control arm with standard counseling was set up. The primary finding that the DA helped 
patients align treatment choices to their personal preferences was published previously 
32. The current study investigated patient reported outcomes related to the decision 
making process, directly following treatment decision-making. We hypothesized 
that with the DA decisional conflict (primary outcome) would be lower and patient 
involvement, Pca knowledge and information satisfaction (secondary outcomes) would 
be better, compared to the control group 18. Moreover, we were interested in individual 
differences (DA format preference, anxiety and depression symptoms) among DA users 
to explain potential differences in outcomes within the trial’s DA arm.
METHODS
Participants and recruitment
All patients from participating hospitals, who were newly diagnosed with localized 
Pca (PSA <20, Gleason <8) between August 1, 2014 and July 1, 2016, had at least two 
treatment options and no mental or cognitive impairments, were suitable for enrollment 
in this trial. Patients were recruited at diagnosis by their urologist or by an (oncology) 
nurse immediately following diagnosis and were given a study package containing 
an information letter, informed consent form, leaflet and a pre-stamped envelope. To 
agree with participation, the informed consent form had to be returned using the pre-
stamped envelope. On the informed consent form patients indicated the date of their 
next consultation, which usually was two or three weeks following diagnosis and the 
moment to discuss treatment choice. A questionnaire was sent within one week after 
this indicated date by email (paper version on request) 18.
Design
Eighteen Dutch hospitals were randomized to the intervention or control arm. All 
hospitals were general hospitals, except for one academic hospital in the control arm. 
Patients in the control arm received information and counseling as usual, patients 




usual information and counseling. Randomization at hospital level was chosen to avoid 
contamination of usual counseling with components of the DA. Patients were informed 
that the topic of the study was to evaluate information provision and treatment decision-
making in Pca care, and were unaware of assignment to trial arm as the DA was not 
mentioned as subject of this study. The regional Medical Ethics Review Board waived 
the need for formal ethical approval (reference: NW2014-03), and the study protocol 
was approved by every individual hospital. The study was pre-registered in the Dutch 
Trial Register (NTR4554).
Intervention
To invite patients to use the DA, patients in the intervention arm received an access 
card from their health care provider with the DA-web address, and a unique username 
and password. The card also stated the patient’s relevant clinical characteristics, that is, 
eligible treatment options (AS, surgery, brachy therapy, or external radiation), PSA, and 
Gleason score. Based on the indicated treatment options, the DA allowed patients to 
skip information about non-eligible treatments. After accessing the DA and entering 
the clinical data from the card, patients first could read general information about Pca, 
before detailed information about AS and treatments was provided. Provided treatment 
information within the DA was similar for each treatment and consisted of information 
about procedures, risks, and pros and cons. Information was based on (inter)national 
guidelines and recent scientific literature. Values clarification methods (VCMs) 
were included to help patients clarify their personal preference for AS or any of the 
treatments. VCMs were designed as statements that required a trade-off between two 
treatment modalities (e.g. ‘If treatment might be unnecessary, I prefer to wait’, as trade-
off between AS and treatment). The DA ended with a summary page that displayed 
how extensive the DA was used (e.g. ‘You have read x out of x topics’), the patient’s 
responses to the VCMs and indicated treatment preference. A printed summary could 
be taken to the subsequent consultation where the treatment decision was discussed 
with the urologist. The goal of the summary page is to enable a SDM conversation as 
it presents the patient’s preferences on the various VCMs and for treatment. A more 
detailed description of the development and content of this novel Dutch web-based DA 
is available in a separate publication, which also provides evidence for IPDAS compliance 
of the current DA 29, 31.
Procedures
In addition to usual information, patients in the intervention arm were granted access 
to the online DA. The pragmatic aspect of the current trial allowed hospitals to follow 
their existing procedures and routines for further counseling. For some hospitals this 
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meant that all newly diagnosed patients saw a radiation oncologist (when eligible for 
radiotherapy) and an oncology nurse, while at other hospitals this only happened by 
patient request. Most patients took two or three weeks to consider their treatment 
choice before a follow-up consultation was scheduled. Patients in the intervention 
arm received explanation that the DA should be used during this period, and that the 
summary provided by the DA, could be taken to the next consultation, although this 
was not mandatory. In the week following the treatment decision, patients in both arms 
were invited to fill out the questionnaire online or a paper questionnaire was sent on 
request. Automatic reminders were sent after two and four weeks if the questionnaire 
had not yet been started or completed.
Measures
Sociodemographic and clinical information was obtained from informed consent 
(date of diagnosis, date of birth) and the questionnaire (marital status, education level, 
treatment options, treatment choice, and self-administered co-morbidities). Eligible 
treatments and the received treatment were verified through the patient’s medical 
record, this data was also used for a separate analyses of treatment choices within 
this trial 32. Individual differences between patients in general anxiety and depression 
symptoms were assessed with the Hospital Anxiety and Depression Scale (HADS) 33.
Main outcome of this study was decisional conflict, which was measured with the 
Dutch version of Decisional Conflict Scale (DCS), incorporating five subscales regarding 
feeling uninformed, values clarity, perceived support, decision uncertainty and the 
perceived effectiveness of the decision. Scales were converted to 0 to 100, with higher 
scores indicating more perceived conflict 34 35. Internal consistency of the full scale was 
good (Cronbachs alpha, 0.87, subscales 0.58-0.86). Secondary outcomes included two 
single items on the patient’s perceived role during decision-making (Problem-Solving 
Decision-Making Scale) and the perceived preparedness to make the treatment decision 
(Preparation for Decision-making Scale, alpha=0.97) 36, 37. Pca knowledge was assessed 
with an estimation of the perceived knowledge level per treatment (e.g. ‘How well do 
you think your knowledge about surgery is?’) and an objective test consisting of five 
multiple-choice test questions from the Pca Decision Quality Instrument 38. Additionally, 
satisfaction with timing and format of the information received was measured with the 
corresponding subscale of the Satisfaction with Cancer Information Profile (SCIP-B, 
alpha=0.96) 39. In the DA arm, participants received additional questions to evaluate the 
DA (e.g. ‘Was the online DA format your preferred format?’ and ‘Would you preferred if 





Descriptive statistics are presented as means (+/- SD) for continuous variables and 
frequencies and percentages for categorical variables. Differences between study arms 
and between responders and non-responders were tested using independent sample 
t-tests for continuous variables and chi-square analyses for categorical variables.
Analyses were performed according to the intention-to-treat principle, assuming 
that counseling in the DA group was different from the control group because of the 
introduction of the DA, regardless of actual DA usage by participants. To take the 
hierarchical structure of the data -due to randomization at hospital level- into account 
and control for hospital specific effects, linear multilevel regression analyses were used 
to test the effect of the intervention (the DA) compared to the control group. Study arm 
(DA vs. usual care) was included in the model as an independent variable. Dependent 
variables consisted of decisional conflict, involvement, knowledge, and information 
satisfaction. Participants’ HADS scores served as covariate as anxiety and depression 
symptoms are common after receiving a cancer diagnosis and are known to be related 
to the evaluation of information provision 40, 41. Subgroup analyses were performed on 
participants from which DA log data indicated the DA was actually used. Participants 
were grouped according to their DA format preference (online versus paper) and HADS 
score. HADS scores were initially categorized into normal (0-7), mild (8-10), moderate 
(11-14), and severe (≥15), according to previous studies 42. Because differences between 
the mild and moderate group are of little clinical relevance, and to ensure higher 
statistical power, the mild and moderate categories were collapsed into one group.
The study was powered to detect a clinically relevant effect size of .50 between both 
study arms on decisional conflict. A conservative intra-class coefficient (ICC) of 0.01 
was taken, therefore, to obtain 80% power and allow for 25% attrition in the current 
questionnaire and follow-ups, 238 patients per study arm were targeted 18. Eventually, 
fewer patients than targeted were recruited for the control group (n=109). Due to the 
conservative sample size calculation, power for making comparisons between arms 
was still sufficient (>.80), but low for comparing smaller subgroups (.65-.67). Statistical 
analyses were conducted using SPSS 22.0 (Statistical Package for Social Sciences, 




Based on national cancer registry data, the estimated total number of eligible patients 
during the trial period was 2,000 patients, of which 484 patients were invited to 
participate in the trial. A total of 382 Pca patients signed informed consent (DA=273 
and control=109, consent rate 79%) and 336 patients filled out the post-decision 
questionnaire (response rate 88%). The mean age of responders was 65.3 (SD=5.9), 
there were no differences in sociodemographic or clinical characteristics in participants 
between both study arms (Table 1). Questionnaire non-responders were younger than 
responders (M=62.9 vs M=65.3, p=.01), although the distribution among age groups 
was comparable (p=.18; Table 2). Furthermore, non-responders were less likely to have 
accessed the DA compared to responders (68 vs. 86%, p=.005). The number of patients 
enrolled per hospital varied between 1 and 64 (Table 1), response rates from all hospitals 
except one were higher than 80% (Table 2).
Between trial arms, no differences were found on involvement or decisional conflict 
(Table 3). Participants in the DA arm felt more knowledgeable, but less prepared to 
make a decision (Table 3). Overall information satisfaction was lower in the DA arm, in 
particular for information usability, the amount of information, and completeness of 
the information (Table 3). The mean objective knowledge (test) scores were comparable 
between trial arms (Table 3), however, within the control arm, knowledge scores were 
lower for patients eligible for 3 or 4 treatments (F(2, 84)=5.84, p=.004), while in the DA 
arm, test scores were unrelated to the number of eligible treatments.
A subgroup analysis revealed that 84% of actual DA users (N=156) were in favor of the 
online DA format and 16% (N=30) would preferred to have received the DA in print. Of 
participants who received but did not access the DA, 56% (N=15) indicated a DA in print 
was preferred. Participants favoring the online DA format were younger (M=64.6 vs. 
M=67.3, p=.02) and more often highly educated (50% highly educated vs 27%, p=.04). 
Mean HADS scores were not statistically significantly different between both format 
preference groups, however, medium or severe HADS scores were more common in 
participants who would prefer a printed DA (p=.03). DA users in favor of the online DA 
format and with HADS scores <8 reported less decisional conflict and more information 
satisfaction compared to other DA users (Table 4). A treatment advice from the DA was 
preferred more often by DA users with severe of high HADS scores, although differences 
did not reach statistical significance (Table 4). No other socio-demographic variables 
were associated to differences between DA users. The same HADS categorization did 













Age at informed consent, mean (SD) 65.3 (5.9) 64.9 (6.0) 66.3 (5.7) .06
≤55, n (%) 23 (7%) 16 (7%) 7 (7%) .09
56-65, n (%) 141 (42%) 109 (46%) 32 (32%)
66-75, n (%) 166 (49%) 106 (45%) 60 (59%)
≥76, n (%) 6 (2%) 4 (2%) 2 (2%)
Marital status, n (%)
Married/living together 295 (88%) 208 (89%) 87 (87%) .70
Other 41 (12%) 27 (11%) 13 (13%)
Education, n (%)
Low 112 (34%) 76 (33%) 36 (36%) .41
Medium 82 (25%) 54 (23%) 28 (28%)
High 137 (41%) 101 (44%) 36 (36%)
Gleason Score, n (%)
6 178 (63%) 134 (61%) 44 (69%) .25
7 106 (37%) 86 (39%) 20 (31%)
PSA level, mean (SD) 7.9 (3.8) 8.3 (3.5) .41
≤10.0, n (%) 253 (79%) 180 (79%) 73 (79%) .88
10.1-20.0, n (%) 68 (21%) 49 (21%) 19 (21%)
Number of eligible treatments
2 74 (23%) 49 (21%) 25 (28%) .51
3 157 (49%) 115 (50%) 42 (46%)
4 89 (28%) 65 (29%) 24 (26%)
Anxiety and depression, mean (SD) 7.3 (6.2) 7.3 (6.4) 7.1 (5.5) .76
Normal (0-7), n (%) 192 (62%) 131 (61%) 61 (63%) .77
Mild (8-10), n (%) 46 (15%) 31 (14%) 15 (16%)
Moderate (11-14), n (%) 36 (11%) 24 (11%) 12 (12%)
High (≥15), n (%) 38 (12%) 29 (14%) 9 (9%)
DA usage
Yes, n (%) 203 (86%) 203 (86%) n/a






























P-values report comparisons between the intervention arm and the control arm according to t-tests for means and χ2-
tests for frequencies.
Numbers may not always add up to the same n due to missing data (e.g. item non-response), percentages were rounded.













Age at informed consent, mean (SD) 65.3 (5.9) 62.9 (6.1) .01
≤55, n (%) 23 (7%) 5 (11%) .18
56-65, n (%) 141 (42%) 25 (54%)
66-75, n (%) 166 (49%) 16 (35%)
≥76, n (%) 6 (2%) 0 (0%)
Number of eligible treatments
2 74 (23%) 9 (21%) .32
3 157 (49%) 26 (60%)
4 89 (28%) 8 (19%)
DA usage
Yes, n (%) 203 (86%) 26 (68%) .005
No, n (%) 32 (14%) 12 (32%)
Hospitals1, n (%)
1 11 (55%) 9 (45%) .02
2 1 (100%) 0 (0%)
3 46 (92%) 4 (8%)
4 28 (82%) 6 (18%)
5 13 (81%) 3 (19%)
6 17 (81%) 4 (19%)
7 64 (89%) 8 (11%)
8 35 (92%) 3 (8%)
9 20 (95%) 1 (5%)
10 6 (100%) 0 (0%)
11 18 (90%) 2 (10%)
12 9 (90%) 1 (10%)
13 9 (90%) 1 (10%)
14 23 (96%) 1 (4%)
15 8 (100%) 0 (0%)
16 20 (87%) 3 (13%)
17 8 (100%) 0 (0%)
18 0 (100%) 0 (0%)
P-values report comparisons between responders and non-responders, according to t-tests for means and χ2-tests for 
frequencies.
1Rows add up to 100% to represent response rates per hospital
Numbers may not always add up to the same n due to missing data (e.g. item non-response), percentages were rounded.
Marital status, Education level, Gleason score, PSA level, and HADS scores were not available for non-responders.
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 Mean (SD) β p
Involvement
Weighing treatment pros and cons 3.3 (0.8) 3.2 (0.8) 0.25 .12
Treatment decision 3.6 (0.9) 3.5 (0.8) 0.07 .50
Preparation for decision-making 3.6 (0.9) 4.2 (0.6) -0.55 <.001
Decisional conflict
Full scale 23.5 (13.4) 24.1 (13.0) -1.30 .39
Informed subscale 16.8 (16.1) 17.7 (17.1) -1.03 .60
Values clarity subscale 30.0 (17.8) 31.8 (17.0) -2.55 .30
Support subscale 22.4 (16.7) 21.1 (16.0) 0.07 .97
Uncertainty subscale 33.9 (23.5) 33.5 (21.2) -0.75 .81
Effective decision subscale 16.8 (14.3) 18.4 (15.9) -1.99 .26
Knowledge
Objective knowledge 7.5 (2.1) 7.2 (2.0) 0.32 .30
Subjective knowledge 7.0 (1.4) 6.6 (1.5) 0.43 .01
Satisfaction with information
Full scale 3.8 (0.8) 4.1 (0.6) -0.25 .04
Information usability for patient 3.8 (0.9) 4.1 (0.7) -0.35 .01
Information usability for spouse 3.7 (1.0) 4.1 (0.7) -0.33 .02
Amount of written information 3.8 (0.9) 4.1 (0.8) -0.37 .02
Amount of oral information 3.7 (0.9) 4.1 (0.8) -0.36 .02
Information completeness 3.7 (0.9) 4.1 (0.7) -0.40 .01
Information comprehensiveness 3.9 (0.9) 4.1 (0.8) -0.14 .31
Information accessibility 3.9 (0.9) 4.1 (0.7) -0.14 .30
Moment of receipt 4.0 (0.9) 4.1 (0.7) -0.10 .39
Delivery method 4.1 (0.9) 4.1 (0.8) -0.06 .58
Means and standard deviations (SD) are presented as observed in the dataset.
Beta’s represent the effect of the DA compared to the control group as obtained from linear multilevel regression analyses, 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































In this pragmatic cluster randomized controlled trial among patients with localized Pca, 
adding an online DA to standard counseling did not lead to different levels of patient 
involvement or decisional conflict in comparison to standard counseling. Patients who 
used the DA did feel more knowledgeable about Pca treatments but scored equally well 
as participants from the control group on a knowledge test. Small negative effects of 
the DA were found on the scales for preparation for decision-making and information 
satisfaction, in particular for DA users with medium or high anxiety and depression 
symptoms or who would preferred the DA to be in print.
With the DA, patients were provided with structured information about Pca and possible 
treatments. Treatment advantages and disadvantages were presented in a balanced 
manner, and VCMs were included to help patients establish a treatment preference 
based on personal values  31. An earlier investigation into treatment choices within this 
trial revealed that with the current DA, the treatment decisions were more often in line 
with the patient’s preference instead of the doctor’s preference 32. However, this did not 
translate into an effect on decisional conflict in the current study, with previous Pca DA 
studies also finding mixed results on this outcome 27 . Possibly, this is because of the 
nature of the concept of decisional conflict. Despite the wide use of decisional conflict 
as an outcome measure in DA evaluations, it has been debated whether lowering 
decisional conflict should actually be the desired outcome of a DA intervention 26, 27, 
43, 44. Careful consideration of all available treatment options, including weighing 
pros and cons against personal preferences, could evoke conflict and the perceived 
decision difficulty, regardless of interventions to support the decision making process. 
If ultimately, the final decision has a better patient-treatment fit, existence or even 
increase of decisional conflict could also be the expense of a thorough decision-making 
process 45, 46. Follow-up evaluation of our trial participants is planned to determine if 
patients are more satisfied with the selected treatment and experience less regret, after 
treatment is completed, compared to patients from the control group.
Next to finding no effect on decisional conflict, the effects from the DA on the secondary 
outcomes, preparation for decision-making and information satisfaction, were small 
but opposite from what was expected and overall findings in DA studies 18, 26. Although 
patients were unaware of randomization at hospital level and were not informed that 
the DA was the subject of this study, care providers were aware that the purpose of 
the study was to compare the DA to usual information routines. During counseling, the 
novelty of the DA might have been over-emphasized, increasing patients’ expectations 
and leading to a more critical evaluation of the DA in the questionnaire. An indication 
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that some participants might have had other expectations from the DA was found in 
the proportion of patients who indicated they would like to have received an explicit 
treatment advice from the DA, while this was not provided by the DA.
Some evidence for an effect of the DA on knowledge was found. Firstly, participants 
with a DA perceived themselves to be more knowledgeable. Secondly, participants in 
the DA group scored equally well on the knowledge test, regardless of the number of 
eligible treatments, while in the control group test scores were lower if the number of 
eligible treatment options increased. This could indicate that when more treatments are 
considered, the DA helps to gain more knowledge about all options resulting in a better 
informed treatment decision, while in the control group there might have been more 
focus on a single treatment 43.
Not all participants seemed equally suited to receive the DA in its current online 
format. Older and lower educated participants indicated more often that a print DA 
was preferred over the current online format. Having internet access is common in The 
Netherlands, also among elderly, of all people aged up to 75 years, 97% has internet 
access at home (statline.cbs.nl). However, with increasing age, actual usage and comfort 
in using internet is lower, which could explain some hesitation among participants to 
engage in an online tool for making a high impact treatment decision 47. Participants 
with anxiety and depression symptoms showed more decisional conflict and less 
information satisfaction with the DA compared to participants with similar symptoms 
from the control condition. Anxiety and depression is common after a cancer diagnosis 
40. However, for participants in the control condition, we did not find a moderating role 
of anxiety and depression symptoms on decisional conflict or information satisfaction. 
This could indicate that without a DA, care providers were able to tailor their counseling 
according to the estimated level of anxiety and depression, while with the DA, all 
information about risks and side-effects was presented equally explicit to all patients. 
Communicating uncertainty can lead to lower satisfaction, in particular if patients are 
more sensible to this because of anxiety or depression 45. Further research is needed 
to determine if these groups require further tailored information provision or more 
guidance in using a DA.
The role of the DA in tailored information should be investigated in future research. 
During the current trial, most men received the DA soon after diagnosis, and were 
instructed to use the DA after consultation, regardless of any psychosocial distress from 
receiving the Pca diagnosis. Distress could have hindered uptake of new information 
from the DA and the decision-making process 48. Possibly, some patients benefit from 




by the diagnosis before the DA is introduced. Detailed analysis (by audio or video) 
of clinical consultations could be helpful to investigate to what extent psychosocial 
distress plays a role during treatment counseling, and if the DA is of more added value 
with a tailored approach with various levels of nurse guidance 49.
  A major strength of this study was the cluster randomized design to reduce the risk of 
contamination of standard counseling with components of the DA. Consequently, care 
providers in the DA arm were able to develop a routine in distributing and explaining 
the DA.  Furthermore, many patients were recruited in the DA arm and once distributed, 
many patients used the DA.
Some limitations need to be mentioned as well. Firstly, recruitment of participants in 
the control arm was slower and resulted in less participants than aimed for. Although 
patient characteristics were very similar in both arms, we cannot exclude a potential 
selection bias in the control arm which may have led to recruiting only patients who 
were more likely to consent. Secondly, as mentioned before, care providers were 
aware of randomization and the true focus of this study. In the control arm this could 
have led to modifications of existing information or counseling routines due to the 
increased attention for SDM from this study, or in the DA group, to the creating of too 
high expectations as care providers could have (over-)emphasized the novelty of the 
DA. Thirdly, although the DA achieved a high usage rate, non-users were more likely to 
also not respond to the questionnaire. The evaluation of patient who chose not to use 
the DA are therefore underrepresented in the current sample. A qualitative study could 
provide more insights in their motives to not use the DA.
This study measured DA effects immediately following treatment decision-making. 
Previous research showed that effects from VCMs included in DAs could also emerge 
at a later point than at treatment decision-making 50. Post-treatment follow-ups in the 
current sample on treatment satisfaction and decisional regret are needed to determine 
if this is also the case for this DA 18.
In conclusion, this study did not find evidence of beneficial effects from the DA on 
patient-reported decision process parameters. Importantly, patients who do not favor 
the online DA format or present with anxiety and depression symptoms could require 
more guidance and support during DA use and treatment counseling. The effect of the 
DA on treatment satisfaction and decisional regret once treatment is completed, needs 
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LONGITUDINAL REGRET AND PATIENT 
SATISFACTION AFTER DECIDING ON TREATMENT 
FOR LOCALIZED PROSTATE CANCER WITH OR 
WITHOUT A DECISION AID. RESULTS AT ONE-
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Objective – To investigate the effect of including an online decision aid (DA) during 
prostate cancer treatment counseling on decisional regret and patient satisfaction in a 
one-year follow-up. 
Methods – Eighteen Dutch hospitals were randomized to DA counseling or care-as-
usual, patients (n=382) completed questionnaires directly after treatment decision 
making, and 6 and 12 months later. Regret was assessed with the Decisional Regret 
Scale, patient satisfaction consisted of satisfaction with information (SCIP-B) and 
treatment satisfaction. Anxious and depressive symptoms (HADS) and the perceived 
patient-doctor trust relation were included as possible covariates.
Results – At follow-up, regret about the choice of treatment was rare (19%) and 
most patients were satisfied with their treatment (91%) and the information that was 
received (64%) at the time of decision-making, regardless of being exposed to the DA. 
The perceived patient-doctor relation and anxious and depressive symptoms were 
associated with the odds of reporting regret and information satisfaction. 
Conclusion – Including a DA in treatment counseling did not result in different decisional 
regret or satisfaction levels twelve months after treatment was chosen, compared to the 
control group. 
An optimal patient-doctor relation and attention for anxious and depressive symptoms 
can help minimizing the risks for decisional regret and patient dissatisfaction.
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BACKGROUND
Prostate cancer is the most common malignancy in men in the Western world (1, 2). When 
detected at an early (localized) stage, multiple curative treatments (surgery, external 
beam radiotherapy, brachy therapy) can be considered, or the disease can be managed 
by active surveillance (AS), with identical survival (3-5). The perceived burden of the 
treatment procedure and impact of side-effects can be different for individual patients 
(6-8). Reaching an optimal fit between patient and treatment is the most important 
goal in treatment counseling. However, many treatment decisions in Pca care tend to 
reflect the doctor’s preference instead of the patient preference (9-11). While involving 
patients in the treatement decision, providing adequate information, and discussing all 
options reduces the risk of patients regretting their decision (12-15).
Decisional regret is defined as ‘remorse or distress over a (health care) decision’ (16). Up to 
a quarter of Pca patients are known to experience regret after choosing and undergoing 
treatment, which can persist up to 15 years after treatment (13, 17). In contrast to the 
expectation that treatment specific side-effects (e.g. incontinence after surgery) cause 
regret, most studies have not found differences across treatment modalities (11, 18-20).
In order to involve patients in the decision-making process and enable well-informed and 
preference-concordant decisions, current Pca guidelines recommend a shared patient-
doctor decision (21). The use of patient decision aids (DAs) is promoted to facilitate 
this process of shared decision making (SDM). DAs provide balanced information on 
all treatments, help clarify personal values, and guide patients to establish an informed 
treatment preference with realistic expectations (22, 23). 
Studies on the long term consequences (i.e. regret) of decisions made after DA 
interventions are less common. The latest Cochrane review on the effects of DAs 
included 7 out of 105 DA studies that reported on decision regret, of which none were 
in Pca patients (24). Only one of these 7 studies reported lower regret in DA users (25). 
Other studies that did focus on Pca patients found weak or no long-term DA effects on 
decision regret (26, 27). Feldman-Stewart and colleagues found beneficial effects from 
values clarification exercises (VCEs) included in a Pca DA on regret at a one-year follow-
up, while no differences were found 3-monthts post-decision, suggesting a positive DA 
effect can still emerge long after the decision is made (28). 
A novel Dutch web-based Pca treatment DA with VCEs has been developed and tested 
in a pragmatic, cluster randomized trial (29, 30). Evaluations directly after treatment 
choice showed that  patients with the DA made different treatment choices compared 
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to patients from the control group, and that these treatment choices were more often 
driven by patient-preference rather than doctor-preference (31). However, in contrast 
to what was hypothesized, no beneficial effects from the DA on decisional conflict, 
information satisfaction, or preparation for decision-making were found immediately 
after treatment decision-making (32).  Moreover, the DA was evaluated less positively 
by patients with anxious and depressive symptoms (32). Since Feldman-Stewart et al. 
(28) found late effects from the VCEs included in their DA, we are interested in possible 
long-term effects from the current DA.
Next to decisional regret, as our primary long-term outcome, we included patient-
reported satisfaction with treatment and information as secondary outcome. We 
hypothesize that since the DA evaluated all treatment options, including their advantages 
and disadvantages, patients´expectations about treatment results will be more realistic, 
resulting in low regret and high treatment satisfaction (33, 34). Furthermore, in line with 
this hypothesis, and Feldman-Stewart´s finding of potential late DA effects, we aim to 
evaluate the DA effect on information satisfaction at follow-up. 
METHODS
Design
The Prostate Cancer Patient Centered Care (PCPCC) trial was set up as a cluster 
randomized controlled trial, with eighteen Dutch hospitals randomized to either include 
the DA into treatment counseling, or to provide information and counseling as usual. 
Randomization at hospital level was chosen to avoid contamination of usual counseling 
with components of the DA. The regional Medical Ethics Review Board waived the 
need for formal ethical approval (reference: NW2014-03), and the study protocol was 
approved by participating hospitals. The study was pre-registered in the Dutch Trial 
Register (NTR4554) (29).
Participants and procedure
All patients newly diagnosed with localized low or intermediate risk prostate cancer 
(T1–T2N0M0), and a minimum of two treatment alternatives (including AS), were 
eligible for participation (35). Exclusion criteria were mental or cognitive impairment, 
or inability to complete a questionnaire in Dutch. Patients were recruited at diagnosis, 
and informed that the topic of the study was to evaluate information provision and 
treatment decision-making in Pca care. On the consent form, patients indicated the 
date of the subsequent consultation during which the treatment decision was planned 
to be finalized. The first questionnaire was sent after this indicated date (T1). Follow-
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up questionnaires were sent 6 (T2) and 12 months (T3) later. Patients were unaware 
of assignment to trial arm as the DA was not mentioned as subject of this study. Care 
providers and researchers were not blinded of trial assignment (29).
Intervention
In addition to all information provided as part of usual care, patients in the intervention 
arm were invited by their care provider to access the DA online. The DA included 
information about all treatments, values clarification exercises (VCEs), and a summary 
that could be taken to the next consultation. Based on which treatments the patients 
was eligible for, the DA allowed patients to skip elements about treatments they were 




Randomization of hospitals, 
N=18 
Hospitals randomized to DA counseling, 
N=9 
Hospitals randomized to standard counseling, 
N=9 
Patients signing informed consent: n=273 
DAs distributed: n=273 
Patients using DA: n=229 
Patients signing informed consent: n=111 
Patients receiving usual counseling:  n=111 
After treatment decision-making: 
Patients receiving questionnaire: n=273 
Patients completing questionnaire:  n=235 
 
6 months: 
Patients receiving questionnaire: n=235 
Patients completing questionnaire: n=214 
 
12 months: 
Patients receiving questionnaire: n=214 
Patients completing questionnaire: n=208 
After treatment decision-making: 
Patients receiving questionnaire: n=111 
Patients completing questionnaire: n=101 
 
6 months: 
Patients receiving questionnaire: n=101 
Patients completing questionnaire: n=94 
 
12 months: 
Patients receiving questionnaire: n=94 
Patients completing questionnaire: n=85 
Enrollment of patients 
Treatment decision-making 





Age, marital status, and education level were obtained from the questionnaire. The 
treatment that was received by the patients was verified through their medical record.  
Regret after the treatment decision was assessed with the five-item Decision Regret Scale 
(DRS) (16). All questions were answered on a 5-point scale, ranging from 1-completely 
disagree to 5-completely agree. Scores were transformed to a 0-100 scale. Previous 
studies used a cutoff score of >25 as indicative for moderate to strong regret (18, 36, 
37). Regret was assessed at T2 and T3. Internal consistency was good (Cronbach’s alphas 
0.84-0.87). Patient satisfaction consisted of treatment satisfaction and information 
satisfaction. Treatment satisfaction was assessed with a single item (‘Are you satisfied 
with how your treatment is or was executed’), to get an overall estimation of satisfaction. 
Since participants in our trial were exposed to different treatments, questions about 
specific aspects of treatment would not apply to all participants. Moreover, the single-
item question contributed to limit the questionnaire length and patient burden when 
completing it. The question was answered on a 5-point scale, ranging from 1-completely 
disagree to 5-completely agree, and transformed to a 0-100 scale. Treatment satisfaction 
was assessed at T2 and T3. Information satisfaction was assessed with the Satisfaction 
with Cancer Information Profile part B (SCIP-B) (38). Answers were given on a 5 point 
scale, ranging from 1-very dissatisfied to 5-very satisfied, and transformed to a 0-100 
score. Information satisfaction was assessed at all three time points. Internal consistency 
was good (Cronbach’s alphas 0.95-0.97). 
An earlier study into retrospective information satisfaction in Pca survivors showed 
that decision role preferences were associated to information satisfaction even at four 
years after decision-making (39). Therefore, the perceived patient role during treatment 
counseling, assessed at T1 with the Problem-Solving Decision-Making (PSDM) Scale, 
was included into our analysis as covariate (40). The PSDM scale represents the level 
of involvement in weighing treatment pros and cons and in making the decision, 
ranging from 1-passive (doctor only) to 5-active (patient only) involvement. The first 
two and last two answer categories were each combined, resulting in a doctor-driven, 
shared or patient-driven role. Furthermore, anxious and depressive symptoms were 
included as covariate, which are a common factor in Pca treatment decision-making, 
and showed an association to the DA evaluation immediately following decision-
making (41, 42). Presence of anxious or depressive symptoms were assessed with the 
Hospital Anxiety and Depression Scale (HADS) (43). Both aspects were measured with a 
seven-item subscale. The answering scale ranged from 0-3, and answers were summed 
to obtain anxious and depressive scores. Scores ≥8 are generally seen as substantial 
levels of anxiety or depression (43). HADS was assessed at all three time points. Internal 
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consistency was good (Cronbach’s alphas 0.87-0.91). To control for any changes in the 
overall patient-doctor relation over time, we included this variable with a single item 
(‘How would you rate your relationship (trust) with your doctor?’) at all time points, 
answered on a 5-point scale, ranging from 1–poorly to 5–excellent (29). The patient-
doctor relation can also be a component of treatment satisfaction (44), however, in 
case of Pca treatment, the clinician responsible for the execution of treatment, could be 
different from the urologist with whom patients have their regular consultations with. 
Therefore, we chose to assess this variable separately from treatment satisfaction.
Statistical analysis
Intention-to-treat analysis included all patients from both arms. Descriptive statistics 
are presented as means (and SDs) for continuous variables and frequencies (and 
percentages) for categorical variables. Differences in characteristics between trials 
arms, and between responders and non-responders were compared with t-tests for 
continuous variables and chi-square tests for categorical variables.
To assess determinants of clinically relevant levels of regret and information satisfaction, 
scores were dichotomized with a score >25 indicating regret and <75 indicating 
dissatisfaction. These new variables each served as outcome variable in a multivariable 
logistic regression that included age, education, marital status, received treatment, 
trial arm, perceived role during decision-making, anxious and depressive symptoms, 
and the perceived patient-doctor relation as covariates. The association between these 
factors and the outcome variable are presented as odds ratios (with 95% confidence 
intervals). Statistical analyses were conducted using SPSS 22.0 (Statistical Package for 
Social Sciences, Chicago, IL). Tests were two-sided and considered statistically significant 
if p<.05.
RESULTS
In total, 384 patients were enrolled in this study (DA: n=273, control: n=111) and 
received the initial questionnaire after treatment decision-making (T1, response rate 
88%). Follow-up questionnaires after 6 months (T2) were sent to 336 patients (DA: 235, 
control: 101, response rate 92%), and to 308 patients after 12 months (T3, DA: 214, 
control: 94, response rate 95%). Completion rates were comparable across participants 
from all hospitals. Men without a partner and men with low education were more often 
lost to follow-up (Table 1).
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P-valueN= 235 N=100 N=270 N=65
Patients
Age at informed consent
Mean (SD) 64.9 (6.0) 66.2 (5.7) .06 65.6 (5.8) 64.2 (6.4) .09
Marital Status, n (%)
Married/together 208 (89%) 87 (86%) .54 244 (90%) 51 (60%) <.001
Other 27 (11%) 14 (14%) 27 (10%) 34 (40%)
Education, n (%)
Low 76 (33%) 36 (36%) .41 81 (30%) 31 (48%) .02
Medium 54 (23%) 28 (28%) 69 (26%) 13 (20%)
High 101 (44%) 36 (36%) 117 (44%) 20 (31%)
Gleason sum, n (%)
6 134 (61%) 44 (69%) .25 141 (61%) 37 (71%) .16
7 86 (39%) 20 (31%) 91 (39%) 15 (29%)
PSA level, mean (SD)
≤10.0, n (%) 180 (78%) 72 (75%) .92 203 (77%) 49 (79%) .94
10.1-20.0, n (%) 50 (22%) 24 (25%) 61 (23%) 13 (21%)
Number of eligible treatments
2 49 (21%) 25 (28%) .51 59 (23%) 21 (27%) .74
3 115 (50%) 42 (46%) 130 (50%) 37 (47%)
4 65 (29%) 24 (26%) 71 (27%) 20 (26%)
Treatment received
Active surveillance 68 (31%) 19 (19%) <.001 63 (24%) 26 (36%) .11
Surgery 87 (39%) 29 (29%) 98 (37%) 26 (36%)
Radiotherapy 67 (30%) 52 (52%) 101 (39%) 21 (28%)
Other/unknown 13 1 9 6
Perceived role in weighing pros and cons, n (%)
Doctor-driven 24 (10%) 16 (16%) .23
Shared 123 (54%) 56 (56%)
Patient-driven 81 (36%) 28 (28%)
Perceived role in treatment decision, n (%)
Doctor-driven 13 (6%) 6 (6%) .94
Shared 104 (45%) 47 (47%)
Patient-driven 113 (49%) 47 (47%)
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P-valueN= 235 N=100 N=270 N=65
Hospitals
1 20 (7%) <.001 9 (3%) 6 (7%) .26
2 1 (1%) 0 (0%) 1 (1%)
3 50 (18%) 37 (14%) 10 (12%)
4 34 (13%) 19 (7%) 12 (15%)
5 16 (6%) 10 (4%) 5 (6%)
6 21 (8%) 13 (5%) 4 (5%)
7 72 (25%) 53 (20%) 13 (16%)
8 38 (14%) 31 (11%) 6 (7%)
9 21 (8%) 18 (7%) 3 (4%)
10 6 (6%) 6 (2%) 0 (0%)
11 20 (18%) 13 (3%) 1 (1%)
12 10 (9%) 8 (3%) 1 (1%)
13 10 (9%) 8 (3%) 2 (2%)
14 24 (22%) 19 (7%) 5 (6%)
15 8 (7%) 5 (2%) 3 (4%)
16 23 (21%) 17 (6%) 3 (4%)
17 8 (7%) 5 (2%) 3 (4%)
18 Merged with hospital 
14
No differences were observed in socio-demographic- or clinical characteristics (PSA, 
Gleason), or the degree of involvement to the treatment decision process between 
participants from both trial arms. Patients in the DA group chose AS or surgery more 
often and radiotherapy less often compared to patients from the control group. 
Although it was aimed to have equal sized samples in both arms and across hospitals, 
fewer patients were recruited for the control group, and patient enrollment varied across 
hospitals (Table 1). Post-hoc power analysis revealed sufficient power at all time points 
(92-87% power) to detect clinically relevant differences (d=0.4) between trial arms at all 
time points, but low power (38-34%) to detect small effects (d=0.2). 
 Overall, 15% of the participants (n=57) indicated regret (with a score >25) at six, and 19% 
(n=43) at twelve months after treatment decision-making. But the largest proportion of 
men from both trial arms reported zero regret at both time points (T2: 36%, n=108, T3: 
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39%, n=114). Differences in regret between trial arms at both time points did not reach 
statistical significance (Table 2). Within the DA group, mean regret was significantly 
lower at T3 compared to T2 (M=13.5 vs M=17.4, t(179)=2.30, p=.02).
At both time points of follow-up, most participants were (very) satisfied with their 
treatment, regardless of trial arm. Information satisfaction was lower for participants 
from the DA group compared to the control group immediately after treatment 
decision-making (M=70.8 vs M=77.8, t(200.5)=3.02, p=.006), but there was no difference 
between trial arm groups 6 and 12 months later (Table 2). The perceived patient-doctor 
relation was equal across trial arms (Table 2).






Decision regret (0-100), Mean (SD)
T2 17.4 (20.6) 13.4 (14.5)
T3 13.5 (16.9) 12.7 (15.4)
Treatment satisfaction (0-100)
T2 80.7 (28.3) 82.6 (24.5)
T3 82.6 (21.4) 81.5 (23.4)
Information satisfaction (0-100)
T1 70.8 (20.1) 77.8 (15.8)**
T2 76.2 (17.2) 78.5 (19.6)
T3 76.4 (17.2) 78.2 (18.7)
Anxious and depressive (0-44)
T1 7.4 (6.5) 7.2 (5.5)
T2 6.8 (6.4) 6.1 (5.7)
T3 6.5 (5.5) 6.2 (5.1)
Perceived patient-doctor relation (1-5)
T1 3.7 (0.8) 3.8 (0.9)
T2 3.8 (1.0) 4.0 (0.9)
T3 3.9 (0.9) 4.0 (0.9)
Note: T1 was before treatment start; treatment satisfaction and decision regret were not surveyed at this time point 
P-values represent comparisons between trial arms of unadjusted means according to independent samples t-tests 
* p<.05, ** p<.01, *** p<.001
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Table 3. Factors associated with regret and information (dis)satisfaction at 12-months follow-
up
Regret Information dissatisfactiona
OR 95% CI P-value OR 95% CI P-value
DA received .86 .95
No 1.00 1.00
Yes 0.94 (0.46, 1.93) 1.02 (0.52, 2.00)
Age 1.01 (0.95, 1.07) .74 0.99 (0.94, 1.05) .85
Education .11 .50
Low 1.00 1.00
Medium 0.37 (0.15, 0.94) 0.91 (0.41, 2.06) 
High 0.71 (0.32, 1.58) 0.66 (0.31, 1.41)
Marital status .61 .36
With partner 1.00
Other 0.76 (0.27, 2.16) 11.63 (0.57, 4.67) 
Treatment received .77 .98
AS 1.00 1.00
RP 1.94 (0.81, 4.63) 1.09 (0.50, 2.36)
EBRT 1.22 (0.34, 4.39) 1.12 (0.36, 3.45)
BT 1.81 (0.69, 4.72) 0.90 (0.37, 2.16)
Perceived role in weighing pros and cons1 .50 .12
Doctor-driven 1.00 1.00
Shared 1.50 (0.45, 4,97) 1.40 (0.45, , 4.37)
Patient-driven 2.22 (0.22, 8.87) 2.95 (0.81, 10.69)
Perceived role in decision-making1 .18 .23
Doctor-driven 1.00 1.00
Shared 0.43 (0.09, 1.95) 0.57 (0.13, 2.57)
Patient-driven 0.25 (0.05, 1.26) 0.34 (0.07, 1.64)
Anxious and depressive symptoms2 1.12 (1.05, 1.26) <.001 1.11 (1.04, 1.18) <.001
Perceived patient-doctor relation2 0.35 (0.24, 0.53) <.001 0.32 (0.22, 0.46) <.001
OR – Odds ratio; CI – Confidence interval
AS – Active surveillance; RP – Radical prostatectomy; EBRTx – External beam radiotherapy; BT – Brachytherapy; 
DA – Decision aid
a Information satisfaction was dichotomized into 1=satisfaction <75, 0=satisfaction ≥75
1 As assessed immediately after treatment decision-making (T1)
2 As assessed at 12-months follow-up (T3)
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In the multivariable logistic regression model (Table 3), receipt of the DA was not 
significantly associated with lower odds of reporting regret (OR 0.94, 95% CI 0.46-
1.93) or dissatisfaction with information (OR 1.02, 95% CI 0.52-2.00) after 12 months. 
Participants who reported anxious or depressive symptoms or a less favorable patient-
doctor relation were more likely to report regret and dissatisfaction with information at 
follow-up. 
DISCUSSION
This study longitudinally assessed regret, as well as patient satisfaction with treatment 
and information received, in a sample of Pca patients who chose treatment with or 
without receiving an online treatment DA. Results showed that at 12-months follow-
up, the DA did not significantly impact any of these outcomes. Anxious and depressive 
symptoms and the perceived patient-doctor relation were associated with the odds of 
reporting regret and information satisfaction at follow-up.
DA effects 
In our study only a few men (19%) regretted their treatment one year after they made 
the treatment decision. This confirms previous findings in similar populations, and 
measured with the same scale and follow-up time (18, 24). However, in contrast to 
Feldman-Stewart’s finding of late VCE effects (28), we did not find an effect on regret 
from the DA, which included VCEs, twelve months post-decision. This does not mean 
that the current DA or its VCEs had no effect during counseling. Patients with a DA 
chose different treatments compared to patients from the control condition. And as 
established earlier, treatment choices with the DA were more consistent with patient 
preferences instead of clinician preferences, while an opposite pattern is common in 
routine care without a DA (9, 31). With this effect established, the DA can potentially 
contribute to reduce unwarranted regional variations in Pca treatments (45, 46). 
Decisional regret
Although no statistically significant difference in regret between trials arms was 
observed, a significant decline in regret within the DA arm appeared between T2 and T3. 
A possible explanation could be found in the larger proportion of patients who chose 
surgery in the DA arm. As Pca surgery has the shortest treatment time, at T2, a larger 
proportion of men in the DA arm was likely to have completed treatment, compared to 
patients from the control arm. However, surgery is also associated with severe adverse 
treatment effects, in particular in the first months after surgery (12, 13, 18). At T3 most 
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patients with active treatment were likely to have completed treatment, and patients 
who underwent surgery had more time to adjust, which may have resulted in similar 
regret levels between trial arms at T3. 
Information satisfaction
Information satisfaction in the DA arm was statistically significantly lower at T1 compared 
to the control arm. At later time points, this difference in information satisfaction between 
trial arms disappeared. With the DA, information about all treatments was provided, 
with equal attention to the benefits and riks of each treatment. This also implied 
explicitly presenting unpleasant information about possible adverse treatment effects 
(e.g. risks, side-effects, procedures) (30). Being exposed to unpleasant information, and 
becoming aware that there are downsides to all treatments, could have led to lower 
information satisfaction in the DA group compared to the control group at T1 (47, 48). 
Without the DA, care providers in the control arm were able to be more implicit about 
risks and could adjust counseling to the level of distress in the patient. Finding similar 
information satisfaction scores in both arms at follow-up could indicate that eventually 
patients were equally satisfied with each approach.
DA implementation
The overall conclusion of little regret and high satisfaction with both treatment and 
information, regardless of exposure to the DA may indicate that high quality care was 
received by most patients in this trial. By implementing the DA we aimed to improve 
quality of care and stimulate SDM between patients and care providers. However, 
execution of SDM involves more than distribution of a DA (49). In The Netherlands, 
uptake of SDM in clinical routine, including Pca care, is increasing (50). An example is 
the opportunity to visit both a urologist and a radiation oncologist to discuss treatment 
options from both viewpoints. In both trials arms most patients perceived a shared 
or patient-driven decision, and treatment satisfaction showed a ceiling effect. In this 
context, the potential beneficial effects from the DA could have been too small to be 
picked up within the broad regret and satisfaction measures of this study. This study 
found that anxious and depressive symptoms and the perceived patient doctor-relation 
were the most relevant factors affecting regret and satisfaction at follow-up. In order 
to optimally utilize the possibilities to manage anxious and depressive symptoms and 
support the patient-doctor relation with a DA, future research should look into the 
best moment to introduce and use the DA. The current DA was provided to all patients 
directly after diagnosis and presentation of the treatment options (29). Possibly, patients 
with anxious and depressive symptoms require more counseling from a nurse at this 
stage, before new information is presented with the DA (51-53). An earlier study found a 
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relation between pre-diagnosis exposure to Pca treatment information and satisfaction 
and regret, indicating that the moment of presentation of information can have an 
effect on patient outcomes (27) 
Future research
Relevant continuations of the current research are to investigate how the web-
based aspect of the current DA is related to anxious and depressive symptoms, and 
incorporation of the DA into direct patient-doctor counseling. The current DA has been 
developed as online tool for its possibilities to tailor presentation of information (e.g. 
only displaying information that is relevant to the patient), include interactive VCEs, and 
because nearly all Dutch citizens have internet access (29, 54). As this study showed, 
anxious and depressive symptoms and the patient-doctor relation are associated with 
both regret and satisfaction. This raises the question how this relates to the fact that 
the DA was only available online. Use of the DA content was not integrated in clinical 
counseling, only discussion of the summary obtained from the DA was embedded 
in the follow-up consultation. Moreover, online sources could be perceived as less 
trustworthy, in particular for patients suffering from anxious and depressive symptoms 
(55-57). Possibly, these patients require offline materials that could be combined with 
the online DA.  
The current study focused on patient-reported outcomes in the first year after treatment 
decision-making. A longer follow-up period (up to 36 months) including clinical data 
about possible tumor recurrences (or further tumor progression in case of AS) could 
provide insight if the patients from the DA groups adjusted better due to more accurate 
risk perceptions (8).
Strengths and limitations
Strengths of the current study include the pragmatic approach that allowed effects from 
every day clinical routine to be included in the trail, and contributing to the external 
validity of our results. Furthermore, drop-out rates were low and equally distributed 
across trial arms. Patients who consented and completed the first questionnaire were 
also highly likely to complete the two follow-up questionnaires.
The cluster randomized design of this trial was chosen to reduce the risk of contamination 
from clinicians that counsel both patients included in the DA arm as in the control arm, 
as in a traditional individually RCT would occur. Such design is recommended when 
behavior is part of the intervention (58).  By taking hospitals as unit of randomization 
instead of patients, we avoided that care providers, after they received DA training, had 
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to counsel patients enrolled in the control arm as well. Moreover, randomization was 
blinded to patients, meaning that patients in the control arm were not aware that they 
were not offered an intervention. However, an important limitation of the cluster RCT 
may have been that it contributed to the unbalanced sampling that occurred between 
both trial arms. Although both arms were targeting the same number of participants, 
inclusion in the control arm stagnated at less then half the size of the DA arm (29). The 
reason could be twofold. First, after DA training, care providers in the DA arm might have 
been more motivated to enroll patients into the trial as they had a nove intervention to 
offer to patients. Second, care providers in the control arm were aware of randomization, 
and that the DA intervention would be compared to usual care, as provided by them. 
This may have caused care providers in the control arm to be more selective in which 
patients to enroll, consequently having an overrepresentation of more satisfied patients 
in the control arm and less of a representative presentation of usual care patients. 
Another limitation following from the unbalanced recruitment was that for some 
hospitals only a limited number of patients was enrolled per treatment group, resulting in 
low power to detect either hospital or treatment specific effects. In particular, enrollment 
of patients on AS in the control group was low, leading to an underrepresentation of 
patients on AS in the control group.
Treatment satisfaction and the patient-doctor relation were measured with a single-
item, which is generally considered to be less valid and reliable compared to multi-item 
measures. However, satisfaction is a construct commonly measured as a single item 
(e.g. in quality of life research, organization psychology, and marketing), and proving 
to be valid and reliable under such conditions (59-61). Existing multi-item scales to 
measure patient satisfaction, often include an item to assess the patient-doctor relation 
(44, 62) However, to answer the research questions in this study, it was preferred to 
obtain separate scores for both variables as the clinician treating the patient can be 
different from the clinician a patient has his regular consultations with. In case of follow-
up studies that investigate treatment satisfaction into more detail, larger samples per 
treatment modality and a multi-item scale are recommended to assess more of the 
aspects that contribute to overall satisfaction. 
CONCLUSION
Men newly diagnosed with localized Pca feel little regret twelve months after deciding 
on which treatment to pursue, and are satisfied with their treatment execution and the 
information received during treatment counseling. Receipt of an online treatment DA 
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did not significantly impact the outcomes at follow-up, if any, the odds of reporting 
regret and information dissatisfaction were associated with anxious and depressive 
symptoms, and a less favorable perceived patient-doctor relation. Opportunities 
to make the current web-based DA a more integrated part of the the patient-doctor 
communication should be investigated further. 
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DECISION AID VERSUS USUAL INFORMATION 
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Objective: To compare care providers’ evaluations of an online prostate cancer 
treatment decision aid (DA) to an evaluation of usual information routines.
Methods: Oncology care providers (urologists and nurses, n=108) enrolled in the 
intervention (DA) or control (standard information) arm of a cluster randomized 
controlled trial were invited to fill out an online questionnaire to evaluate working with 
the DA or to evaluate usual information provision. Response rate was 58% (n=63).
Results: The DA was provided to 368 patients and distributing care providers were 
supportive of the DA content and usability. Satisfaction (1-10) with the DA or standard 
information was comparable (M=7.8 vs M=8.1, p=.14), although in the control arm, care 
providers perceived that patients already receive too much information. Time barriers 
were not expected or perceived. All care providers involved felt suitable to distribute 
DAs. Care providers with DA experience were more supportive of including DAs in 
clinical guidelines.
Conclusion: Care providers were satisfied with the DA and reported no time barriers. 
However, many care provider are already satisfied with standard information materials 
and fear to overload patients with information.
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1. INTRODUCTION
To increase shared decision-making (SDM) in clinical encounters, use of patient decision 
aids (DAs) is recommended 1-4. DAs come in multiple formats and, in addition to regular 
consultation, help to explain options, clarify values for benefits and harms, and guide 
deliberation and communication 5. Studies have shown that DAs can lead to increased 
choice awareness, more knowledge and reduced decisional conflict 6. Some studies even 
suggest patients select less invasive treatments after consulting a DA 7. Although DAs 
have been developed and are available for a wide variety of treatment and screening 
decisions, routine use  in clinical care remains limited 8.
Clinician attitudes towards SDM and DAs are an important aspect when trying to 
promote DA uptake 9 10. Barriers for applying SDM were identified in earlier studies and 
included time constraints and perceptions that the patients or the clinical situation 
were not suitable for applying SDM. Identified facilitators consisted of clinician 
motivation, positive impact on the clinical process and patient outcomes 11. More 
specific research on DA implementation showed that the method of delivering DAs to 
patients often is an important barrier for routine DA use. Although evidence suggests 
a more systematic delivery approach (e.g. automated sending though a link with the 
electronic patient record) is more effective compared to a clinician initiated method, 
clear recommendations for optimal DA delivery to patients are not yet available 8.  
A clinical area in high need for SDM, and therefore ideally suited for DA use, is prostate 
cancer treatment decision-making 12, 13. Prostate cancer (Pca) is the most common 
cancer in men in the western world 14. Depending on patient and tumor characteristics, 
Pca patients could be offered a choice between surgery, radiotherapy and active 
surveillance. Oncological outcomes of these options are considered to be equivalent, 
however, each option has a specific risk and side-effect profile 15-17. Pca treatment 
guidelines do not indicate a single superior option but encourage SDM to select the 
alternative that fits best with the patients’ characteristics and preferences 18. As SDM 
should include creating choice awareness, providing information about treatment 
harms and benefits, and preference elicitation, DAs are helpful tools to support this 
process.
For application in Dutch clinical care, a novel web-based Pca treatment DA has been 
developed and a cluster randomized controlled trial (RCT) has been conducted to 
evaluate patient outcomes and implementation 19, 20. To gain insight in underlying 
clinician motivations for the adoption of this DA in routine clinical care, we evaluated 
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health care providers’ experiences with the DA from the trials’ intervention arm and 
evaluations of standard information routines and DA expectations from health care 
providers in the control arm.
2. METHODS
2.1 Design
In the Prostate Cancer Patient Centered Care (PCPCC) trial, eighteen Dutch hospitals 
were enrolled in a cluster RCT to investigate patient outcomes after implementing 
a Pca DA in routine clinical care compared to standard care 20. Nine hospitals were 
randomized to implement the DA (intervention arm) and nine hospitals provided care 
and information as usual (control arm). In the intervention arm, the DA was provided 
to patients at diagnosis and could be further consulted at home. After usage, the DA 
provided a summary to discuss in the subsequent consultation with the patient’s 
urologist. Between August 2014 and June 2016, 368 patients in the intervention arm 
were invited to use the DA and 136 patients were recruited for the control group to 
evaluate usual care. For the current study, health care providers from both arms were 
asked for their evaluation of routines that included either the DA or standard information 
practices.
2.2 Participants and procedure
One hundred and eight urologists and (oncology) nurses from both trial arms were 
invited to fill in an online questionnaire. The questionnaires were adjusted according to 
trial arm; health care providers involved in the intervention arm evaluated working with 
the DA, health care providers in the control arm evaluated usual information routines 
and were asked for their expectation about working with the DA. Questionnaires 
were sent a year after trial start. For the intervention arm, a minimum was required of 
having offered a DA to at least 15 patients. If this number was not reached within a 
year, questionnaires were sent when this number was achieved. As the evaluation of 
usual information was not affected by the number of patients included in the trial, no 
minimum requirements were set for this group and all questionnaires were sent a year 
after trial start. Reminders were sent 7 and 14 days after the first invitation.
2.3 Questionnaire
The questionnaire in the intervention arm focused on DA experiences and was based 
on the Measure Instrument for Determinants of Innovation (MIDI), a validated Dutch 
instrument designed to evaluate health innovations 21. The MIDI questionnaire consisted 
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of 34 questions, grouped into four categories of factors determining implementation 
success; 1) instrument related factors (e.g. ‘The DA provides all information necessary to 
work with it appropriately’), 2) advantages and disadvantages of DA use in daily routine 
(e.g. ‘The DA makes it easier to discuss treatment options with patients’), 3) outcomes 
of DA use (e.g. ‘DA use reduces uncertainty about treatment choice in patients’), and 
4) procedural factors (e.g. ‘I offer the DA to every eligible patient’). All statements were 
answered on a five point likert-scale (‘totally disagree – totally agree’ or ‘never – often’). 
The questionnaire ended with an overall evaluation of DA satisfaction (‘Overall, how 
satisfied are you with the DA’, with 1-very dissatisfied to 10-very satisfied). All questions 
were in Dutch, derived from the original Dutch MIDI questionnaire and further specified 
to DA use 22. The MIDI has proven to be a useful evaluation instrument in a range of 
Dutch studies on implementation of health innovations 23, 24. Additional introductory 
questions were asked about the familiarity with the DA (‘To what degree are you familiar 
with the DA content’, with the answer scale ranging from 1-‘I do not know the DA 
content’ to 4-‘I have read the DA thoroughly’), the number of patients to whom a DAs 
had been offered by the individual respondent (with answer categories ‘none’, ‘between 
1 and 5’, ‘between 6 and 10’ ‘more than 10’) and reasons for not offering a DA to an 
eligible patient, with ten response categories of often reported barriers from literature 
(e.g., time constraints) and an open answer option.
As participants in the control arm group had no DA experience, they were only asked for 
their expectations on the MIDI-categories outcomes and procedural factors for when a DA 
would be implemented. Additionally, questions were asked about the content of usual 
information routines (‘what is provided to patients as usual information’, with seven of 
the most common materials as answering scale; e.g. oral information, hospital leaflets 
or brochures and an open field to report additional materials), health care providers’ 
satisfaction (‘how satisfied are you with the content of information patients receive 
in your hospital’, with answers ranging from 1-not at all satisfied to 10-very satisfied) 
and perceived patient satisfaction with usual information (‘how satisfied do you expect 
that patients are with the current information’, with answers ranging from 1-not at 
all satisfied to 10- very satisfied). We also asked health care providers to estimate the 
information burden experienced by patients (‘how do you perceive the current amount 
of information that is provided to patients’ with answers ranging from 1-patients receive 
too little information to 10-patients receive too much information) and the estimated 
decision-making difficulty (‘in general, how difficult do you expect patients experience 
treatment decision-making’, with answers ranging from 1-no difficulty to 10-much 
difficulty). All participants were asked for basic demographics (gender, age, occupation 
and affiliation). Due to the limited number of participants per individual institution, 




To determine DA implementation levels per hospital, the number of patients who 
received a DA within the trial was compared to the absolute number of Pca patients 
per hospital. For continuous questionnaire data, descriptive statistics were presented as 
means with standard deviations (SD). Categorical data were presented as frequencies 
with percentages. Differences between both study arms were tested with independent 
sample t-tests for continuous data and chi-square tests for categorical data. Some 
questions allowed more than one answer and some health care providers did not answer 
all questions, therefore not all n’s always added up to the same number. All statistical 
analyses were conducted using SPSS version 22.0 (Statistical Package for Social Sciences, 
Chicago, IL, USA), and p-values <.05 were considered statistically significant.
3. RESULTS
Response rate was 58%, equally distributed between both arms (30/33). Responses were 
obtained from health care providers out of all participation hospitals, with a minimum 
of 2 and a maximum of 7 responders from the same hospital. Differences in gender and 
profession between both arms were not statistically significant (Table 1).
3.1 Intervention groups’ evaluation of DA use
During the trial period 368 patients received a DAs in the intervention arm, ranging 
from 1 to 83 patients per hospital. Most respondents (24/29) provided DAs to patients 
themselves. At the moment of filling out the questionnaire, almost half the health 
care providers had offered the DA to a maximum of ten patients (n=15), and a third 
offered the DA to more than ten patients (n=10). Thirty-three reasons were reported 
for not offering a DA, most often because of patient characteristics (patient had already 
decided, refused the DA or was cognitively impaired; mentioned 15 times) or because it 
was forgotten by health care providers (mentioned 5 times). Most urologists (10/14) felt 
they were the most appropriate care provider to deliver the DA to patients, while more 
than half of the oncology nurses (7/12) felt equally or even more suitable for delivering 
the DA to patients.
Health care providers supported the DA content and working procedures; the DA was 
considered practical in use, the content was trusted, and DA use was not perceived to 
be burdensome to patients (Table 2). Mean scores on statements about easier patient-
clinician conversations, clearly noticeable DA effects, and increased patient satisfaction 
were close to the scale midpoints (Table 2). Further, health care providers mainly 
indicated the DA contributed to reaching information goals (comparing treatments 
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options, providing insight in pros and cons), whereas preference clarification and 
uncertainty reduction were mentioned less frequently (Table 2). The mean overall 
satisfaction with the DA was 7.8 (SD=0.7). A large proportion of health care providers 
(24/29) indicated to continue DA use after the trial period.
3.2 Control groups’ evaluation of usual information provision and DA 
expectations
A variety of information routines was reported by health care providers from the 
trial’s control group. Verbal information and hospital specific materials were reported 
to be offered by all health care providers (97%). Additional information next to verbal 
information and hospital specific materials were not standard in all hospitals (Table 3). 
Patients are referred to oncology nurses for additional consultation in hospitals where 
oncology nurses are available, while additional consultation with a radiation oncologist 
is less common (indicated by 60% of respondents). Health care providers are satisfied 
with their current information routines (M=8.1, SD=0.9; with 1=very dissatisfied-
10=very satisfied), but acknowledged that patient satisfaction with usual information 
might be lower (M=7.3, SD=0.7; Table 3). Only 7 respondents (23%) indicated the 
amount of information that patients receive is appropriate, all other respondents (n=23, 
77%) felt Pca patients already receive too much information. On a 1-10 scale, the mean 
decision-making difficulty was estimated at 6.1 (SD=1.8; with 1=no difficulty – 10=much 
difficulty).






























Responses per hospital (min-max) 1-7 1-7 2-7
Overall satisfaction with DA/standard  information
(1=not at all – 10=very much) (mean, sd)
7.8 (0.7) 8.1 (0.9) .14
1 Based on comparison between both study arms, according to applied t-test or chi-square test
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Table 2. Evaluation of DA use in intervention arm
DA group (n=30)
Mean  (SD)
DA content (1=completely disagree – 5=completely agree)
 The DA is based on factual, correct knowledge 4.1 (0.7)
 The DA is based on actual knowledge 4.1 (0.6)
 The information in the DA is complete 3.8 (0.7)
 The DA is steering towards a certain treatment choice 2.4 (0.9)
Procedural (1=completely disagree – 5=completely agree)
 It is clear to me which activities should be executed in what order 4.2 (0.7)
 The DA offers all information needed to work with 3.8 (0.7)
 The DA is too complicated for clinicians to work with 2.4 (1.1)
 The DA fits with standard workflows 3.9 (0.6)
 I have insufficient trust in the DA 2.2 (0.8)
 The DA is suitable for all patients with localized Pca 3.6 (1.1)
 Using the DA saves me time 2.7 (0.8)
Patient outcomes (1=completely disagree – 5=completely agree)
 Effects from using the DA are clearly noticeable 3.2 (0.5)
 Using the DA is stressful to patients 2.1 (0.6)
Activities (1=never – 5=always)
 Indicating all treatment options, each with their pros and cons 4.7 (0.5)
 Indicate for which treatments patient is eligible 4.8 (0.5)
 Indicate where to find relevant information 4.2 (0.9)
 Stimulate patient to weigh pros and cons 4.7 (0.5)
 Offer the DA to all eligible patients 4.2 (1.0)
 Ask for patients’ preferences 4.3 (1.1)
 When needed, further explain the DA 4.2 (1.1)
Expectations on DA outcomes by health care providers in the control group did not 
differ from experiences by health care providers in the intervention group (Table 4). Both 
groups evaluated information goals (comparing treatments, provide insight in pros and 
cons, actual DA usage) slightly higher than patient outcomes (satisfaction, uncertainty, 
clarifying preferences), although differences did not reach statistical significance. Time 
constraints during consultation were not perceived nor expected from DA use. While 
health care providers in the intervention group felt DA implementation had a good fit 
with guidelines (M=4.0, SD=0.3), health care providers in the control group were more 
neutral about DA use being incorporated in treatment guidelines (M=3.1, SD=1.0, 
p<.001; Table 4).
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Table 3. Control groups’ evaluation of standard information routines
Usual care
(n=30)
Current information to Pca patients (n, %):
Verbally 29 (97)
Hospital specific materials 27 (90)
Brochures from patient or professional association 18 (60)
Referral to website 19 (63)
The ‘Prostate book’1 15 (50)
Another DA 13 (43)
Patient group meetings 1 (3)
Other 3 (10)
Standard referral to (n, %):
Oncology nurse 26 (87)
Radiation oncologist 18 (60)
How satisfied are you with current information practices?
(1=not at all – 10=very much) (Mean, SD)
8.1 (0.9)
How satisfied do you expect patients are with current information practices?
(1=not at all – 10=very much) (Mean, SD)
7.3 (0.7)
How do you perceive the current amount of information to Pca patients (1=patients receive too little 
information – 10=patients receive too much information) (Mean, SD)
7.0 (0.8)
How difficult do you expect patients find treatment decision-making?
(1=no difficulty – 10=much difficulty) (Mean, SD)
6.3 (1.8)
DA expectations (1=completely disagree – 5=completely agree) (mean, SD)
Patients better understand information about illness and treatments 3.7 (0.5)
Patients will value clinicians’ advice less 2.4 (0.8)
Patients will be better prepared to ask questions 3.9 (0.6)
It will be easier to discuss what matters most to patients 3.7 (0.7)
The DA should be offered by a urologist 2.9 (1.0)
Patients will have a more active role in treatment decision-making 3.5 (0.6)
1 The ‘Prostate book’ is distributed for free by a pharmaceutical company to all Dutch hospitals 
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Procedural (1=completely disagree – 5=completely agree) (mean, SD)
The DA is (would be) practical in use 3.8 (0.5) 3.5 (0.9) .10
The DA makes (would make) it easier to discuss treatment options 
with patients
3.4 (0.6) 3.7 (0.7) .11
The DA fits (should be part of ) guidelines and procedures 4.0 (0.3) 3.1 (1.0) <.001
Time constraint (n, %)
Shorter consultations 1 (4) 2 (8) .76
Equally long consultations 25 (86) 22 (84)
Longer consultations 3 (10) 2 (8)
Information goals (1=completely disagree – 5=completely agree)
(mean, SD)
Comparing treatment alternatives 4.0 (0.4) 3.7 (0.7) .08
Provide insight in treatment pros and cons 4.1 (0.5) 3.9 (0.6) .24
Patients actually using the DA 3.7 (0.5) 3.6 (0.6) .34
Patient outcomes (1=completely disagree – 5=completely agree)
(mean, SD)
Reduce uncertainty about treatment choice 3.7 (0.6) 3.9 (0.5) .43
Increase satisfaction with information received 3.8 (0.5) 3.7 (0.6) .24
Clarify patient preferences 3.8 (0.5) 3.8 (0.6) .93
1 Based on comparison between both study arms, according to applied t-test or chi-square test
4. DISCUSSION AND CONCLUSION
4.1 Discussion
To increase understanding of health care providers’ opinions about DA use and standard 
information routines, this study surveyed health care providers who were involved in a 
cluster RCT that compared a novel online Pca treatment DA to standard information 
routines.  Care providers who were randomized to the trial’s DA group and used the DA 
in clinical practice, were positive about the DA content and recommended continued 
use after the trial. Time was not expected nor perceived as a barrier for DA use by care 
providers from both groups. In the control group we found health care providers to 
be equally satisfied with standard information routines, although they acknowledged 
that satisfaction might be lower for patients and the amount of information provided to 
patients could be too much.
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Models on successful implementation of health innovations emphasize the facilitating 
role of positive patient outcomes 11, 21, 25. The intended goal of DAs is to increase 
knowledge, help clarify personal values and to help patient take a more active role 
in the process of treatment selection 5. For the particular DA used in this study, it was 
already found that treatment choices made with the DA were more often in line with 
the patient’s preferences compared to preferred option by the clinician 26. Nevertheless, 
this study indicates that healthcare providers from both groups did not have strong 
experiences or expectations about patient outcomes after DA use. Health care providers 
answered items related to these aspects most often around the scale midpoints. This 
could indicate two potential barriers for DA implementation; first, care providers could 
be insufficiently aware of patients outcomes associated with DA use, and secondly, 
patient outcomes could be insufficiently observable by care providers at the moment 
of treatment decision making.
To revolve both issues, care providers should be made more aware of the potential 
benefits associated with DA use. Once implemented, care providers could be motivated 
to continue DA distribution by receiving structural feedback on DA usage rates and 
patient outcomes (e.g. knowledge, satisfaction with decision, and regret). This should 
also take into account that effects may emerge long after the decision was made (e.g., 
one year post-decision), requiring long-term follow-ups 9, 27.
In contrast to earlier studies, this study showed that time constraints were not perceived 
by health care providers who worked with the DA nor expected by health care providers 
from the control arm 11, 28. Possibly, this is the result of the growing awareness and interest 
for SDM and DAs in recent years 29-31. More awareness for DA use could have adjusted our 
respondents’ expectations about consultation length when using DAs. Moreover, three 
major clinical trials with different Pca treatment DAs have been conducted recently in 
The Netherlands, with involvement of almost half of all Dutch hospitals in one of these 
trials and thus increasing scientific and public attention for DA usage 20, 32, 33. This may 
have contributed to our finding that time constraint is not considered a barrier for DA 
use in Dutch Pca care. It has to be noted that care paths in Dutch Pca care already allow 
for multiple contact moments needed to facilitate SDM and DA use (e.g. choice talk, 
option talk, decision talk), whereas for DA use in other diseases or conditions some of 
these moments need to be added 34.
We found that the number of patients who received a DA varied widely between hospital 
sites. The majority of respondents in this study indicated when a DA was not offered to an 
eligible patient, this was because it was forgotten or the clinician estimated the patient 
was not suited or willing to use a DA which could potentially be a misinterpretation 
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of patient preferences 35. In our study we did not make use of automated systems to 
distribute the DA (e.g. automated sending though a link with patient record), although 
some studies suggested a system-based delivery method is potentially most successful 
8.  Automated systems could help recognizing eligible patients with a lower risk of 
forgetting or misinterpreting patient preferences to use a DA.
Furthermore, our study found mixed views on whether a DA should be introduced 
by a urologist or an (oncology) nurse and if DA distribution should be part of formal 
treatment guidelines. In this study, both urologist and oncology nurses felt themselves 
suited to distribute the DA. When this responsibility is not clearly defined in a local 
hospital’s care path, a diffusion of responsibility could emerge that hinders sustained 
DA implementation.
Another potential barrier for DA implementation in Pca care is that health care providers 
in our control arm reported high levels of satisfaction with their existing (hospital 
specific) information materials and verbal information provision. Although health care 
providers in the current study acknowledged that patient information satisfaction might 
be lower compared to their own satisfaction, this might even be an overestimation of 
actual patient satisfaction. Previous studies showed that considerable proportions of 
Pca patients are dissatisfied with information received and that large discrepancies 
exist between actual information preferences and their physician’s perceptions 36, 
37. This difference between actual and perceived information satisfaction could lead 
to reluctance among health care providers to use externally developed tools such as 
DAs. It is therefore important to inform health care providers about patients’ actual 
(information) needs, but also to provide the opportunity to adapt the DA to hospital 
specific materials that care providers already feel satisfied with.
Some limitations of this study need to be mentioned. First, the current trial increased 
awareness for applying SDM in Pca treatment decision-making and for DAs in both 
study arms. Moreover, other Pca DAs initiatives were enrolled in a large number of 
Dutch hospitals as well 32, 33. It can therefore not be assumed with certainty that no 
individual patient from the control group came into contact with any of the available 
DAs. However, we do not expect a significant effect on our results from this potential 
contamination, as no DAs were actively implemented in the hospitals from our study’s 
control group.
A second limitation is the fact that DA use in this study was linked to the RCT, meaning 
that patients who were provided with the DA, were also asked to take part in the RCT 
and fill out three questionnaires. Discussing the DA with a patient therefore always 
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coincided with explaining the trial as well, which could be experienced as an additional 
burden by health care providers. Moreover, when health care providers distributed a 
low number of DAs this could be because they were unsupportive of DA use or because 
of low involvement with the trial. Potentially, those less involved health care providers 
could also have been less likely to fill out the questionnaire for this study. This holds the 
risk that the opinion of these health care providers are underrepresented in this study.
4.2 Conclusions
Health care providers who implemented the DA in clinical practice supported content 
and usability. Expectations on the effects of DA use were mainly related to improved 
information practices and less often to other patient outcomes. This could point at 
unawareness among care providers about common DA effects. More training and 
feedback on DA usage could be needed to educate care providers about possible DA 
effects. Importantly, this study disconfirmed time constraints as a barrier for further 
implementation. Health care providers reported high satisfaction with usual information, 
in particular hospital specific and own oral information, and fear of providing too 
much information. Distributing a DA through an external source could therefore be an 
implementation barrier. A single optimal mode of DA delivery was not identified in this 
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UPTAKE AND USAGE OF AN ONLINE PROSTATE 
CANCER TREATMENT DECISION AID IN DUTCH 
CLINICAL PRACTICE: A QUANTITATIVE ANALYSIS 






L.V. van de Poll-Franse




Implementation of patients decision aids (DAs) in routine clinical care is generally low. 
This study evaluated uptake and usage of a novel Dutch web-based prostate cancer (Pca) 
treatment DA within the Prostate Cancer Patient Centered Care trial (PCPCC). From an 
estimated total patient sample 1,006 patients, 351 received a DA (35% implementation 
rate; hospital ranges 16-84%). After receipt of the DA, most patients accessed the DA, 
utilized most functions, although not completely, and discussed the DA summary in a 
subsequent consultation with their care provider. Including nurses for dissemination 
of DAs seemed to positively affect DA uptake. Once received, patients seemed able to 
use the DA and engage in SDM as intended, however, DA uptake and complete usage 
of all DA components should be further improved. Prior to the diagnosis consultation, 
handing out of the DA should be prepared.
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BACKGROUND
When diagnosed with localized prostate cancer (Pca), patients can face a choice between 
multiple surgical and radiotherapy options, or decide not to be treated immediately by 
following an active surveillance (AS) protocol. In the absence of a generally superior 
treatment option, patient preferences should guide this treatment selection process 
1-3. When such a preference-sensitive health decision has to be made, a collaborative 
approach from both the patient and care provider is preferred to select the best suiting 
treatment 4. In this process of shared decision-making (SDM) a doctor provides all 
relevant information about the disease, treatments and consequences, and the patient 
shares his preferences and concerns 5.
SDM can be initiated or enhanced with help from decision support tools, such as 
decision aids (DAs). DAs come in multiple formats (e.g. booklet, web-based), but all 
provide structured and balanced information about the disease, available treatments, 
and the risks and benefits associated with these treatments 4, 6. Often, DAs also include 
values clarification exercises (VCEs) to elicit patient preferences 7. Previous studies have 
shown that patients, after using a DA, have more knowledge, lower decisional conflict, 
and more accurate risk perceptions 8. If VCEs are included, patients are also more likely 
to select a treatment that is consistent with their values 8.  
While many trials have reported beneficial patient outcomes after the use of  decision 
support tools,  routine use of such tools in clinical care still is low 9. Only a few examples 
are known of sustained DA use after their initial evaluation in a clinical trial 10, 11. Studies 
that have evaluated DA implementation from a care providers’ perspective identified 
important barriers, such as limited confidence in the (content of the) tools, time pressure 
and concerns about disrupting work procedures 9, 12. A common patient-reported 
barrier is the feeling of being unable to engage in SDM or to use a DA, rather than being 
unwilling to do so 13.
Recently, policy makers in The Netherlands adopted SDM and DAs in their effort to 
improve quality of care 14. Funding programs are encouraging SDM and usage of DAs. 
As such, patient groups, professional bodies, health care insurers and hospitals are 
stimulated to implement DAs for multiple medical conditions, and DA developers are 
stimulated to develop new DAs 15. Although much is known about attitudes, barriers 
and facilitators towards SDM and DAs, there is limited data available about actual 
achieved degrees of implementation and the precise proportion of patients using DAs 
once distributed. Often this is because the tool or patient population does not allow 
for detailed registration of the exact number of eligible patients, number of tools 
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distributed or monitoring of actual usage. For example, leaflet DAs could be distributed 
in waiting room areas, and in such circumstances it is unknown who takes them. For 
an online DA that is publicly available, it is often unknown which visitors are actually 
patients facing a treatment decision at that particular moment. Moreover, if a DA is used 
in multiple hospitals, and detailed information on actual uptake and usage is lacking, 
less can be learned from local best practices.
A novel web-based Dutch Pca treatment DA, which was investigated in a cluster 
randomized controlled trial, allowed for structural monitoring of DA uptake and 
usage in a quantifiable patient population 16. Therefore, this study aimed to improve 
understanding of the implementation results by comparing the DA uptake across 
hospitals and the actual usage of the DA and its elements (e.g. VCEs) by patients.
METHODS
Study sites
Eighteen Dutch hospitals agreed to participate in the trial, and after randomization, 
the DA was implemented in nine Dutch hospitals. The other nine hospitals formed the 
control arm and delivered care as usual 17. One academic medical center participated in 
the trial, which was randomized into the control arm. All other hospitals were teaching 
hospitals. Two hospitals that were involved in DA development (before randomization) 
were randomized by pure chance into the intervention arm. Randomization was 
performed by an independent statistician, blind to hospital names 17. The hospitals 
involved offered either one (AS) or two treatments (AS and surgery or radiotherapy) 
at their own location. Referral to another hospital for specific treatments is common in 
The Netherlands. Implementation started in August 2014 and data collection ended in 
January 2016. The need for ethical approval was waived by the regional medical ethics 
committee (reference: NW2014-03).
Implementation/delivery method
All urology departments of the hospitals enrolled in the trial’s DA group were visited 
by the researchers and received an explanation of the purpose of the RCT. The DA was 
presented to the medical staff and the proposed method of delivery was explained. The 
explanation included that the DA would be introduced to patients in addition to the 
presentation of standard information. Depending on local work routines, the DA would 
usually be introduced by the urologist at diagnosis or by an oncology nurse during 
consultation following diagnosis. Next to the DA, patients received all information 
and materials (e.g. hospital brochures) that would also have been provided otherwise. 
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Patients accessed the DA with an individual access code that was provided to them 
on a card by their care provider. On that card, the care provider also indicated which 
of the treatments covered by the DA (AS, radical prostatectomy, brachytherapy, and 
external beam radiotherapy) were eligible for the patient. For gathering DA user data, 
receiving the post-questionnaire, and combining DA user data and questionnaire data, 
patients signed informed consent. The DA could be used by patients regardless of trial 
participation and consent, DA usage was then still monitored, as this was anonymized 
data not linked to individual patients.
Decision aid
The DA is in Dutch language and available online-only after login (http://prostaat.
keuzehulp.nl). After accessing the DA, patients are presented with general information 
about Pca and treatments first. Based on the treatments available to the patient, detailed 
information is then provided about all treatments. Information about treatments 
is broken up into a section about active surveillance versus treatment, and a section 
about survery versus radiotherapy. Per section, values clarification exercises (VCEs) are 
included to elicit patient preferences for treatment. These VCEs are presented as tradeoffs 
between treatment attributes. The DA ends with a summary of all indicated preferences, 
including a treatment preference. The DA summary can be printed and brought to the 
following consultation with their clinician, or re-accessed online, to enable a shared 
patient-doctor conversation about aspects relevant to the patient. The development 
process and DA content (including examples of the VCEs and DA summary page) have 
been described in more detail before 16.
Data collection and patient questionnaires
For this study, data was gathered on the number of DAs provided by healthcare 
providers and the usage of the DA by patients. As the DA was provided as part of a RCT, 
both healthcare providers and patients signed informed consent. Study numbers on 
the informed consent forms were hospital specific and linked to the DA access codes. 
An informed consent signed by a healthcare provider represented a DA being provided 
to a patient; actual patient use of the DA was monitored by means of log files. Data 
from the questionnaires were linked to DA user data based on study number. Patient 
characteristics from informed consent were saved separately from the DA user data to 
ensure anonymity.
To determine the degree of implementation, information on the total number of 
eligible Pca patients per hospital was obtained from The Netherlands Cancer Registry 
(NCR) for a five year period (2009-2013) prior to the start of DA implementation. All 
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participating hospitals allowed the NCR to provide us with data about their number of 
patients diagnosed, except for one. From these registry data, an estimation was made 
on the expected number of eligible Pca patients during the trial period. Eligibility was 
defined as being diagnosed with low or intermediate risk Pca (PSA level below 20 and a 
maximum Gleason score of 7) 18. Additionally, patients were required to have access to 
the Internet and to be able to read and understand Dutch language.
An online questionnaire to evaluate DA usage by patients, was sent (paper version on 
request) to patients after the treatment decision was made. The questionnaire included 
items about when the DA was received and from who (urologist or nurse), whether the 
DA was sufficiently explained, and whether the DA summary was discussed during a 
subsequent consultation.
Data analysis
The degree of implementation was calculated by dividing the number of DAs provided 
to patients (based on access cards distributed by care providers) by the estimated total 
number of eligible Pca patients (based on national registry data) per hospital. Descriptive 
statistics were presented as means (and SDs) for continuous variables and frequencies 
(and percentages) for categorical variables. Group comparisons between DA users and 
non-DA users and between questionnaire responders and non-responders were made 
with t-tests for continuous variables and chi-square tests for categorical data. Statistical 
analyses were conducted using SPSS 22.0 (Statistical Package for Social Sciences, 
Chicago, IL). Tests were considered statistically significant if p<.05.
RESULTS
From national registry data, it was estimated that during the trial period, 1,006 patients 
were diagnosed with localized Pca in participating hospitals. With 351 DAs distributed to 
patients, the average achieved degree of implementation across all study locations was 
35%, varying between 16% and 84% across hospitals. Highest implementation levels 
(84 and 79%) were achieved in hospitals who were also involved in DA development. 
Implementation did not succeed in one hospital due to a lack of organizational support 
(also no registry data were obtained for this hospital), this hospital was therefore 
excluded from further analyses. Detailed implementation results across all participating 
hospitals is presented in Table 1.
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From all patients (N=351) receiving a DA, 277 patients accessed the DA (79%; Table 1). 
Age did not significantly differ between DA users versus non-DA users (65.2 vs 65.6, 
p=.60). A larger proportion of non-DA users was lower educated, but differences in 
education level between DA users and non-users did not reach statistical significance. 
The DA was used more often by patients with a Gleason grade 6 tumor (usage rate 92%), 
compared to patients with a Gleason grade 7 tumor (usage rate 83%, c2(1, N=220)=5.18, 
p<.02; Table 2).
DA log file data showed that of 106 patients eligible for AS, 69 patients (65%) read all 
information about the comparison between AS and treatments, and 163/277 (59%) 
completed the section about surgery and radiotherapy (all DA users were eligible for at 
least one of these treatments). The VCEs after the first step (AS versus treatment) were 
fully completed by 67 of 106 eligible DA users (63%), and after the second step (surgery 
versus radiotherapy) by 66/277 (24%). A treatment preference was indicated by 197 DA 
users (71% of all DA users). Usage of the DA elements was consistent among patients 
from different hospitals (Table 3).
The post-decision making questionnaire was sent to 273 patients who gave informed 
consent (consent rate 78%) and was filled out by 235 respondents (response rate 86%). 
Questionnaire responders were more likely to have also used the DA (usage rate 86% 
vs 68%, c2(1, N=273)=7.81, p<.01), and where slightly older (62.5 vs 64.9, t(271)=-2.29, 
p=.02) compared to non-responders. Marital status, educational level, PSA level and 
Gleason score were collected with the questionnaire and therefore not available for non-
responders (Table 2). The flow diagram of patients included in this study is presented 
in Figure 1.
From the questionnaire responders who used the DA (N=193), 137 responders (71%) 
indicated that the summary obtained from the DA, was discussed with their urologist 
in a subsequent consultation (Table 1). Most respondents indicated that the DA was 
received within a week from diagnosis (154/208, 74%), and 158 respondents (85%) 
felt the DA was sufficiently explained (28 respondents indicated no or insufficient 
explanation was received). One out of four patients received the DA from an (oncology) 
nurse in, ranging between hospitals from 0 up to two out every three patients. In all 
other occasions, the DA was received from the urologist. A majority of the questionnaire 
responders (163/209, 78%) indicated that the online format of the DA also was the 
preferred format, 46 responders (22%) would have preferred a paper DA instead (Table 
3). Figure 2 presents a flowchart of the most common workflow for DA dissemination 
across participating hospitals.
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Total estimated population newly diagnosed Pca patients in hospitals randomized to DA 
implementation (n=1,006) 
Patients not receiving DA (n=655) Patients receiving DA (n=351) 
Patients not included in analysis Patients not using 
DA (n=74) 






























Patient has first consultation in outpatient clinic after referral for prostate complaints or elevated PSA 
test (consultation with urologist) 
Patient undergoes diagnostic tests (e.g. echography, prostate biopsy, blood tests) 
Eligible treatments are discussed in oncology 
meeting, and assessment of whether patient can 
receive DA (based on treatment options) 
(Oncology) nurse prepares DA invitation and includes 
a note to hand out the DA in the electronic medical 
record  
Patient returns to outpatient clinic for test results/diagnosis (consultation with urologist). DA is 
provided by urologist during consultation   
In case of a follow-up meeting with (oncology) nurse: 
DA is handed out and explained by the nurse 
Additional consultations by patient request  
(e.g. radiation oncologist)  
Patient returns to outpatient clinic for treatment decision (consultation with urologist). DA summary is 
discussed 
Figure 2. Flow chart of most common workflow for DA dissemination in participating hospitals
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DISCUSSION
This study structurally evaluated implementation of a web-based Pca treatment DA in 
nine Dutch hospitals. All hospitals included the DA as part of their information routine 
following Pca diagnosis. On average, one in every three newly diagnosed Pca patients 
received a DA, but large differences were observed in implementation rates per hospital. 
Once a DA was distributed, most patients accessed the DA, indicated a treatment 
preference, and discussed the summary obtained from the DA with their urologist.
Implementation was highest in hospitals of care providers who were also involved in 
the development of the DA, and by random assignment enrolled in the intervention 
arm. Involvement during DA development may have increased intrinsic motivation to 
implement the DA. This motivational approach is identified as an important driver for 
implementing change in health care and applied in other DA development processes as 
well 19, 20. To increase intrinsic motivation for care providers from institutions who were 
not involved in the DA development, it could be useful to offer opportunities to become 
more involved with the DA. For example, customization of the DA to match hospital 
layout, as well as the possibility to integrate the DA with existing hospital materials 
could improve adoption of the DA by care providers in other hospitals.
Most patients received the DA from their urologist within the first week after diagnosis 
and felt that the DA was sufficiently explained to them. In most hospitals the role of 
nurses in this process of distributing DAs was limited. In an earlier study among care 
providers we found that nurses and urologists consider themselves equally suitable to 
provide patients with a DA, and that distributing DAs should not be an exclusive clinician 
task 21. Therefore, overall implementation could be further improved if nurses become 
more involved in the process of distributing DAs. As in hospitals that implemented best, 
nurses either prepared DA distribution prior to the diagnosis consultation, or handed 
out the DA themselves in a subsequent follow up consultation (Figure 2).
Respondents with a Gleason grade 6 tumor used the DA more often compared to 
respondents with a Gleason grade 7 tumor. Gleason scores provide a prognosis of 
oncological outcomes; a Gleason 6 score (or lower) represents the most favorable 
condition 22. Consequently, patients with a Gleason grade 6 more often had all four 
available treatment options to choose from, while the choice set of eligible treatments 
for patients with a higher Gleason grade 7 tumor, was often reduced. Choosing from a 
smaller choice set can be perceived as less difficult, resulting in a different information 
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search behavior compared to patients who need information about more options 23-25. 
Therefore, the DA could have been perceived as less needed by patients with a Gleason 
grade 7 tumor.
DA users differed in the amount of information that they read and which VCEs they 
answered within the DA. This could indicate that DA users differed in their information 
needs or did not fully understand how to navigate within the DA. However, in the 
questionnaire, a large majority of responders (both DA users and non-DA users) felt 
the DA was sufficiently explained and in previous usability tests, easy navigation was 
confirmed 16. It is therefore more likely that the DA was used for specific information, 
beyond the information that was already known from other sources. The selective 
answering of VCEs could be because patients were undecided on the VCEs that were not 
answered, or instead, already had a clear treatment preference and did not feel the need 
to provide an explicit answer to the VCEs. This is confirmed by the large majority of DA 
users who were able to indicate a treatment preference. Follow-up research is needed 
to determine if the degree of DA completion has led to differences in patient reported 
outcomes (e.g. information satisfaction and regret).
A majority of DA users indicated that the DA summary was discussed with their clinician 
in a subsequent consultation. The summary reported the patient’s VCE responses and 
treatment preference. With such a summary on paper during consultation, patients 
were encouraged to overcome the barrier of feeling unable to engage in SDM 13. To 
further stimulate SDM in routine clinical care and engage patients and care providers in 
discussing preferences and values, distribution of the DA among eligible patients should 
be further optimized. One way to increase delivery could be to automate DA delivery, 
for example by having the electronic medical record automatically signal if a patient 
should receive a DA 26. Alternatively, eligibility for the DA could be included as part of 
the multidisciplinary team meeting, where all newly diagnosed patients are discussed, 
and in the preparation of the consultation (e.g. ‘did the patient already receive a DA?’).
A major strength of this study is that it is one of the first to analyze DA implementation in 
a structured manner, with data on every step from DA distribution to treatment choice 
(number of DAs distributed, log file data on DA usage, and a post-decision evaluation). 
This study covers a largely neglected area in (Pca) DA implementation studies, that is, 
actual DA usage data 27. Our results showed that implementation of DAs should not only 
be evaluated based on the number of distributed DAs, but require a more thorough 
investigation of the distribution procedures (e.g. role of nurses) and usage of specific DA 
elements (e.g. VCEs completed).
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A limitation of the current study was that distribution of the DA was linked to trial 
participation measuring the DA’s effectiveness 17. Next to introducing the DA, care 
providers also had to explain enrollment in the trial and had to obtain informed 
consent to have patients participate in the questionnaire study. Although patients were 
informed that the DA could also be used without participation in the trial, it could have 
served as a barrier for DA use for some patients. Also, determination of the total number 
of eligible patients was estimated based on the number of Pca patients registered in 
the Netherlands cancer registry in previous years (2009-2013). Regional trends (hospital 
mergers, changes in offered treatments) could potentially have caused some inaccuracy 
in the estimation of the number of patients during the trial per hospital. Nevertheless, as 
these number are fairly stable over time it is unlikely that this would have a large influence 
on our findings. Moreover, the estimation was based on tumor stage only (cT1 and cT2), 
which could mean that the registry data included patients that would not have met 
the DA inclusion criteria due to comorbidities or other clinical characteristics. Therefore, 
the calculated degrees of implementation could underestimate actual implementation 
slightly. This, however, is likely to occur in all hospitals and could therefore contribute 
to a margin of error within the estimation that is equal for all hospitals and as such, is 
unlikely to explain variations in implementation rates observed across hospitals.
Conclusion
While many studies have provided evidence that DAs can be effective tools to support 
SDM in clinical practice, this study is one of the first to provide a detailed analysis of 
the implementation results and usage rates of a DA in clinical routine. Eight out of nine 
hospitals involved in this study succeeded to implement a novel Dutch web-based Pca 
treatment DA in clinical routine within the trial period. Uptake between these hospitals 
varied from incidental to structural and patients varied in the extent to which they 
utilized all DA components. Most patients expressed a treatment preference and used 
the DA summary to talk about values and preferences with their urologist. Based on our 
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Objectives: To assess implementation rates after multi-regional implementation of 
three different prostate cancer treatment decision aids (DA) in The Netherlands and 
patient-perceived barriers and facilitators to use a DA. 
Patients and Methods: In total, 33 hospitals were asked to implement a DA in their 
routine care and to participate in this implementation study. Implementation rates 
for each DA were calculated per hospital. After treatment choice, patients (n=1,033) 
completed a survey on pre-formulated barriers and facilitators to use a DA. 
Results: Overall implementation of the DAs in all hospitals was 40%. For each DA, 
implementation varied largely between hospitals from incidental (<10% of eligible 
patients receiving a DA) to high rates of implementation (>80%). All three DAs were 
evaluated positively by patients, although the concise and paper DAs yielded higher 
satisfaction scores compared to an elaborate online DA. Overall, patients were most 
satisfied when they received the DA within a week after diagnosis. The pre-formulated 
barriers to DA usage were experienced by less than 10% of the patients, and most 
patients confirmed the pre-formulated facilitators.
Conclusion: Overall implementation rate of the DAs in clinical routine was 40%  and a 
wide variation in uptake across hospitals was observed for each DA. Most patients were 
satisfied with the DA they received. Sustained implementation of DAs in clinical routine 





Prostate cancer (Pca) is the most common malignancy diagnosed in men in the western 
world. In case of localized prostate cancer, patients are typically required to choose 
between multiple equivalent treatment options. Although survival perspectives with 
each treatment are similar, treatment procedures and risk for side-effects vary, and many 
patients have poor understanding of these differences between treatments 1. Therefore, 
clinical guidelines concerning localized Pca suggest a shared patient-doctor decision to 
incorporate patient preferences and values into the treatment decision 2-5. Decision aids 
(DAs) have been developed to assist patients and care providers with shared decision 
making (SDM) 6. 
Evidence for the beneficial effects of applying DAs is widely available and shows that 
patients have better knowledge of the treatment options, and are more aware of their 
personal preferences and values 7. As a consequence, DAs help patients to take a more 
active role in the decision-making process 8. So far, most DA trials, including those 
related to Pca treatment, focused on determining the DA effects, with limited attention 
for implementation aspects 7, 9. Many DA trials took place within a single institution 
or location, and even if the absolute number of the DAs distributed was known, their 
relative reach within the targeted patient population often remained unknown 10, 11. 
Moreover, uptake of DAs in daily routine, outside of clinical trials, is low, resulting in 
limited knowledge about successful DA implementation at a large scale 7, 12-17. 
After distribution of the DA to eligible patients, the next step in implementation is actual 
DA use by patients. Patient-perceived barriers and facilitators related to DA usage, have 
been studied more extensively 13, 18-22. Common barriers against DA usage from the 
patients’ perspective are insufficient trust in the DA quality or its benefits, the DA being 
unpractical in use, inadequate timing (e.g. the DA being offered too late after diagnosis) 
or inadequate explanation of how to use the DA. Patient-perceived facilitators include 
that the DA is practical in use, and that the presented information is complete and 
trusted 13, 18-22.
With the current implementation study, we aimed to investigate the implementation rate 
of these three DAs in routine Pca care in the Netherlands, and aimed to identify possible 
barriers and facilitators from the patients´ perspective. This study was conducted by 
the Joint Implementation Prostate cancer Patient-centered care (JPPPA) consortium, 




The three decision aids
Each of the three DAs involved was developed according to the International Patient 
Decision Aids Standards (IPDAS) and contained information about the disease, treatment 
options, and (dis)advantages of all options based on (inter)national guidelines and 
international literature 23. Patients, urologists and radiation oncologists were involved 
in the development and review process of the DAs 24-26. In each DA, the same choice 
options were presented: surgery, brachytherapy, and external beam radiotherapy, as 
well as the option of active surveillance. The DAs varied in their format and length. 
DA1 was a concise booklet (14 pages), DA2 was an even more concise (in diagram style 
with short explanations) booklet or online DA (by patient choice), and DA3 was an 
elaborate online DA with values clarification exercises (VCEs). The DA format coincided 
with the intended moment of use. DA1 and DA2 aimed to be used within consultations, 
while  DA3’s intended use was outside consultation. The characteristics of the DAs are 
presented in Table 1.  Detailed descriptions of the separate trials investigating the DA 
effects have been published earlier 24-27.
Setting and participants
Thirty-three hospitals (out of a total of 90 hospitals in The Netherlands) implemented one 
of the three DAs in treatment counseling. Each DA was implemented in a specific region 
of The Netherlands (DA1 – East; 8 hospitals; DA2 – North-West: 16 hospitals; DA3 – South: 
9 hospitals). Per DA, hospitals were recruited to participate based on convenience (e.g., 
distance), allocation of DAs to hospitals was not randomized. The DAs were handed out 
to patients newly diagnosed with localized Pca. For all 3 DAs, patients were eligible to 
participate if they had the possibility to choose between at least two treatments covered 
by the DA. Assessment of whether the DA was applicable (e.g. eligibility for at least two 
treatments covered by the DA) was done by the patient’s urologist. Actual distribution 
of the DA was done by either the urologist or a specialized nurse, depending on what 
best fitted with existing local care pathways. After the treatment decision was made, 
but before treatment started, patients received a questionnaire to evaluate receipt and 
usage of the DA. All data were collected between July 2013 and June 2016. Research 
protocols from each DA group were reviewed by their respective local institutional 
























































































































































































































































































































































































































































































































































































































































































































































































































































Our primary outcome measure was the implementation rate. This rate was calculated by 
the proportion of patients who received a DA compared to the estimated total number 
of eligible Pca patients per hospital during the period the DA was implemented. Since 
the total number of eligible patients was not prospectively registered in a structured 
manner in all participating hospitals, an estimation was based on hospital-specific 
registry data of the six years prior to the current project, retrieved from the Netherlands 
Cancer Registry.
After a treatment decision was made, a questionnaire was used to collect self-reported 
data about patient’s demographic variables (age, marital status, having children and 
educational level). Evaluation measures consisted of DA distribution procedures (e.g. 
‘Who presented the DA to you?’), DA user-friendliness (e.g. ‘Did it occur fonts were too 
small?’), and a 24-item list of barriers and facilitators for DA use (e.g. ‘I had insufficient 
trust in the DA’) based on literature 22 (items presented in Table 3). All three DA groups 
used the same questionnaires to evaluate DA use in order to enable combined data 
analyses.
Data analysis
Descriptive questionnaire data are presented as means (Ms) with standard deviations 
(SDs) for continuous variables, and frequencies and percentages for categorical 
variables. Comparisons between DAs for continuous variables were made with 
analyses of variance (ANOVA) and Bonferroni post-hoc tests and with chi-square tests 
for categorical variables. Statistical analyses were conducted with SPSS 22.0 (Statistical 
Package for Social Sciences, Chicago, IL). Tests were two-sided and considered 
statistically significant if p<.05.
RESULTS
 During the study period, 908 newly diagnosed Pca patients received a DA out 
of an estimated total of 2,285 eligible patients, resulting in an overall implementation 
rate of 40%. With each DA, high implementation levels (>80%) were achieved in 1 or 
2 hospitals, whereas for the other hospitals implementation varied considerably (2-
80%). Highest average implementation was achieved with the concise paper DA1 
(60%), average implementation levels for DA2 and DA3 were comparable (34-35%). 




Out of the 908 patients who received a DA, 673 patients (Mage= 65.7, SD=6.0) agreed to 
complete the post-decision questionnaire evaluating DA use (response 74%). Compared 
to participants from both other DA groups, participants from DA3 were slightly younger 
and more often highly educated (Table 2). Mean PSA and Gleason scores were lower for 
participants from DA3, but the same distribution across categories was found between 
DA groups (Table 2). 
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Figure 1. Implementation rates per hospital
Most participants indicated that they received the DA from their urologist (n=478, 71%) 
and perceived that the urologist is the most suitable person to hand out a DA (n=511, 
76%; Table 3). However, of the participants who received the DA from a nurse (n=192, 
29%), 60% considered the nurse to be the most suitable person for this (data not shown). 
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Barriers against DA usage were reported by less than 10% of the participants, regardless 
of which DA they received (Table 3). Differences  found between DAs, were related 
to format (unpractical, insufficiently adjusted to personal preferences) or subjective 
evaluations (no confidence, expected no benefit). Overall, most barriers were reported 
for the elaborate online DA3. 
Facilitators for DA use were reported by a large majority of participants (Table 2). For all 
DAs, more than 80% of participants found the DA pleasant to use and well organized 
and were confident in the DA quality. Overall, facilitators were reported mostly by 
respondents who used the most concise DA (DA2) and least by patients who used DA3. 
A full overview of the responses to perceived barriers and facilitators for all DA formats 
is presented in Table 3.







Age at informed consent, mean (SD) 66.0 (5.9) 66.3 (6.2) 64.9 (6.0) .04
Marital status, n (%)
Married/living together 222 (87%) 149 (81%) 208 (88%)
Single/Other 33 (13%) 34 (19%) 27 (12%)
Education, n (%)
Low 94 (37%) 64 (35%) 76 (33%) .008
Medium 62 (25%) 66 (36%) 54 (23%)
High 96 (38%) 53 (29%) 101 (44%)
Gleason score, mean (SD)1 6.5 (0.7) 6.6 (0.9) 6.4 (0.8) .05
≤6, n (%) 158 (63%) 90 (56%) 134 (61%)
≥7, n (%) 93 (37%) 71 (44%) 86 (39%)
Missing, n 4 22 15
PSA level, mean (SD)1 9.2 (5.3) 9.9 (8.3) 7.9 (3.9) .002
≤10.0, n (%) 183 (73%) 110 (68%) 180 (77%)
10.1-20.0, n (%) 60 (24%) 42 (26%) 49 (21%)
≥20.1, n (%) 8 (3%) 9 (6%) 5 (2%)
Missing, n 4 22 1
P-values report comparisons between trials for the control groups and DA groups, according to t-tests and analysis of 
variance (ANOVA) for means and χ2-tests for frequencies.
Numbers may not always add up to the same n due to missing data (e.g. item non-response), percentages are rounded.











Practical implementation, agreed with statement, n (%)
Received DA from doctor 189 (78%) 138 (76%) 151 (64%) .003
Doctor is most suitable to provide DA 200 (82%) 143 (81%) 168 (72%) .02
Received DA within a week from diagnosis 175 (69%) 159 (87%) 154 (66%) <.001
Satisfied with moment of receipt 232 (92%) 173 (95%) 196 (92%)
DA was sufficiently explained 226 (89%) 161 (88%) 186 (87%)
Satisfied with DA format 250 (99%) 176 (96%) 168 (79%) <.001
DA added much to other information 181 (83%) 141 (83%) 107 (56%) <.001
Implementation barriers confirmed, n (%)
Forgot to use the DA 6 (2%) 4 (2%) 9 (4%)
DA was too difficult 7 (3%) 3 (2%) 10 (5%)
DA was steering towards a treatment 21 (9%) 14 (8%) 20 (10%)
DA was unclear 5 (2%) 9 (5%) 12 (6%)
DA was unpractical 10 (4%) 9 (5%) 25 (12%) .002
Was not confident in DA 20 (8%) 8 (4%) 24 (12%) .03
Expected no benefit 15 (6%) 15 (8%) 29 (14%) .01
Expected DA would be burdensome 12 (5%) 4 (2%) 11 (5%)
Not motivated to use DA 11 (5%) 4 (2%) 13 (6%)
Expected DA would increase uncertainty 17 (7%) 5 (3%) 13 (6%)
DA was insufficiently adjusted to specific needs 30 (12%) 8 (4%) 28 (14%) .006
Implementation facilitators confirmed, n (%)
DA was pleasant to use 223 (91%) 166 (91%) 166 (80%) .001
DA was well organized 234 (95%) 172 (94%) 175 (85%) <.001
DA enabled treatment comparisons 222 (90%) 164 (90%) 163 (79%) .001
DA gave insight in treatment (dis)advantages 226 (92%) 170 (93%) 168 (81%) <.001
Felt DA information was complete 204 (84%) 154 (84%) 154 (74%) .02
DA was important addition to other information 217 (90%) 166 (91%) 152 (73%) <.001
Pleasant to use DA as additional source of information 231 (94%) 160 (87%) 165 (80%) <.001
Confident in DA quality 231 (94%) 170 (93%) 170 (82%) <.001
Expected DA would reduce uncertainty about decision 167 (69%) 146 (80%) 124 (60%) <.001
Used the DA to determine treatment 176 (72%) 153 (84%) 123 (59%) <.001
DA made easier to talk with relatives 202 (83%) 160 (87%) 129 (62%) <.001
DA made easier to talk with care providers 196 (81%) 157 (86%) 123 (59%) <.001
Recommend DA to others 219 (100%) 171 (99%) 172 (90%) <.001
Percentages are calculated based on item response, not as a proportion of the group total presented in table header.
P-values represent the outcomes of chi-square tests comparing all three DAs, significant differences caused by a single DA 




Many DA initiatives struggle to get structurally embedded in clinical routine, despite 
ample evidence revealing the benefits of using DAs when making medical decisions 
7, 13. At the onset of a multi-regional implementation initiative of three new Pca 
treatment DAs in Dutch clinical practice, a consortium was formed to jointly measure 
implementation rates and patient evaluations (i.e., barriers and facilitators from 
the patients’ perspective) from these three DAs. Overall, 40% of eligible Pca patients 
received a DA. For all DAs alike, implementation was quite successful (implementation 
rate >80%) in a limited number of hospitals, whereas uptake varied widely at other sites 
(2-80%). Overall, patient evaluations were supportive of implementation of each DA, 
however, the online DA3 was evaluated as having the least facilitators. 
The format of the implemented DAs as well as their level of information density varied 
24-26. DA1 and DA2 could be incorporated in clinical consultation, or used at home, while 
DA3 was, by design, supposed to be used outside of consultations. Despite the variation 
between DAs, implementation results showed the same variation between hospitals 
with each DA, and successful implementation (>80%) was only achieved in a limited 
number of hospitals. Increasing the number of hospitals for implementation, as DA2 
was implemented at 16 hospitals, compared to 8 and 9 hospitals for DA1 and DA3, did 
not result in more hospitals with successful implementation. This could suggest that for 
each DA support was present in some hospitals prior to the start of implementation, 
and that for upscaling implementation more structural encouragement and monitoring 
of implementation progress is needed in hospitals were the baseline support (in terms 
of care providers attitude or available resources) for DAs might be lower. 
When patient-perceived barriers were reported, most were related to DA characteristics 
(unpractical, unadjusted to needs) or expectations (no confidence, expected no benefits 
or reduction of uncertainty). Although overall report of barriers was low, barriers were 
reported most often for the online, elaborate DA3, and least for the very concise hybrid 
DA2. However, both DAs achieved similar implementation rates that were lower than 
the concise paper DA (DA1). This finding seems inconsistent with previous studies 
concluding that web-based DAs are the most promising modality for improving 
implementation 28, 29. However, care providers have also shown hesitance towards 
online tools 30, 31. Future research is needed to gain a deeper understanding of how the 
benefits of online tools, such as tailoring to patient information needs and enabling 




paper format. One solution might be to provide concise, paper add-ons to online tools, 
which can be introduced during consultation and may enhance the user friendliness of 
online tools. 
The joint implementation efforts by the JIPPA consortium may have contributed to 
raising national awareness for SDM in both urology and oncology in the Netherlands. 
Many care providers have been introduced to the DA and to the principles of SDM, 
and during the course of the projects, consortium members contributed to national 
Pca treatment guidelines with a section on SDM and DAs (www.oncoline.nl). Therefore, 
the study in itself increased awareness for SDM and the existence of DAs and educated 
many teams in using DAs in clinical routine. However, it may also have caused a barrier, 
as clinical practice was unclear about which DA should be applied, and what the 
differences between the available DAs entailed. To the best of our knowledge, no earlier 
studies have reported (national) implementation rates for Pca DAs, and comparability to 
other DA implementations studies is difficult to interpret as they were aiming at different 
patient populations (e.g. women with breast cancer, or orthopedic patients) and settings 
(e,g, screening decisions often include the general practitioner) 10, 11, 32  Further research 
is needed to determine if having different types of DA can help implementation since 
patients and care providers can select the DA they prefer most, or that the variety in 
available DAs hinders implementation since each DA has its specific characteristics and 
usability aspects that require training. Moreover, future research could study if specific 
DA characteristics have an effect on implementation rates, by randomizing distribution 
of different DA types across hospitals.
A strength of the current study was that we were able to investigate implementation of 
three DAs by using a similar questionnaire at a similar point in time. As a consequence 
of studying three different DAs, sample size and number of participating hospitals was 
higher than most previous Pca DA studies 9, 33. Eventually, one in three Dutch hospitals 
was exposed to one of the three DAs. Hospitals from different levels (academic and 
non-academic) and from different regions were included in the study, increasing the 
generalizability of our findings.
A limitation of the current study is that the implementation rate was calculated 
based on actual receivers of a DA as proportion of an estimation of the total number 
of eligible patients. Since the number of patients eligible for study inclusion were not 
systematically registered by each of the three DA studies, we relied on the hospital 
specific retrospective cohorts of PCa patients from the cancer registry. This ensured 
the sample was determined via the same method for every hospital. However, since 
the total number of patients eligible for DA receipt was estimated, this entailed that 
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no information was available about patient characteristics from those patients who 
were possibly eligible but were not offered a DA. In particular in hospitals with low 
implementation rates, a selection bias could have occurred if only patients were 
included who favored DA use. Another limitation is that the implementation period was 
not exactly simultaneous for all three DAs. Implementation of DA1 started almost a year 
ahead of DA2 and DA3. Moreover, a previous version of DA1 was studied in an earlier 
trial, which could have helped achieving the higher overall implementation of DA1 26. 
Furthermore, each participating hospital was linked to one of the three regions, and 
consequently implemented its respective DA. Possibly, some patients or care providers 
could have been more supportive of another DA and overall DA uptake would have 
been higher if all formats would be matched according to patient or care providers’ 
preferences. For example, one patient might benefit more from an elaborate DA, while 
for another patient optimal understanding and satisfaction is reached with a concise DA 
34-37. Finally, no information was available from patients who received, and possibly also 
used a DA but did not consent  to participate in the survey study. 
Patient evaluations from the three DAs in the current study were all favorable towards 
implementation. To further understand the observed differences in implementation 
rates between hospitals, future steps towards sustained DA use should include further 
investigation into barriers at the level of care providers and organizational barriers.
Conclusion
Overall implementation rate of the DAs in clinical routine was 40%. A wide variation in 
uptake across hospitals was observed for each DA. Most patients were satisfied with the 
DA they received, and only few barriers of usage were perceived by patients. Offering 
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SUMMARY OF RESULTS
In this chapter, the main findings of the studies reported in this thesis are summarized. 
Based on these results, considerations for DA development and implementation, and 
implications for clinical practice and future research are discussed.
This thesis started with an investigation into the preferences for involvement into 
treatment decision-making and satisfaction with information received in a sample of 
Pca patients who already chose a treatment previously (Chapter 2). For seven hospitals 
within the southern area of the Netherlands Cancer Registry (NCR), a random selection 
of 150 Pca patients per hospital was made consisting of patients diagnosed between 
2006 and 2009. These patients were sent a questionnaire measuring decision-making 
role preferences and the evaluation of information received, within the Patient Reported 
Outcomes Following Initial Treatment and Long-Term Evaluation of Survivorship 
(PROFILES) Registry. After exclusion of high-risk Pca patients, who fall out of the scope of 
this dissertation, response was obtained from 562 patients with low- or intermediate risk 
Pca (response 71%). A majority of these men preferred a collaborative (shared patient-
doctor) or active (patient-driven) decision-making role (81%), and 19% of the men 
in our sample preferred a passive (doctor-driven) role in treatment decision-making. 
A disadvantage of the measure that was used to determine role preferences (Control 
Preferences Scale) consisted of not being able to differentiate between a preference for 
involvement into the decision process or the for making the decision itself, which could 
be different. Men who preferred a passive role were significantly older and less educated 
compared to both other role preference groups. Information satisfaction was lower for 
men with a passive role preference, they reported to have received less information, 
and judged the information as less helpful. Across all role preferences groups, between 
25-30% of men indicated they would have wanted to have received more information 
before they made their treatment decision. However, the cross-sectional design of this 
study did not allow to infer causality from these results. 
Where chapter 2 retrospectively assessed satisfaction with information, and the relation 
with decision role preferences, we intended to obtain more insights in the impact of 
receiving a Pca diagnosis and the following process of treatment selection. Therefore, 
we undertook a prospective study including patients when scheduled for prostate 
biopsy because Pca was suspected, but had not been confirmed yet (Chapter 3). It is 
known that many patients experience a decline in health-related quality of life (HRQoL) 
as a consequence of Pca treatment and its associated side-effects. Our expectations 
were that a decline in HRQoL would already appear before treatment onset as a result 
of the burden of receiving the diagnosis and choosing a treatment. Moreover, we were 
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interested if individual differences (optimism, self-efficacy, and personality traits) were 
associated with changes in HRQoL before treatment onset. Patients with suspected Pca 
(n=377) were surveyed before biopsy, making this study one of the first to take a pre-
diagnosis baseline measure. In case PCa was detected (n=126), a follow-up questionnaire 
was sent after treatment was chosen but had not yet started. Compared to the pre-
diagnosis baseline, HRQoL was lower after receiving a Pca diagnosis and selecting 
treatment. In particular, role and cognitive functioning worsened, and elevated fatigue, 
constipation, and prostate specific symptoms were reported. In contradiction to the 
impaired overall HRQoL evaluation, sexual activity and functioning improved in the 
period between the first and second questionnaire. Baseline HRQoL was not associated 
to subsequent treatment choice, but if a curative treatment was chosen, worse HRQoL 
was reported at follow-up compared to men who chose active surveillance, however, 
it has to be noted that treatment subgroups at follow-up consisted of small samples, 
impairing statistical power of these findings. At baseline, an association between 
HRQoL and optimism was found, and at follow-up an association between HRQoL and 
self-efficacy. No associations with personality traits were found, indicating that no traits 
could be identified that predict how a patient would respond to being diagnosed with 
Pca (i.e. experience lower HRQoL after diagnosis). 
Results from the studies presented in chapter 2 and chapter 3 supported the need for 
improved information provision and further support during Pca treatment decision-
making. Decision aids (DAs) are interventions that have proven to be beneficial to help 
engaging patients and care providers in shared decision making (SDM). In absence of 
a Dutch DA with values clarification exercises for the treatment decision in Pca, a novel 
Dutch DA was developed (Chapter 4). A pre-existing, evidence-based, Canadian Pca 
DA, and consultation routines in Dutch clinical care were analyzed, in order to adjust 
the original DA to the Dutch context. Although patients were not directly involved to 
the development of current DA, all DA content was based on a cross-cultural study 
identifying which information is required by Pca patients when selecting treatment, 
including Dutch patients 1. Usability testing (n=11) was undertaken with patients 
and care providers, and resulted in 212 comments, which were all addressed in final 
adjustments to the DA. Prior to enrollment of the DA in routine clinical care, patients 
and care providers consented that the DA was comprehensible and well-structured, 
and that use of the DA in routine care was recommended. Patients included in usability 
testing all recently made a treatment decision to ensure an accurate evaluation what 
is required when choosing treatment, without the distress resulting from just being 
diagnosed being present. Key features of the newly developed DA included presenting 
information about active surveillance separately from detailed information about 
curative treatments (surgery and radiotherapy), and values clarification exercises which 
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were designed as statements and required a tradeoff between treatment specific 
aspects (e.g. ‘I fear surgery’ (reason for radiotherapy) versus ‘I do not fear surgery’ (reason 
for surgery)). 
To test the effectiveness of this newly developed DA, and to measure the level of 
implementation in clinical care, a cluster randomized controlled trial (RCT) was set up 
(Chapter 5). Within the Prostate Cancer Patient Centered Care (PCPCC) trial, eighteen 
Dutch hospitals were randomized to either include the DA during treatment counseling 
or to provide counseling as usual. Health care providers from the trial’s intervention 
arm were invited to evaluate working with the DA, care providers in the control arm 
evaluated usual information routines. Patients who were newly diagnosed with Pca 
in one of the participating hospitals were invited to complete questionnaires after 
treatment was chosen (but before treatment started), and 6 and 12 months later. 
Log data from the DA and national cancer registry data were used to determine the 
level of implementation of the DA. The primary outcome measure of the PCPCC trial 
was patient reported decisional conflict, as it was hypothesized that including a DA 
during treatment counseling would lower decisional conflict. Secondary outcomes 
were patient satisfaction, preparation for decision-making, knowledge, and decisional 
regret. As previous studies found anxiety and depression symptoms to be common in 
Pca patients, in particular for patients who consider postponing immediate curative 
treatment by means of AS, we measured these symptoms (HADS) across all timepoints 
and included them in further analyses as covariate. 
Patient-reported decision process parameters of the PCPCC trial, measured immediately 
after decision-making, were examined in Chapter 6. A total of 382 patients (DA arm, 
n=273; control arm, n=109) were enrolled in the trial, of which 336 participants (88%) 
filled out the first post-decision questionnaire. The levels of decision involvement and 
decisional conflict were comparable between patients from both trial arms. Patients 
with a DA felt more knowledgeable but scored equally well on a Pca knowledge test as 
patients from the control arm. Small, statistically significant negative effects were found 
on satisfaction with information and preparation for decision-making. A preference 
for a DA in print over online and depression and anxiety symptoms were negatively 
associated with satisfaction and conflict scores in the DA arm. 
To assess regret, treatment satisfaction, and information satisfaction after Pca treatment 
was completed, participants in the PCPCC trial received follow-up questionnaires 6 
months (n=336, response 92%) and 12 months (n=308, response 95%) after their initial 
treatment decision (Chapter 7). One year after treatment for Pca was chosen, most 
respondents reported very little regret about their decision and were satisfied with their 
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treatment and the information received. Main effects from the DA on these outcomes 
were not found. A less favorable patient-doctor relation and anxiety and depression 
symptoms were associated with increased odds of reporting regret about the chosen 
treatment. 
In addition to positive patient evaluations, is commitment from care providers an 
important factor for sustained use of DAs in routine clinical practice. Previous studies 
showed that care providers’ motivations are an important facilitator for implementation 
of DAs. In Chapter 8 we assessed care providers’ evaluation of DA usage in the DA arm of 
the PCPCC trial, and the evaluation of usual information routines among care providers 
from the control arm. From both trial arms, 108 care providers (urologists and nurses) 
were invited, and 63 filled out the questionnaire (response 58%). Care providers from 
the DA arm were supportive of the DA content and usability. Satisfaction with the DA 
was comparable to satisfaction with usual information among care providers from the 
control arm. However, care providers from the control arm did perceive that patients, 
with their usual information routines, already receive too much information. In contrast 
to earlier studies, care providers from both trial arms did not experience neither expect 
time barriers from DA use.
Next to assessing outcomes reported by patients and care providers, the PCPCC trial 
aimed to measure the level of DA implementation in routine clinical care (Chapter 
9). The level of DA implementation within the PCPCC was determined per individual 
hospital by taking the number of DA users (based on DA log data) as proportion of 
the estimated total number of eligible Pca patients during the trial period, based on 
historical registry data. With 351 patients receiving a DA, the average achieved level of 
implementation was 35% across all hospitals. Between hospitals, implementation varied 
from 16% to 84%. After receiving the link to the online DA, most patients (79%) accessed 
the DA. In the post-decision questionnaire, 79% of the patients indicated that the DA 
summary was discussed with their doctor. With being one of the first studies to provide 
such detailed implementation and usage data, these results indicate that most patients 
used the DA once received, and that care provider and organizational (hospitals) factors 
should require further investigation in order to improve implementation. 
The DA developed and tested within the PCPCC trial was one of three Dutch Pca 
treatment DAs that were simultaneously implemented in routine clinical care for 
newly diagnosed Pca patients in The Netherlands, within a collaboration of the Joint 
Implementation Prostate cancer Patient-centered care (JIPPA) consortium. These DAs 
varied in format, consisting of a ‘concise paper DA’ (i.e print booklet) , a ‘very concise 
paper or online DA’ (i.e presented in a diagram style with short explanations), and the 
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elaborate online-only DA as described in this dissertation. In the final empirical chapter 
of this dissertation (Chapter 10), we reported the joint JIPPA assessment of patient 
evaluations and implementation results across the three DAs. Although the regions in 
which each of the three DAs was evaluated were not randomly allocated, and patient 
groups differed, each DA achieved comparable patient evaluations and implementation 
rates across hospitals. Implementation across participating hospitals ranged from low 
(<20%) to (almost) complete implementation (80-100%) in all three trials. All DAs were 
well received by patients. With the ‘concise paper only DA’ and the ‘very concise paper 
or online DA’, most patients (96-99%) were satisfied with the DA format. For our online 
only DA, 21% indicated to have preferred a paper format instead. All DAs were handed 
out most often by the urologist (71-78% of the cases), and most patients (79-82%) 
perceived the urologist was also the most suitable person to hand out the DA. However, 
the majority of patients who received a DA from a nurse, perceived the nurse as most 
suitable care provider to hand out the DA (60%). When the DA was received within the 
first week after diagnosis, the largest proportion of patients (93%) felt this was the best 
moment.
GENERAL DISCUSSION
The research presented in this dissertation included (1) development, (2) implementation, 
and (3) evaluation of a web-based DA for patients newly diagnosed with early-stage Pca 
in everyday care in multiple healthcare centers in the Netherlands. This included the 
description of an alternative development method of adapting a pre-existing, evidence-
based DA to a different language and cultural setting. In contrast to conclusions from the 
latest Cochrane review 2, commonly found DA effects (e.g. less decisional conflict, more 
knowledge) were not replicated in the PCPCC trial. At a 12-months follow-up, also no 
beneficial patient-reported outcomes were found. Evaluation of the DA implementation 
included structured reporting on uptake and usage, and allowed linkage of DA usage to 
the patient-reported outcomes. This revealed that patients with anxiety and depression 
symptoms or a preference for an offline DA, were less supportive of the current DA 
version. Finally, our consortium approach allowed to evaluate implementation results 
for three different Pca DAs in Dutch routine Pca care, showing that for each DA alike, 
implementation rates between hospitals varied widely.
Building on the results of the studies included in this dissertation, as summarized 
above, three themes require further discussion in this section. First, considerations 
about DA development will be discussed. Second, the most important methodological 
considerations (strengths and weaknesses) of the PCPCC trial will be reviewed here, 
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beyond specific strengths and limitations that have been discussed in previous 
chapters. Third, considerations about DA implementation will be discussed. This general 
discussion ends with implications for clinical practice and for future research, before a 
general conclusion is presented.
Considerations about DA development
The decision to develop an online-only DA was based on the high degree of internet 
access among the entire Dutch population (>97%) 3, and the wider possibilities to 
tailor information provision and present values clarification methods. We modified 
a pre-existing, evidence-based tool that was developed in Canada 4.Patients differ in 
their information needs, capabilities to process information, and their desired level of 
involvement into a medical (treatment) decision 5-7. Yet, DAs aimed to support patient 
decision-making and initiation of SDM, have been developed according to a single 
one-size-fits-all format. Also the DA evaluated in this dissertation was developed to be 
universally applicable to all Pca patients. Perhaps it was for this reason that we learnt 
that 20% of participating patients would have preferred a paper format over the online 
format. This evaluation was actually provided by patients who consented to complete the 
questionnaires which were also online by default (paper on request). It could therefore 
be possible that these 20% of participants are actually an underrepresentation of the 
total population of Pca patients who would prefer to use a paper DA over an online 
DA. Although it was determined prior to DA development that almost all citizens in the 
Netherlands have internet access at home, it is possible that for a serious – potentially 
life threatening – disease, and the associated process of selecting treatment, many 
patients prefer an offline environment for information and decision support. Compared 
to online tools, which are often intended to be used outside consultations, an important 
advantage of offline tools is that they can be incorporated  more easily in clinical 
consultations. Based on the results of the studies in this thesis, it can be suggested 
that patients who are lower educated and report anxious or depressive symptoms, 
could benefit from more counseling or integration of the DA into the actual clinical 
consultation. More variation in DA format and delivery methods in order to personalize 
to patients needs is therefore important. As seen within the JIPPA study, with the offline 
and more concise DAs, an even larger proportion of patients was satisfied with the 
format (chapter 10).
Compared to the other two JIPPA DAs evaluated in chapter 10, the current DA was the 
most extensive, and also the only to include explicit values clarification exercises (VCEs) 
(chapter 3). Such exercises help patients in the process of clarifying personal values that 
are relevant to the decision, and are therefore a widely recommended element in DAs 1, 4, 
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8. However, a clear definition of VCEs is not available, resulting in a broad variety of tasks 
that can be seen as values clarification, with most common exercises at least including 
the rating, ranking or discussion of pros and cons 8. When patients engage in such 
exercises, this helps the cognitive processing of all options, offers time to process new 
information and to retrieve memories relevant to the decision. Furthermore, it allows 
comparing options and stimulates reviewing treatment-specific aspects or personal 
values that might not have been considered otherwise 9.
Inclusion of VCEs can be seen as an effort to stimulate deliberation about the presented 
treatment aspects. Whereas in many real-life situations, and for medical decisions 
specifically, the general assumption often is that deliberative analysis is the best 
strategy to make a decision, this may not always be the case 10, 11. Earlier scenario-based 
studies suggested that this may result in people choosing treatment that has more risks 
than the disease itself or avoiding treatment with possible adverse effects, while the 
mortality risk of the disease is higher 12, 13. Stimulating deliberation might result in people 
feeling better about their decision, as they put more effort in reaching a decision, while 
the decision itself might be the same and possibly still not provide an optimal patient-
treatment fit 14 15. This could have been reflected in the knowledge scores reported in 
chapter 6; while DA users felt more knowledgeable, their knowledge test scores were 
similar to the scores of participants from the control arm. 
The VCEs within the current DA presented two unique treatment option attributes as 
a trade-off to elicit a preference towards one of the two presented treatments (e.g. the 
fear of postponing active treatment with AS versus undergoing possibly unnecessary 
active treatment with the risk for adverse effects; chapter 4). Although trade-offs have 
been recommended to reach value-congruent decisions 16, the tasks were developed 
without specific (evidence-based) development guidelines 16, 17. The following two 
suggestions for further refinement and improvement of the DA in later DA versions 
may be considered. First, the VCE trade-offs in the current DA were presented with their 
corresponding treatment, however, identifying the associated treatment can influence 
preferences 18. For a patient, the tendency to be consistent with a pre-existing (biased) 
preference could then be confused with the true treatment preference. Second, one in 
three DA users preferred a treatment advice as outcome after DA use, possibly caused 
by the expectation of receiving an output after providing input by answering the 
VCEs.  Providing an advice would also have to include weighing of attributes, since one 
particular treatment aspect (e.g. avoiding adverse treatment effects) could outweigh all 
other presented treatment aspects. Including best-worse scaling of the current trade-
offs could be considered 19.
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Another development issue was the information density of the current version of 
the DA (chapter 4). According to Fuzzy trace theory, the delivery of this amount and 
type of precise information could be suboptimal to support decision-making. Fuzzy 
trace theory explains that people might rely on the gist of information, rather than its 
exact details.20. For future versions of the current DA, or for novel DAs, the amount of 
presented information should be reconsidered. Ongoing research in presentation of 
risk information provides opportunities to further optimize presentation of quantitative 
information, so that the risk for judgement biases and errors is minimalized, consisting 
of clear reference categories, the use of numbers over words, and additional visual 
formats, whereas in the current DA still large amounts of text were included 21-24. 
Also, further developments in the dissemination of big data in healthcare, within the wider 
perspective of delivering value-based healthcare, could influence the future approach 
to DA development 25, 26. Evaluating appropriate and effective care is increasingly relying 
on big data analyses. Insights that become available in this way, may also be useful for 
other purposes in the care process, such as decision support. For example, presenting 
the best available scientific evidence in a DA, can include presenting a broad margin of 
uncertainty (e.g. ‘between 40 and 80 out 100 patients will experience side effect X’). For 
a local hospital, individual doctors, and individual patients, other, more accurate, risk 
estimates may apply, and become insightful from big data analysis. In recent years, the 
number of studies into practical applications of big data to use in individual decisions 
has increased dramatically, and can enable personalized estimates of the effectiveness 
of different treatments 26. Within Pca care, personalized risk estimates can already be 
calculated for Pca screening or suitability of patients for active surveillance, based on 
individual patient characteristics, 27-31. Cancer in general, and cancer treatment choices 
specifically, are fields where data does not only come from scientific studies, but 
many (national) cancer registries routinely collect relevant data as well. With current 
developments in these fields, big data could be integrated into DAs and VCEs to present 
data in a personalized format, with risk estimation, and outcome predictions relevant 
to the individual patient. However, most of the data that are available for such analyses 
were not collected with the intention to support decision-making. It should therefore 
be critically evaluated it the available data is relevant to the individual patient. 
Methodological considerations PCPCC trial
A main strength of the Prostate Cancer Patient Centered Care (PCPCC) trial (Chapters 
5-10) entails the cluster randomized design. With cluster randomization, hospitals 
were randomized to the DA arm or control arm, instead of randomizing individual 
patients. As a result, all patients within the same hospital received the same care, and 
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care providers did not need to switch between DA counseling and usual counseling per 
patient. This avoided the risk of contamination of the usual care arm with components 
of DA counseling. 
Another important advantage of cluster randomization was that the DA intervention 
could be included in clinical routine as naturally as possible, without having an 
artificial randomization procedure before handing out a DA or not. This is why a cluster 
randomized design is recommended when the studied intervention includes changes 
in clinical routine and care providers’ behavior 32. Moreover, patients in our trial were 
not aware of randomization, and thus the existence of two separate trial arms. Patients 
from both trial arms were informed about a questionnaire evaluating the process of 
information provision and treatment decision-making, without explicitly mentioning 
that the DA was part of the study.  
Furthermore, participants in the control arm were not aware that a novel tool was not 
available to them. Participants being blinded to trial arm reduces the risk for potential 
biases, as participants are less likely to behave differently, or to provide answers they 
expect are desirable for the study 32. Care providers and researchers within the PCPCC 
trial were aware of randomization and assignment of hospitals to their respective trial 
arm. This aspect is discussed further on as a potential limitation.
A second strength is the pragmatic approach that was chosen during the PCPCC trial. 
During the introduction to the trial, care providers were advised to distribute the 
DA immediately after diagnosis, or at the moment other information materials were 
provided, in case this was at a later moment. However, to let the DA fit as natural as 
possible with existing routines during clinical consultations, hospitals and care providers 
were free to select the exact moment they felt was optimal to hand out the DA to the 
patient. In this way, enrolling the DA into clinical routine was as least disruptive for 
existing work flows as possible. Consequently, the effectiveness of the DA intervention 
could be measured including real-life practice conditions 33. As many previous DAs 
failed to achieve structural implementation in routine clinical practice after their initial 
clinical trial, the pragmatic approach of the PCPCC was essential to gather evidence of 
uptake of the DA under real-life conditions 34, 35. 
However, this methodology also resulted in important limitations. One limitation was 
the unbalanced recruitment of participants in both trial arms. The required sample 
size for the PCPCC trial was estimated at 225 participants per trial arm (aiming at 25 
patients per hospital). Although conservative sample size calculations were made, 
inclusion in the control arm stagnated at n=109. Moreover, none of the nine hospitals 
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in the control arm completed recruitment of the required number of 25 participants. 
During the same period of time, an equal amount of hospitals in the intervention arm 
did succeed in completing the required sample. Therefore, it is very likely that selection 
bias was introduced into the control arm with care providers being more selective in 
which patients they recruited to enroll in the trial, while care providers in the DA arm 
could have been more motivated to include patients as they were supportive of DA 
use 36. Although comparison between available patient characteristics did not indicate 
substantial differences between samples from both trial arms, it remains possible that 
patients who were more likely to consent in the control arm had different characteristics 
compared to participants from the intervention arm. Post-hoc analyses revealed that 
with the current sample statistical power was still sufficient (>.8) to detect medium 
effects (d=.04), but low for smaller effects. Also, with five hospitals in the control arm 
including less than 10 participants, meaningful hospital specific effects could not be 
determined within this trial.
A second limitation, as mentioned earlier, is related to the awareness among care 
providers of trial assignment and aim of the study. Care providers in the DA arm were 
aware that the DA was tested within their hospital, and care providers from the control 
arm knew results from the DA arm would be compared to the results from their usual 
care. Emphasis on the novelty of the DA could have led to a more critical evaluation 
by participants in this arm, while care providers in the control arm could have been 
more motivated to engage in SDM as they were aware of comparison with the DA arm 
(performance bias) 37, 38. Moreover, the unbalanced sampling between both arms (2:1 
ratio) suggests fewer eligible patients were enrolled in the control arm as compared 
to the intervention arm. This could have introduced sampling bias in the control arm, 
with patients who were likely to be (very) satisfied with usual care, being included more 
often compared to patients who appeared to be more critical or distressed following 
diagnosis. However, the JIPPA DA evaluations in chapter 10 showed similar findings, 
while these evaluations were obtained from trials that had different designs and 
methods of patient inclusion.
A third limitation was that implementation of the DA was linked to participation in the 
PCPCC trial. With our pragmatic approach we tried to enroll the DA as natural as possible 
in clinical routine. However, with each DA that was handed out during the trial period, 
the questionnaire study within PCPCC trial needed to be explained to patients as well. 
Although patient consent was not needed to use the DA, and patients were free to use 
the DA without consenting to participate in the trial, explanation about the trial and 
informed consent forms were introduced at each moment the DA was also introduced. 
Having to explain the trial could have been a barrier for care providers, while patients 
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who refused to participation in the PCPCC trial might have been unaware that the DA 
could still be used and was part of the ‘new’ usual care. Because treatment preferences 
from both the care provider and patient were collected before DA usage, it was not 
possible in this study to ask for consent at a later point after the DA was introduced.    
Considerations about DA implementation
The hybrid efficacy-implementation design of the PCPCC trial, enabled to test the tool 
in its natural environment, while simultaneously collecting data on implementation 
(chapters 5-9). The evaluation of DA implementation included registry data about 
the estimated total number of eligible patients, and DA log data provided insights in 
actual DA usage. Many previous studies were not able to report these parameters due 
to their study design or DA format (e.g. paper). Furthermore, a 12-months follow-up, as 
presented in chapter 7, is rare in DA research. Finally, the JIPPA consortium approach 
to joint DA implementation and evaluation was promising; most patients used the DA 
that was received, and all DAs were evaluated positively. With the three DAs, the JIPPA 
consortium engaged 33 Dutch hospitals in DA use and SDM, which would not have 
been achieved with an individual trial.
A main implementation result from the PCPCC trial was the wide variation in DA uptake 
across participating hospitals (Chapter 9). Similar patterns of implementation were 
obtained by the two other Pca DA initiatives that were enrolled simultaneously in other 
hospitals across The Netherlands (Chapter 10). 
The current DA was implemented with a minimum of requirements or usage guidelines. 
Possibly, more training is needed on how to introduce the DA and integrate discussion of 
the DA summary into treatment counseling. Earlier studies showed that care providers 
can overestimate the extent of SDM they are already applying, and misinterpret patient 
preferences for involvement 39-41. Following these mechanisms, some care providers 
in the PCPCC trial possibly underestimated patients’ eligibility for a DA, in terms of 
willingness and capability, and the need to introduce the DA to patients. Structural 
feedback on DA distribution across hospitals and between individual care providers, 
and structural patient evaluations could provide insights into how many patients were 
reached compared to relevant peer groups (other doctors and/or other hospitals), and 
where improvements in distribution routines are possible based on patient evaluations. 
A second consideration on DA implementation following the PCPCC trial is the total 
information load for patients after Pca diagnosis. In the current trial, the DA was added 
to all existing information routines. Usually patients receive oral information from 
their care provider(s), and hospital specific materials about their disease, treatments, 
218
Chapter 11
and procedures. Often, additional information is provided from national organizations 
(e.g. Dutch Cancer Society, patient association), and are patients referred to additional 
websites (e.g. Dutch urology association). Besides the information that is received at 
the hospital, various other sources are available to the patient as well (e.g. general 
practitioner, health insurer, own searches for (online) information, and personal 
networks). In this overwhelming availability of information of varying quality, it can be 
challenging for patients to determine which source is the most reliable or helpful 42. 
Instead of piling new information sources on existing materials, it should be considered 
to introduce the DA as primary information and decision tool, and adjust or incorporate 
existing (hospital) information materials into the DA. 
Implications for clinical practice and future directions
The PCPCC trial did not replicate effects that are typically found in DA studies (i.e. lower 
decisional conflict, higher information satisfaction, more knowledge) 2. Partly this was 
due to unexpected positive outcomes in our control arm (chapter 6). As discussed in 
previous sections, this could have been caused by care provider effects or selection bias. 
However, it could also be that current routine Pca care in The Netherlands already involves 
patients better into the decision process and informs them better compared to what 
we reported in the retrospective cohort of Pca survivors (chapter 2) or control groups 
included in previous international studies 2. Moreover, SDM has emerged in the past 
decade in The Netherlands, not only by endorsement from researchers and clinicians, 
but implementation of SDM is also encouraged by government, health insurers, and 
patients associations 43. Therefore, with the wide body of evidence available on the 
beneficial effects of DAs, and still increasing awareness for SDM, make it likely that DAs 
in some format will continue to be included in clinical practice 2, 43. 
In this context, an important continuation of the studies presented in this thesis relate 
to the role of DAs in the broader context of SDM. Many other studies have looked into 
the effects of DAs on patient-reported outcomes (e.g. decisional conflict, and perceived 
SDM) and decision outcomes (e.g. selected treatment) for other diseases and screening 
decisions; the latest Cochrane review (2017) included 105 studies2. And apart from these 
DA studies, much more literature is available that describes the model, and benefits 
of SDM itself 44-47. As also explained in this dissertation, it is often assumed that DAs 
help to initiate SDM, and that the beneficial effects after DA use are the result of more 
SDM occurring. Consequently, it is often advised that more DAs are needed in order 
initiate and facilitate SDM. It can however be questioned if beneficial effects from DAs 
are the result of (more) SDM occurring, or solely effects from the DA itself (e.g. more 
knowledge, increased self-efficacy) 48. The studies included in this dissertation did not 
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directly measure the impact from the DA on SDM. Although both patients and care 
providers evaluated the current DA positively in their respective evaluations (chapter 6 
and chapter 8), we did not measure the degree of SDM occurring before or after the DA 
intervention. Moreover, we had no direct observations of how consultations looked like 
when the DA was introduced, or when the DA summary was discussed. That DAs and 
SDM are beneficial to patients and overall quality of care, is well supported by scientific 
literature, however, DAs are not SDM and vice versa, more studies are needed that 
investigate the role DAs have in SDM outcomes 2, 24, 48, 49 .  
General conclusion
Treatment decisions in Pca care are preference-sensitive and require careful consideration 
by patients and care providers to select the best suiting treatment. To support 
patients, and guide both patients and care providers during the treatment decision-
making process, a Dutch web-based DA was developed to help patients construct an 
informed treatment preference. The DA was positively evaluated by patients and care 
providers. However, no substantial effects from the DA on patient-reported outcomes 
were detected within our PCPCC trial. The pragmatic approach of our trial allowed to 
investigate the DA in the context of routine clinical care, but also introduced a risk for 
selection and performance bias into the study. DA effects could be more subtle when 
the DA is part of routine care instead of what has been found in more controlled clinical 
trials. Methodological limitations prevented a meaningful investigation of hospital 
specific effects or specific patient subgroups, and should be addressed in future 
studies. However, following the results, the most important implications for clinical 
practice relate to DA development and implementation. Future DA developments and 
adjustments to the current DA should consider their format and the construction of 
VCEs, and incorporate the possibility to tailor according to specific patient needs (e.g. 
anxiety and depression). Achieving high implementation rates in many hospitals proved 
to be difficult, and this finding was confirmed in parallel implementation studies from 
two other Pca DAs within the JIPPA consortium. 
From an ethical perspective, patients should be offered all available resources -including 
DAs- in order to be fully informed about all treatment options. Clinical guidelines, patient 
and professional associations, and health insurers should therefore advice that all 
preference-sensitive (treatment) decisions should include a DA. This ensures individual 
treatment decision-making processes are less dependent on the performance and 
engagement of individual care providers. Moreover, it helps patients and care providers 
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to structure the process of informing and deciding about treatment. To upscale DA 
implementation, care providers should receive more training in distribution routines 
and including DA components into clinical counseling as part of SDM.
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De studies in dit proefschrift hebben allen betrekking op de behandelkeuze bij 
gelokaliseerd prostaatkanker. 
In hoofdstuk 2 werd onderzocht welke voorkeur voor betrokkenheid bij de 
behandelkeuze patiënten hadden die reeds eerder een behandeling voor prostaatkanker 
kozen. Daarbij werd tevens onderzocht of er een verband was tussen die voorkeur en 
hun tevredenheid over de informatie die ten tijde van de behandelkeuze was ontvangen. 
Hierover vulde 562 respondenten, bij wie tussen 2006 en 2009 prostaatkanker werd 
vastgesteld, een vragenlijst in. Een meerderheid van de respondenten had op het 
moment van invullen van de vragenlijst een voorkeur om bij een behandelkeuze samen 
met de arts of (voornamelijk) zelfstandig te beslissen (81%). Negentien procent van de 
respondenten gaf de voorkeur aan een passieve rol, waarbij voornamelijk de arts het 
initiatief heeft. De groep respondenten die een voorkeur voor deze passieve rol uitsprak 
was ouder en lager opgeleid in vergelijking met de respondenten die een voorkeur 
hadden voor een gezamenlijke of actieve rol bij de besluitvorming. Respondenten 
met een voorkeur voor een passieve rol bleken vaker een niet-invasieve behandeling 
(afwachten of bestraling) te hebben ondergaan in vergelijking met de andere 
groepen. Ook was deze groep minder tevreden met de informatie die ten tijde van de 
behandelkeuze was ontvangen, gaf het aan minder informatie te hebben ontvangen, 
en vonden de ontvangen informatie minder nuttig dan respondenten met een andere 
voorkeur. Ongeacht de uitgesproken voorkeur voor een bepaalde beslisrol, had 25-30% 
van de respondenten liever meer informatie ontvangen ten tijde van de behandelkeuze.
Om vervolgens dieper in te gaan op de impact die het ontvangen van de diagnose 
prostaatkanker en het daarop volgende proces van behandelkeuze hebben, wordt in 
hoofdstuk 3 een prospectieve studie beschreven die patiënten volgde vanaf het moment 
dat prostaatkanker vermoed werd, maar nog niet was vastgesteld. Hiervoor werden 
patiënten die een afspraak hadden om een prostaatbiopt te laten nemen gevraagd 
om deel te namen aan een vragenlijstonderzoek. Een belangrijke uitkomstmaat in dit 
onderzoek was gezondheidsgerelateerde kwaliteit van leven (KvL). Reeds bekend was 
dat de behandeling van prostaatkanker -meer nog dan ziekte zelf- kan leiden tot een 
daling van KvL bij patiënten, die zich pas in de loop der jaren weer hersteld. Vanwege 
de impact van de diagnose en de belasting van het kiezen van een behandeling was 
echter het vermoeden dat een daling in KvL al merkbaar zou zijn vanaf het moment 
van diagnose en niet pas bij de start van behandeling. Daarnaast werd onderzocht of er 
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een verband bestond tussen veranderingen in KvL en persoonskenmerken die relevant 
zouden kunnen zijn bij diagnose en behandelkeuze (o.a. optimisme, self-efficacy en 
persoonlijkheid). 
Voorafgaand aan biopsie vulden 377 deelnemers de vragenlijst in. Bij 126 van hen 
werd er prostaatkanker vastgesteld en zij ontvingen een tweede vragenlijst nadat een 
behandeling was gekozen maar nog niet was gestart. Op het tweede meetmoment 
rapporteerde deelnemers een lagere KvL dan bij de eerste meting. Ondanks dat er 
bij deze patiëntengroep tussen de twee metingen weinig medische veranderingen 
te verwachten waren, werd er slechter cognitief en rol (werk en prive) functioneren 
gerapporteerd en meer vermoeidheid, constipatie en prostaat-specifieke klachten in 
vergelijking met de eerste meting. In tegenstelling tot de slechtere algemene KvL, werd 
er wel een verbeterde seksuele activiteit en functioneren gerapporteerd. In het geval 
dat prostaatkanker werd vastgesteld, waren de KvL scores die werden gemeten bij 
het biopt niet voorspellend voor een latere behandelkeuze. Echter, bij de tweede KvL 
meting bleek een lagere KvL vooral gerapporteerd te worden door respondenten die 
kozen voor een actieve behandeling (operatie of bestraling), en werd er minder verschil 
gevonden bij patiënten die kozen voor een actief volgen beleid. Bij de eerste KvL-
meting, voorafgaand aan diagnose, werd er een associatie gevonden met optimime. 
Bij de tweede meting werd een samenhang met self-efficacy gevonden. Er werd geen 
verband gevonden tussen verandering in KvL en persoonlijkheid. 
De voorgaande twee hoofdstukken belichtte verschillende aspecten (beslisrol, 
tevredenheid met informatie, KvL bij diagnose en behandelkeuze) uit het proces van 
diagnose en behandelkeuze bij prostaatkanker. Uit deze en eerdere onderzoeken, en 
ervaringen uit de praktijk, is bekend dat samen beslissen tussen arts en patiënt bij een 
behandeling voor prostaatkanker moeilijk is. Naast alle medisch relevante informatie, 
moeten de arts en patiënt ook overleggen over de persoonlijke situatie en voorkeuren 
van de patiënt. Een keuzehulp is in zo’n situatie een nuttig hulpmiddel voor arts en 
patiënt om tot een gezamenlijk behandelbesluit te komen. Een keuzehulp bevat vaak 
taakjes of opdrachten die patiënten helpen om hun eigen waarden en voorkeuren te 
verhelderen. In Nederland was nog geen geschikte keuzehulp voor prostaatkanker 
beschikbaar met dergelijke waarde verhelderende oefeningen. De ontwikkeling van 
deze keuzehulp wordt in hoofdstuk 4 beschreven.  
De keuzehulp is gebaseerd op een Canadese versie waarnaar eerder onderzoek is 
gedaan. Na observaties bij Nederlandse consulten, werd de keuzehulp aangepast aan 
de Nederlandse praktijk. De medisch inhoudelijke informatie werd geverifieerd aan de 




conceptversie van de keuzehulp werd vervolgens gebruikersonderzoek gedaan 
met 11 deelnemers. Deelnemers waren zowel patiënten als zorgverleners (urologen, 
verpleegkundigen en een radiotherapeut). Er werd gekozen voor patiënten die reeds 
een behandelkeuze voor prostaatkanker hadden gemaakt omdat verwacht werd dat zij 
beter in staat zouden zijn om te reflecteren op wat noodzakelijk en nuttig is om aan te 
bieden in een keuzehulp voor prostaatkanker. Nieuw gediagnosticeerde patiënten zijn 
vaak nog belast met de emotie van de diagnose, en voor willekeurige testpersonen is 
het vaak moeilijk om zich in te leven in een situatie waarbij men voor de behandelkeuze 
bij prostaatkanker staat. 
De deelnemers aan het gebruikersonderzoek gaven 212 opmerkingen over het 
gebruiksgemak, inhoud en indeling van de keuzehulp. Alle opmerkingen werden 
geanalyseerd en verwerkt in aanpassingen aan de keuzehulp. Voordat de keuzehulp 
werd geïntroduceerd in de praktijk, waren alle deelnemers aan het gebruikersonderzoek 
het eens dat de keuzehulp duidelijk en goed gestructureerd was, en dat gebruik in de 
dagelijkse praktijk aan te bevelen was.
Een belangrijk element uit de keuzehulp bestaat uit het opdelen van informatie over 
behandelen in twee delen, waardoor patiënten niet overladen worden met alle informatie 
ineens. In het eerste deel wordt uitleg gegeven over actief volgen in vergelijking 
met behandelen in het algemeen, daarna volgt pas gedetailleerde informatie over 
operatie en bestralen. Een tweede belangrijk element uit de keuzehulp zijn de waarde 
verhelderende oefeningen. Deze oefeningen bestaan uit stellingen waarbij telkens een 
afweging gemaakt moet worden tussen aspecten van een behandeling (bijv. ‘Ik ben 
niet angstig voor een operatie’ versus ‘Ik heb angst voor een operatie’). Voorkeur voor 
de eerste stelling zou een reden kunnen zijn om voor operatie te kiezen, terwijl een 
voorkeur voor de tweede stelling een reden kan zijn om voor bestraling te kiezen. Op 
een samenvatting, die door de keuzehulp wordt gegenereerd  worden de voorkeuren 
op alle stellingen weergegeven en kan de patiënt samen met zijn arts bespreken welke 
aspecten hij het meest belangrijk vindt en waar hij nog vragen over heeft.
Om het effect van deze keuzehulp en de implementatie in de dagelijkse praktijk te 
onderzoeken is een cluster gerandomiseerde studie opgezet. De studieopzet wordt 
beschreven in hoofdstuk 5. Binnen deze Prostate Cancer Patient Centered Care (PCPCC) 
trial werden achttien Nederlandse ziekenhuizen gerandomiseerd naar de interventie of 
controle arm van de studie. In de interventie-arm werd de keuzehulp toegevoegd aan 
het bestaande prostaatkanker-zorgpad. Hierdoor ontvingen patiënten na de diagnose 
en bovenop alle andere informatie, ook een uitnodiging om de keuzehulp te gebruiken. 
In de controle arm werd de standaard zorgverlening voortgezet zoals gebruikelijk was. 
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De studie kende een pragmatisch karakter waardoor per ziekenhuis de keuzehulp zo 
goed mogelijk kon worden aangesloten op gebruikelijke werkwijzen. Hierdoor was 
het mogelijk om invloeden uit de dagelijkse praktijk die effect konden hebben op de 
uitkomst mee te nemen in het onderzoek.  
Na inclusie werd aan deelnemende patiënten op drie momenten een vragenlijst 
voorgelegd; na de behandelkeuze (maar voor de start van behandeling), en 6 en 12 
maanden later. In de interventie-arm werd aan de hand van gebruikersdata uit de 
keuzehulp vastgelegd in welke mate keuzehulp daadwerkelijk werd gebruikt. Aan de 
hand van historische patiëntaantallen (uit de kankerregistratie) werd per ziekenhuis 
bepaald hoeveel procent van het aantal nieuwe prostaatkankerpatiënten werd 
bereikt met de keuzehulp. De primaire uitkomstmaat van de studie was de mate van 
gerapporteerde keuzeconflict over de gemaakte behandelkeuze. De hypothese was 
dat met behulp van een keuzehulp, patiënten minder keuzeconflict zouden ervaren. 
Secondaire uitkomsten bestonden uit tevredenheid met ontvangen informatie, 
voorbereiding op besluitvorming, prostaatkanker-specifieke kennis en spijt van de 
behandelkeuze. Aanvullend aan het onderzoek onder patiënten, werd aan zorgverleners 
een vragenlijst voorgelegd om de gebruikelijke informatievoorziening (controle arm) 
en werken met de keuzehulp (interventie arm) te evalueren.
De resultaten die betrekking hadden op het keuzeproces, inclusief het effect van de 
keuzehulp op keuzeconflict, is beschreven in hoofdstuk 6. Er waren 382 deelnemers 
in de PCPCC studie (273 in de keuzehulp-arm en 109 in de controle arm), waarvan 
uiteindelijk 336 respondenten de eerste vragenlijst hebben ingevuld (respons 88%). 
In tegenstelling tot de hypothese bleek de mate van keuzeconflict vergelijkbaar 
tussen respondenten uit beide groepen. Ook werden er geen verschillen gevonden 
in de mate van betrokkenheid bij het keuzeproces. Respondenten uit de keuzehulp-
arm vermoedde meer kennis te bezitten dan respondenten uit de controle arm, maar 
respondenten uit beide groepen behaalden vergelijkbare scores op een kennistest. Ten 
opzichte van de controle arm,  werden in de keuzehulp-arm kleine, maar statistisch 
significante, negatieve effecten gevonden op tevredenheid met informatievoorziening 
en voorbereiding op de besluitvorming. Angst en depressie symptomen en de voorkeur 
voor een keuzehulp op papier in plaats van online waren geassocieerd met lagere 
tevredenheid en conflict scores in de keuzehulp-arm.
Om te onderzoeken of het beslissen met of zonder keuzehulp effecten had op spijt, 
en tevredenheid met de behandeling en informatie op langere termijn, werden 
deelnemende patiënten binnen de PCPCC-studie gevolgd voor 12 maanden (hoofdstuk 




behandelkeuze werd gemaakt ontvingen alle deelnemers vervolgvragenlijsten. Uit de 
resultaten bleek dat de meeste patiënten een jaar na de behandelkeuze weinig spijt 
hadden van hun keuze en tevreden waren met de informatie die destijds was ontvangen. 
Hierbij werden geen verschillen gevonden tussen de keuzehulp en controle arm van de 
studie. Een minder positieve patiënt-dokter relatie en angst en depressie symptomen 
bleken verband te houden met het rapporteren van spijt over de behandelkeuze.
Naast een positieve patiëntevaluatie is commitment van zorgverleners een belangrijke 
factor voor duurzame implementatie van keuzehulpen in de dagelijkse praktijk. In 
hoofdstuk 8 werd de keuzehulp door zorgverleners uit de PCPCC -studie geëvalueerd. 
Aan zorgverleners uit de controle arm werd om een evaluatie van de gebruikelijke 
informatievoorziening gevraagd. In totaal werden 108 zorgverleners (urologen en 
verpleegkundigen) uitgenodigd voor een vragenlijst-onderzoek (respons 58%, n=63). 
Uit de resultaten bleek dat zorgverleners uit de keuzehulp arm tevreden waren over 
de inhoud en gebruiksgemak van de keuzehulp. Tevredenheid met de keuzehulp was 
vergelijkbaar met de tevredenheid over de gebruikelijke informatievoorziening door 
zorgverleners uit de controle arm. Zorgverleners in de controle arm waren van mening 
dat met de gebruikelijke informatie, patiënten al het risico lopen om te veel informatie 
te ontvangen. In tegenstelling tot eerdere studies, werd er geen tijdsdruk ervaren 
door zorgverleners als gevolg van het werken met de keuzehulp, en werd dit ook niet 
verwacht door zorgverleners in de controlegroep.
In de PCPCC studie werd naast de evaluatie door patiënten en zorgverleners ook 
de implementatie in de dagelijkse praktijk onderzocht (hoofdstuk 9). Precieze 
inschattingen van de implementatiegraad en mate van daadwerkelijk gebruik van de 
keuzehulp zijn vaak moeilijk te bepalen. Doordat de huidige keuzehulp web-based is, 
gebruikers een persoonlijke inlogcode ontvingen, en er informatie beschikbaar was over 
de vermoedelijke omvang van de totale patiëntengroep, konden zowel implementatie 
als gebruik nauwkeurig in kaart gebracht worden. Binnen de studieperiode verschenen 
ongeveer 1.000 prostaatkankerpatiënten in de deelnemende ziekenhuizen, waarvan er 
351 de keuzehulp hebben ontvangen (implementatiegraad 35%). Tussen ziekenhuizen 
varieerde de implementatie tussen 16 en 84%. Na ontvangst, logde de meeste 
patiënten in de keuzehulp in, en in de vragenlijst gaf 79% van de patiënten aan dat de 
samenvatting uit de keuzehulp was besproken met de uroloog.
Gelijktijdig met de PCPCC vonden twee andere studies naar keuzehulpen voor 
prostaatkankerpatiënten plaats in Nederland, onder de naam JIPPA (Joint Implementation 
Patient-centered care). De drie onderzochte keuzehulpen verschilden van elkaar in 
format (papier of online), hoeveelheid informatie (beknopt tot uitgebreid) en waarde 
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verhelderende opdrachten (wel of niet). De evaluaties van de keuzehulpen door 
patiënten werd volgens dezelfde methode uitgevoerd. Hierdoor konden de resultaten 
van de patiëntenevaluaties uit de drie verschillende onderzoeken met elkaar vergeleken 
worden (hoofdstuk 10). In iedere studie werd de keuzehulp positief beoordeeld 
door patiënten en werden vergelijkbare implementatieresultaten gevonden. Met 
een beknopte keuzehulp op papier waren de meeste patiënten tevreden. Bij de 
uitgebreide online keuzehulp had een deel van de patiënten liever een keuzehulp op 
papier ontvangen. De meeste patiënten ontvingen de keuzehulp van de uroloog, en 
beoordeelde de uroloog ook als meest geschikte persoon om de keuzehulp uit te reiken. 
Echter, van de patiënten die de keuzehulp van een verpleegkundige ontving, vond 60% 
de verpleegkundige het meest geschikt. De eerste week na diagnose werd door de 





Een proefschrift is geen proefschrift zonder een overdreven lang dankwoord. Paradoxaal 
genoeg ben ik mij ervan bewust dat ik de minste tijd besteed aan het schrijven van dit 
stuk, terwijl het waarschijnlijk het best gelezen hoofdstuk is. Al weten de mensen die mij 
goed kennen dat dat misschien ook niet helemaal waar is. Van die tijd dan.
Maar al het harde werk aan de hoofdstukken hiervoor was niet mogelijk geweest zonder 
de inzet van een aantal mensen die het verdienen om hier benoemd en bedankt te 
worden.
Allereerst Marieke. Het eerste waar ik bij Marieke aan moet denken is zwangerschapsverlof. 
Drie kinderen binnen de tijd van één proefschrift, dat is eigenlijk een nog grotere 
prestatie dan dat ik dit proefschrift heb voltooid. Maar je was er altijd, ook toen je Tilburg 
verruilde voor Nijmegen. Met een kind op de arm aan de telefoon over een paper, ´s 
avonds laat voor de deadline van een subsidie-aanvraag en de laatste loodjes van dit 
proefschrift bij een tijdsverschil van 10 uur. Dank dat je in mij geloofde op het moment 
dat de mogelijkheid zich voordeed. ´Geen uitgesproken onderzoeksprofiel´ weet ik nog 
na het sollicitatiegesprek. Het is goed gekomen. En wie weet komt zelfs het door ons 
bedachte vervolgproject er nog!
Paul, een groot deel van het werk in dit boekje is ontstaan uit jouw ideeën en visie. 
Tijdens mijn afstudeerstage zat ik al naast je op het krukje in de spreekkamer en zag 
ik waar het allemaal om draaide. Jouw expertise, ervaring in de dagelijkse praktijk en 
kritische blik hebben de hoofdstukken in dit proefschrift onmiskenbaar beter gemaakt. 
Niemand anders kon meer bevlogen de relevantie van ons werk uitleggen.
Lonneke, altijd juiste adviezen en rake feedback. Wat was het fijn dat jij door iets meer 
afstand altijd met rust en overzicht de juiste adviezen kon geven. Ook jij verliet Tilburg, 
maar bleef vaak de eerste die op mails reageerde. En in de hectische afrondende fase 
van dit proefschrift was jij een baken van rust. Ik ben erg blij met jou als promotor.
Romy, zonder jou was dit boekje maar half zo dik geweest. Toen we begonnen, hadden 
we geen idee hoe we in hemelsnaam allebei een proefschrift moesten gaan vullen over 
hetzelfde onderwerp. Maar hoe nuttig was het om samen met jou alle ziekenhuizen 
af te gaan om de studie uit te leggen. Al snel bleek onze samenwerking de perfecte 
aanvulling op elkaars werk. Dat Marieke ook jouw co-promotor is, is duidelijk merkbaar. 
Want terwijl ik dit stukje schrijf, ben ook jij met zwangerschapsverlof. Daarnaast ben je 
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tweede auteur van bijna alle hoofdstukken, schrijf je een eigen proefschrift en doe je 
tussendoor ook nog even de opleiding tot uroloog. Je draait je hand er niet voor om, en 
daarom weet ik ook zeker dat ik mij geen betere paranimf kan wensen.
Jippa collega’s Julia, Hoda, Nelly, en Linda. De samenwerking was al opgetuigd op het 
moment dat ik begon, maar in de loop van het project realiseerde ik pas hoe uniek onze 
samenwerking eigenlijk was. Ik heb fijn samengewerkt met jullie.
Ik ben ook veel dank verschuldigd aan alle mensen die het praktische werk van 
de studie hebben uitgevoerd. Urologen en oncologieverpleegkundigen hebben 
honderden patiënten met prostaatkanker voor zich gehad met wie ze deelname aan 
deze studie bespraken. En steeds ontving ik weer ingevulde toestemmingsformulieren, 
gescand, gefaxt of per post. Zelfs toen we steeds maar weer opbelde om te informeren 
of er nog nieuwe deelnemers in zicht waren.  Ook dank ik dus alle patiënten die bereid 
waren om vaak meerdere -en niet hele korte- vragenlijsten in te vullen. Zonder hen 
had ik niets om over te schrijven. En in het bijzonder een dankjewel voor Nicole, mijn 
steun en toeverlaat voor alles wat met Profiel te maken had. Een scherpe blik bij het 
aanleveren van vragenlijsten, en het trouw iedere week meenemen van nieuwe 
toestemmingsformulieren van patiënten. Het was fijn dat ik altijd een beroep op je kon 
doen, en wist dat het dan goed kwam.
De leden van mijn promotiecommissie, Neil Aaronson, Anne Stiggelbout, Marcel 
Zeelenberg, Harm van Melick en Julia van Tol, veel dank dat jullie bereid waren mijn 
proefschrift te lezen en te beoordelen. En Emiel Krahmer, dank voor het willen 
opponeren tijdens mijn verdedigingszitting.
Co-auteurs Olga Husson, Erik Cornel, Regina The, Klemens Karssen, Peep Stalmeier, Inge 
van Oort, Rik Somford, Jeroen van Moorselaar en Irma Verdonck, bedankt voor jullie 
kritische blik, goede tips, complimenten en bovenal prettige samenwerking.
Isabel en Fieke, jullie namen Romy´s onderzoekstaken over. Nieuwelingen in shared 
decision making en keuzehulp-onderzoek. Ik mocht antwoord geven op al jullie vragen, 
en af en toe meeschrijven aan artikelen en abstracts. Zo kon ik toch nog regelmatig een 
onderzoeksdag in het Elisabeth houden. Er ontstonden weer nieuwe keuzehulpen, en 
konden nu alles uiteraard in één keer goed doen. Ik heb hoge verwachtingen van jouw 
proefschrift, Isabel!
Op de universiteit in Tilburg liep ik met mijn medische onderzoek rond op een afdeling 
met voornamelijk sociaal psychologen. Dat is een wereld die vooral bestaat uit veel 




worden zelfs effecten gevonden die repliceren. Ondertussen schreef ik een proefschrift 
vol schreef op basis van één klinische trial met echte patiënten. Hoewel de context van 
onze onderzoeken vaak ver uit elkaar lag, heb ik veel gehad aan de soms verassende en 
vernieuwende interpretaties van resultaten en nuttige tips om nog eens opnieuw naar 
de data te kijken. Gelijkgestemden zocht ik daarom maar wat vaker op bij congressen 
en summer schools. In Miami, Venetië, Sydney, St.Louis, Londen, Heidelberg, Vancouver, 
Boston, Lyon en Pittsburgh. Het was fijn altijd weer met nieuwe ideeën en positieve 
feedback terug te keren. Mocht onderwijl iemand nog advies willen over hoe je optimaal 
een reisbudget kan besteden, welke vliegvelden fijn zijn om over te stappen of welke 
congreslocaties aan te bevelen zijn, dan weet je me te vinden.
Ik kan ook niet onbenoemd laten dat ik een schrikbarende hoeveelheid aan 
kantoorgenoten heb gehad in de afgelopen vier jaar. Of dat met de voorgaande 
paragraaf te maken heeft, weet ik niet. Ellen, Irene, Xiaoyue, Job, Ilker, Cong, Sander, 
Mehmet, Hannes, How, en nog een handvol stagiaires en visiting researchers, het was 
gezellig met jullie.
Ilja, je gaf me het zetje om na een jaar toch te kiezen om onderzoek te gaan combineren 
met lesgeven. Ondanks dat ook voor jou niet altijd duidelijk was hoe alles was 
georganiseerd toen ik in Tilburg bleef terwijl al mijn begeleiders vertrokken, kreeg ik 
van jou het vertrouwen dat alles toch wel in orde kwam. En na vier jaar vertrok ik zelfs 
met mijn BKO certificaat op zak.
Na vier jaar promotieonderzoek in Tilburg wilde ik graag verder in een universitair 
medisch centrum en die kans kreeg ik in Nijmegen. Ook hier word ik weer omringd door 
fijne collega´s. Ik ben heel blij met de kans die ik hier krijg om mij verder te specialiseren 
als epidemioloog.
Tot zover dan het goede nieuws. Het leven is wat je overkomt terwijl je andere plannen 
maakt, zei John Lennon ooit. Dat maakt alles wat ik hiervoor beschreef weer heel relatief. 
Dat leven is ook dat mijn vader ziek werd in de loop van mijn promotieproject. Er werd 
kanker vastgesteld. Hoewel ik als geen ander wist wat die diagnose betekende, hoopte 
ik met alles en iedereen dat het bij ons anders zou zijn. Het leek er ook even op dat het 
verloop rustig was. Maanden was er geen progressie en konden we nog vooruit kijken. 
Thomas zijn diploma-uitreiking heb je nog mee kunnen maken, maar de geboorte van 
Stijn en de voltooiing van dit proefschrift niet meer. Tijdens mijn verdedigingszitting zal 
er een stoel leeg blijven. Dat is klote, wat was je trots geweest!
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Daarom is het fijn om zowel de mooie als droevige momenten te kunnen delen met 
familie. Mama, oma, Thomas, Saphira, Inge, Michel, Tim, Daan en Stijn, bedankt dat jullie 
zijn er altijd zijn. En ook al moet ik soms nog even uitleggen wat ik nu precies voor 
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